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Abstract 
This PhD project focused on investigating the structure-activity relationships (SARs) of the ribbon 
isomer of α-conotoxins, providing the basis for using α-conotoxin ribbon isomers as scaffolds in drug 
design to target nicotinic acetylcholine receptors (nAChRs). Chapter 1 provides an introduction to 
the structure and function of nAChRs and to α-conotoxins, as well as introducing the concept of 
disulfide isomers of α-conotoxins. Chapters 2 to 5 describe the engineering of ribbon isomers of α-
conotoxins for drug design application, as summarised below.  
 
Chapter 2 describes a strategy to improve the yield of synthesis of a ribbon conotoxin, enabling the 
creation of mutants for SAR studies. The three-disulfide isomers of αO-conotoxin GeXIVA, i.e. the 
globular, ribbon and beads isomers, have similar potency at the α9α10 nAChR, which is considered 
to be a pain target. Owing to its potent activity, GeXIVA prompts further studies to investigate its 
analgesic potential. Unfortunately, the directed folding using orthogonal protection of cysteine 
residues is difficult for GeXIVA because it has a long sequence and has poor assembly yields arising 
from numerous Arg residues. Chapter 2 of this thesis shows that the folding of the ribbon GeXIVA 
could be achieved directly using rationally designed backbone cyclising linkers instead of using an 
orthogonal protection strategy. Additionally, backbone cyclisation of the ribbon GeXIVA was shown 
to improve peptide stability in human serum and have comparable activity as the parent peptide. 
 
Chapter 3 focuses on the determination of the binding mode of an α-conotoxin, AuIB, which is an 
essential step for structure-based design of ribbon α-conotoxins. The ribbon isomer of α-conotoxin 
AuIB has 10-fold higher potency than the wild-type globular isomer at inhibiting nAChRs in rat 
parasympathetic neurons, and unlike its globular isoform, ribbon AuIB targets a specific 
stoichiometry of the α3β4 nAChR subtype. This specificity for a particular stoichiometry is 
remarkable and suggests that the ribbon isoform of α-conotoxins has potential applications in drug 
design. In Chapter 3, the binding mode and SAR of ribbon AuIB were investigated to determine the 
features that underpin its specific activity using a combination of molecular modelling and 
electrophysiology recording. An alanine scan showed that positions 4 and 9 of ribbon AuIB are the 
main determinants of the interactions with rat (α3)3(β4)2 nAChR. Computational models indicated 
that the first loop of ribbon AuIB bound in the “aromatic box” of the acetylcholine orthosteric binding 
site. In contrast, the second loop and the termini of the ribbon isomer had different orientations and 
interactions in the binding sites than those of the globular isomer. 
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In Chapter 4, several computation methods for predicting mutational energies of α-conotoxins were 
compared, and the optimal method could be used for rational computational design. Binding free 
energy predictions are potentially an important tool for designing selective inhibitors based on 
globular and ribbon α-conotoxins but these computational methods need to be benchmarked to assess 
their accuracy in the context of nAChR/conotoxin systems. Computational free energy predictions 
are especially sensitive to the accuracy of the structural models; ultimately they should be used with 
high-resolution experimental structures. Unfortunately, there is so far no crystal structure of nAChR 
in complex with α-conotoxin. By contrast, the acetylcholine binding proteins (AChBPs), which are 
structurally homologous to the extracellular domains (ECDs) of the nAChRs, can be relatively easily 
crystallised and studied using X-ray crystallography. The crystal structures of AChBP/α-conotoxin 
complexes provide important information on the binding mode of the α-conotoxin. In Chapter 4, we 
evaluated four mutational energy prediction methods (BeAtMuSic, Foldx, MMPBSA/MMGBSA, 
and coarse-grained umbrella sampling) using the crystal structure of the complex between AChBP 
and α-conotoxin LsIA and between AChBP and LvIA, and associated experimental affinity change 
of these complexes after mutations. Foldx was identified as the most reliable method for mutational 
energy prediction. Notably, this method was successful at predicting variations with increased or 
decreased affinities.  
 
Chapter 5 combined results from the two previous chapters to the study of the binding mode of the 
α-conotoxin GID with the α4β2 nAChR. The α4β2 nAChR is linked to a range of diseases and 
disorders including nicotine addiction, epilepsy, and Parkinson’s and Alzheimer’s diseases. 
Designing α4β2 nAChR selective inhibitors could help refine the role of α4β2 nAChR in disease 
states. In Chapter 5, we aimed to modify globular and ribbon α-conotoxin GID to selectively target 
the α4β2 nAChR through competitive inhibition of the α4(+)β2() or α4(+)α4() interfaces. The 
binding modes of the globular α-conotoxin [Gla4E]GID with rat α3α4and α7 nAChRs were 
built using computational methods, and they were validated using published experimental data. The 
binding mode of globular [Gla4E]GID at α4nAChR can rationally explain the experimental 
mutagenesis data, suggesting that it could be used to design GID variants rationally. The predicted 
mutational energy results showed that globular [Gla4E]GID seemed to be already optimal for binding 
to α4nAChR and its activity cannot further be improved through amino-acid substitutions. The 
cryo-electron microscopy structure of (α4)3(β2)2 nAChR has been recently released, providing an 
optimal template to build the binding mode of the ribbon GID with (α4)3(β2)2 nAChR using 
information on the binding mode of ribbon AuIB studied in Chapter 3. The Foldx predicted the 
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mutational energies of ribbon [Gla4E]GID at α4(+)α4() interface, and a number of ribbon 
[Gla4E]GID mutants were suggested to have desirable properties to inhibit (α4)3(β2)2 nAChR. 
 
Chapter 6 provides an overview of my findings and highlights the major conclusions of the thesis, as 
well as suggesting ideas for future studies in this field. In summary, my PhD thesis has shown that 
ribbon α-conotoxins can be used in the design of specific nAChR inhibitors. 
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1.1 Overview 
The marine environment provides plenty of habitats that support life, with the biodiversity of 
marine species accounting for half of the global species (1). Marine organisms produce many 
kinds of bioactive marine natural products (MNPs) whose activity significantly differs from 
bioactive compounds obtained from terrestrial environments, making them interesting from a 
pharmacological perspective (2). Thousands of new MNPs have been characterised over past 
years (3,4), providing a valuable source for many pharmaceutical companies positioning 
themselves to reap the benefit by developing MNP-based novel drugs. More than 30 MNP-
based drugs are in clinical trials to treat various diseases (5,6), such as pain and cancer. The 
FDA has approved three MNPs: Prialt®, a disulfide-rich peptide from Conus magus that is used 
to treat neuropathic pain (7,8); Adcetris®, an antibody-drug conjugate medication used to treat 
relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It was 
derived from a peptide isolated from a mollusk associated cyanobacteria (9); and Yondelis®, a 
drug initially isolated from Ecteinascidia turbinate and used to treat soft tissue sarcoma and 
recurrent platinum-sensitive ovarian cancer (10). Hence, the potential of MNPs to be developed 
into therapeutics is substantial.  
The disulfide-rich conopeptides from the venom of the marine cone snails is a large class of 
MNPs, and several compounds from this class are drugs or drug leads, such Prialt®, Vc1.1, 
RgIA and MrIA (11). This thesis focuses on conopeptides and their potential in drug design, 
specifically the α-conopeptide or α-conotoxin, which target the pharmacologically important 
nicotinic acetylcholine receptors (nAChRs). This chapter will introduce the general 
background on nAChRs and conopeptides along with the aims and scope of this thesis. 
1.2 nAChRs 
nAChRs belong to the pentameric Cys-loop family receptors and are integral allosteric 
membrane proteins. They can be divided into muscle-type and neuronal-type nAChRs, and are 
involved in a broad range of physiological processes (12-14). Five subunits (α1, 1, δ, γ and ε) 
form the muscle-type nAChRs, and 12 subunits are known to assemble to form neuronal-type 
nAChRs. The 12 neuronal subunits are further classified into two superfamilies, namely the α 
subunits (α2-α10) and the β subunits (β2-β4). The subunits are expressed in the nervous system 
and cochlea as well as in some non-neuronal tissues (13).  
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The combinatorial assembly of nAChR subtypes into homo- and hetero-pentamers creates a 
large number of nAChR subtypes, which are involved in different physiological aspects and 
thus are connected with various pathologies (15). α1β1εδ AChRs are involved in the treatment 
of amyotrophic lateral sclerosis therapy (16). The nAChR subtypes displaying two or three α3 
subunits (α3-containing nAChRs) are engaged in a wide range of diseases, including chronic 
pain, cancer and cardiovascular diseases (17). The α4β2 nAChR subtype is a potential target 
for several pathologies, such as nicotine addiction, depression, and Parkinson’s and 
Alzheimer’s diseases (18-20). Some α6-containing nAChRs have been implicated in the 
development of neuropathic pain (21) and addiction to nicotine or alcohol (22). The homomeric 
α7 nAChR is involved in memory and cognitive functions, and is a potential target for 
Alzheimer’s disease (20). The α9α10 is present in outer hair cells (23) and lymphocytes (24,25) 
and is a potential target for the treatment of neuropathic pain (26,27). The different 
physiological involvement of each subtype emphasises the importance of developing selective 
probes for each nAChR subtype. 
1.2.1 Structure of nicotinic receptor subtypes 
The first glimpse of the structure of a nAChR came from a low resolution (4 Å) electron 
microscopy structure of a fish muscle-type nAChR (PDB: 2BG9) (28), which shows that the 
five subunits are arranged symmetrically around a central pore. The nAChR structures are 
divided into three domains: a hydrophilic extracellular domain (ECD), a transmembrane 
domain (TMD), which consists of four mainly hydrophobic transmembrane segments (M1-
M4) in each subunit, and a hydrophilic intracellular domain (ICD) (Figure 1.1A). Higher-
resolution structural information on nAChRs has recently become available with the 
determination of the X-ray crystal structure of the ECD of the human homomeric α2 nAChR 
in complex with the agonist epibatidine at 3.2 Å (PDB: 5FJV) (29); the X-ray crystal structure 
of the human heteromeric (α4)2(β2)3 nAChR in complex with the agonist nicotine at 3.9 Å 
(PDB: 5KXI) (30) and the cryo-electron microscopy structure of (α4)3(β2)2 nAChR with the 
agonist nicotine at 3.9 Å (PDB: 6CNK) (31). In these structures, the agonists are deeply buried 
in the orthosteric ACh binding site located at the α-β interface in the ECD (orthosteric ACh 
binding site; Figure 1.1B). The interaction of the agonists with the ECD triggers the opening 
of the channel in the TMD (29-31).  
In neuronal nAChRs, each subunit in the ECD is composed of one α-helix, which lines the 
pore, and two β-sheets made of 10 β-strands (Figure 1.1A and B). The ACh binding site in  
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Figure 1.1 Basic structure of neuronal nAChRs. A: The structure of nAChRs comprises three 
domains: an extracellular domain (ECD), a transmembrane domain (TMD), and an intracellular 
domain (ICD; ICD has not been resolved in the crystal structure). The ribbon representation of 
the nAChR used the coordinates from the X-ray crystallography structure of the α4β2 nAChR 
(PDB ID: 5KXI). The membrane is represented by a purple rectangle, the extracellular (Ext.) 
and intracellular (Int.) sides of the membrane are indicated. B: Structure of the agonist binding 
site in the ECD. C: Crystal structure of α-conotoxin PnIA (orange) binding to Aplysia 
californica AChBP. D: Simplified diagram of the subunit arrangement of homomeric α7 
nAChR and heteromeric α4β2 nAChRs. The ACh binding sites are identified by orange discs. 
The nAChRs are shown as seen from the extracellular side, parallel to the membrane with the 
pore in the centre of the pentamer. The C-loop of each subunit is indicated by a curved line. 
The α7(+)α7(-), α4(+)β2(-) and α4(+)α4(-) agonist binding sites are indicated by orange discs. 
 
neuronal nAChR subtypes is differently contributed by two subunits: the principle (+) subunit 
is typically an α subunit (α2, α3, α4, α6, α7 or α9) (13,32) and contacts the agonist with the A-
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, B- and C-loops; and the complementary () subunit (which could be an α or a β subunit) 
contributes to the binding site through the β-strands 2, 5 and 6 (Figure 1.1B) (13,33-36).  
Although there is no available experimental structure of nAChRs in complex with α-
conotoxins, the acetylcholine binding proteins (AChBPs) are homologous to ECDs of the 
nAChRs, which can be relatively easily crystallised and studied using X-ray crystallography. 
Despite low sequence identity with nAChRs, the AChBPs have a similar three-dimensional 
structure to nAChRs and can bind ACh as well as other ligands, such as α-conotoxins. AChBPs 
are therefore considered as structural surrogates of nAChR ECDs (37). A large number of X-
ray structures of AChBP bound to various ligands have been determined, and seven α-
conotoxins have been crystallised in complex with AChBP (38-43), namely the α-conotoxins 
PnIA (PDB:2BR8), ImI (PDB:2BYP and 2C9T), TxIA (PDB:2UZ6) and more recently LvIA 
(PDB:5XGL), GIC (PDB:5CO5), LsIA (PDB:5T90) and PeIA (PDB:5JME).  
Figure 1.1C illustrates how conotoxin PnIA occupies the ACh binding site of AChBP. All 
seven crystal structures of conotoxin/AChBP display a very similar binding mode. Homomeric 
nAChRs have five identical binding sites (e.g. α7 nAChR; Figure 1.1D). In contrast, the ACh 
binding sites of heteromeric nAChRs can be different and can vary with different 
stoichiometries, i.e. the number of subunits of a given type. For example, α4β2 nAChR exists 
in vivo as two main stoichiometries: the (α4)3(β2)2 nAChR and the (α4)2(β2)3 nAChR (44). The 
(α4)2(β2)3 has two binding sites but the other stoichiometry displays an additional binding site 
between two α4 subunits (noted α4(+)/α4(-) binding site; “+” and “-” means the principle and 
complementary subunits, respectively) (33), as illustrated in Figure 1.1D. 
1.2.2 nAChR stoichiometries  
Different subunit stoichiometries with distinct functional properties have been identified in 
heteromeric nAChR subtypes (34-36,44). The (α4)2(β2)3 and (α4)3(β2)2 differ in their 
sensitivities to agonists, antagonists and allosteric modulators, and have distinct single-channel 
conductance, mean open lifetime, activation and deactivation kinetics. These differences arise 
from an additional agonist binding site located at the α4(+)α4(-) interface for the (α4)3(β2)2 
nAChR (33,45,46). Interestingly, the two α4(+)β2(-) binding sites, which are surrounded by 
different neighbouring subunits, contribute differently to the activation within and between the 
(α4)2(β2)3 and (α4)3(β2)2 isoforms (47). Subunit stoichiometries of other nAChR subtypes such 
as the α3β4, α7β2 and α9α10 nAChR have been reported (34-36). In these receptors, an 
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additional binding site was predicted to exist at the α3(+)α3(-), α7(+)α7(-) and α9(+)α9(-), 
affecting the function of the α3β4, α7β2 and α9α10 nAChR subtypes, respectively (34-36). 
Although the subunit stoichiometries of nAChR subtypes were shown to have different 
functions, the connection between these different functions and pathophysiology states is still 
unknown, mostly because the identification of nAChR subtype stoichiometries is challenging.  
1.3 Toxins from cone snails  
Marine snails of the genus Conus produce a vast array of bioactive peptides used primarily for 
prey capture and defence against predators (48-50). Most of these peptides, namely 
conopeptides, bind to a range of mammalian ion channels and receptors that have been 
implicated as targets in some diseases, including pain, Alzheimer’s disease, Parkinson’s 
disease, schizophrenia, epilepsy, cancer, and tobacco addiction. Conopeptides are divided into 
two main classes, those that contain one or no disulfide bond and those that contain two or 
more disulfide bonds; with the latter referred to as conotoxins (48).  
 
Each cone snail species can produce up to thousands of conopeptides (51,52), and it is 
estimated that more than 100,000 different conopeptides exist (53). They are typically 10 to 30 
residues in size and are often post-translationally modified. ConoServer 
(www.conoserver.org), a database of conopeptides, catalogues more than 2,000 such peptides 
(54,55). In addition to the broad classification in disulfide-rich and disulfide-poor peptides, 
conopeptides are classified according to three other criteria: their evolutionary relationships 
(gene superfamily classification), the cysteine residue patterns along their primary sequence 
(cysteine framework classification; Table 1.1), and their activity at pharmacological targets 
(pharmacological family classification; Table 1.2) (56).  
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Table 1.1 Cysteine frameworks of conotoxins[a] 
Framework Cysteine pattern No. of cysteines No. of conotoxins[b] 
I* CC-C-C 4 366 
II CCC-C-C-C 6 3 
III CC-C-C-CC 6 334 
IV CC-C-C-C-C 6 57 
V CC-CC 4 206 
VI/VII* C-C-CC-C-C 6 705 
VIII C-C-C-C-C-CC-C-C-C 10 23 
IX* C-C-C-C-C-C 6 39 
X CC-C.(PO)[c]C 4 10 
XI C-C-CC-CC-C-C 8 109 
XII C-C-C-C-CC-C-C 8 49 
XIII C-C-C-CC-C-C-C 8 4 
XIV C-C-C-C 4 93 
XV C-C-CC-C-C-C-C 8 29 
XVI C-C-CC 4 12 
XVII C-C-CC-C-CC-C 8 1 
XVIII C-C-CC-CC 6 2 
XIX C-C-C-CCC-C-C-C-C 10 2 
XX C-CC-C-CC-C-C-C-C 10 43 
XXI CC-C-C-C-CC-C-C-C 10 6 
XXII C-C-C-C-C-C-C-C 8 22 
XXIII C-C-C-CC-C 6 6 
XXIV C-CC-C 4 6 
XXV C-C-C-C-CC 6 1 
XXVI C-C-C-C-CC-CC 8 1 
[a] Frameworks with an asterisk are those that have been cyclised. [b] Data from ConoServer 
(54,55). [c] Any amino acid residue followed by either a proline (P) or hydroxyproline (O) 
residue. 
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Table 1.2 Pharmacological classes of conotoxins[a] 
Class Target 
Representative 
conotoxin(s) 
Cysteine 
framework 
Refs 
α (alpha) 
Nicotinic acetylcholine receptors 
(nAChR) 
Vc1.1* 
I, II, III, IV, V, 
VIII, XIV, XX, 
XXIV 
(57) 
γ (gamma) 
Neuronal pacemaker cation currents 
(inward cation current) 
PnVIIA, 
TxVIIA 
VI/VII (58) 
δ (delta) 
Voltage-gated Na channels (agonist, 
delay inactivation) 
EVIA* VI/ VII, XXVII (59) 
ε (epsilon) 
Presynaptic calcium channels or G 
protein-coupled presynaptic 
receptors 
TxVA V (60) 
ι (iota) 
Voltage-gated Na channels (agonist, 
no delayed inactivation) 
RXIA III, XI (61) 
κ (kappa) Voltage-gated K channels (blocker) PVIIA* 
III, IV, VI/ VII, XI, 
XIV, XXVII 
(62) 
μ (mu) 
Voltage-gated Na channels 
(antagonist, blocker) 
SIIIA*, 
MrVIB* 
III, IV, V, VI/VII (63,64) 
ρ (rho) α1-Adrenoceptors (GPCR) TIA* I (65) 
σ (sigma) 
Serotonin-gated ion channels 
(GPCR) 
GVIIIA* VIII (66) 
τ (tau) Somatostatin receptor CnVA V (67) 
χ (chi) Neuronal noradrenaline transporter MrIA* X (65) 
ω (omega) 
Voltage-gated calcium channels 
(blocker) 
MVIIA* VI/VII, XVI, XXVI (68) 
[a] Conotoxins labelled with an asterisk were reported to have clinical potential in pain and 
cardiac reperfusion. 
Conotoxins have attracted considerable attention as drug leads due to their high selectivity for 
ion channels, transporters and receptors (48). The pharmacological properties of representative 
conotoxins are listed in Table 1.2, with some reported to have clinical potential in the treatment 
of neuropathic pain (50,56,69-73). Presently, there is only one conotoxin-based drug to have 
reached the clinic: MVIIA (ziconotide/Prialt), a peptide derived from Conus magus, which has 
been approved since 2004 as a drug for the treatment of neuropathic pain (7,8). Its applications 
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are primarily directed at late stage cancer or AIDS patients who are intolerant or non-
responsive to morphine therapy as it requires intrathecal injection.  
1.4 Conotoxins as drug leads 
1.4.1 Interactions between ω-conotoxins and calcium channels 
Voltage-dependent calcium channels (Cav) are complexes of several subunits, including a pore-
forming α1 subunit, and several associated subunits (α2δ, β1–4 and γ subunits). There are 10 
human Cav α1 isoforms, which can be classified into five types: Cav1.1–1.4 (long-lasting L-
type), Cav2.1 (P/Q-type), Cav2.2 (neural non-L N-type), Cav2.3 (residual R-type), and Cav3.1–
3.3 (transient T-type). These isoforms are associated with a range of diseases, including 
neuropathic pain and neurological disorders (74-76). ω-Conotoxins act at mammalian Cav 
channels and especially as inhibitors of neuronal Cav2.1 and Cav2.2 (77-79). Cav2.2 is 
expressed by nociceptive primary afferent neurons and has been reported to play a crucial role 
in pain signalling (80). ω-Conotoxin MVIIA antagonises N-type Cav2.2 channels with 100-
fold greater potency than morphine and is used in the clinic to treat chronic pain (81). Positions 
Lys2, Arg10, Leu11, Tyr13 and Arg21 of MVIIA have been reported to be important for its 
affinity to Cav2.2 (77,82-84).  
1.4.2 Interactions between conotoxins and voltage-gated sodium channels 
Human voltage-gated sodium channels (Nav) comprise nine isoforms (Nav1.1–1.9) (85-88). 
Each isoform is made up of four homologous domains, comprising a voltage-sensing unit 
formed by four α-helices and a central pore contributed by two α-helices from each of the four 
domains. Nav isoforms are expressed in the central nervous system, cardiac myocytes and 
skeletal muscle, and they are associated with some diseases (85-88).  
Cone snails produce several families of Nav modulators, including μ-, δ- and ι-conotoxins 
(61,89-91), which have various activity on Nav channels. Here we focus on μ-conotoxins 
because some members of this family have been reported to be promising drug candidates. 
Framework III μ-conotoxins target the Nav channel pore (92) and are selective inhibitors of 
Nav1.4 and/or Nav1.2 (93). For example, μ-SIIIA is an irreversible blocker of Nav1.2, which 
has clinical potential in the treatment of pain (94). Structure-activity relationship (SAR) studies 
show that Lys11, Trp12, Arg14, Asp15, His16 and Arg18 of SIIIA are key residues modulating 
its activity (95). Framework IV/VII μ-conotoxins often referred to as μO-conotoxins, act on 
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the voltage sensor of Nav domain II (96). μO-MrVIA and MrVIB selectively target Nav1.8, 
which is associated with neuropathic and inflammatory pain, and show analgesic effects in 
animal models (64,97,98). There are currently no detailed SAR studies reported on these 
peptides. 
1.4.3 Interactions between κ-conotoxins and voltage-gated potassium channels 
Voltage-gated potassium channels (Kv) are tetramers of four identical α subunits, each having 
a voltage-sensor unit and contributing to the central pore, similarly to the individual domains 
of Nav. The human genome has 40 Kv α-subunit genes, which are classified into 12 functional 
classes, including outward-rectifying, inwardly-rectifying or slowly inactivating, as described 
in the IUPHAR database (99).  
Eleven κ-conotoxins that block Kv channels, have been discovered so far, and they display a 
range of cysteine frameworks, including Frameworks III, IV, VI/VII, XI, and XVI. Two κ-
conotoxins are disulfide-poor conopeptides. Most of these conotoxins have µM to high nM 
activity, and the most active κ-conotoxin, PVIIA, blocks the shaker Kv channel with an half-
maximal inhibitory concentration (IC50) of 57 nM (100). This 27-residue conotoxin exhibits 
cardio-protective properties in animal models and has clinical potential associated with cardiac 
reperfusion (101). SAR studies of PVIIA show that Arg2, Lys7, Phe9, Phe23, Asn24 and Lys25 
are important for blocking the pore of the shaker Kv channel (100,102,103).  
1.4.4 Interactions between conotoxins and G protein-coupled receptors  
G protein-coupled receptors (GPCRs) are renowned for being the class of receptor that is the 
most targeted by current drugs. These receptors are highly diverse and account for about 400 
human coding genes (104). The GPCRs targeted by conopeptides are the α1-adreno receptors, 
which are associated with the central nervous system and are pharmaceutical targets implicated 
in cardiovascular diseases. There are three homologous α1-adrenoceptor subtypes: α1A, α1B and 
α1D (105). ρ-Conotoxin TIA, isolated from Conus tulipa, is a selective inhibitor of the α1B-
adrenoceptor with an IC50 of 2 nM (65,106). SAR studies showed that residues Asn2, Trp3, 
Arg4, Leu7, Ile8 and Arg12 are important for the activity of TIA at the α1B subtype (107).  
1.4.5 Interactions between conotoxins and the norepinephrine transporter  
Chapter 1: Introduction 
 
12 
 
χ-Conotoxins are inhibitors of the norepinephrine transporter (NET). Many neurological 
conditions, such as neuropathic pain, depression and anxiety, are related to NET function (108). 
χ-MrIA specifically acts on NET and a slightly modified analogue, Xen2174, progressed to 
clinical trial (phase II) as an analgesic; although, ultimately it was withdrawn due to safety 
concerns (109). The native disulfide connectivity of MrIA is a ribbon isomer (Cys I–Cys IV, 
Cys II–Cys III) and displays a Framework X (65). The 3D structure of MrIA revealed that it 
adopts a hairpin structure and that the Cys I–Cys IV and the Cys II–Cys III disulfide bonds are 
located on opposite sides of the β-sheet (110). Gly6, Tyr7, Lys8 and Leu9, which are in the γ-
turn, as well as His11 in Loop 2, are thought to interact with the NET (111).  
1.4.6 Interactions between conotoxins and ligand-gated ion channels  
The two pharmacological families of conotoxins acting on LGICs are the α- and σ-conotoxins, 
which act on nAChRs and serotonin-gated ion channels, respectively (72). The best studied of 
the two pharmacological families, the α-conotoxins, block nAChRs by competing with 
acetylcholine (72,112). The general background of the α-conotoxins and the studies about 
isomers of the α-conotoxins are introduced below. 
1.4.6.1 α-Conotoxins are potent and specific inhibitors of nAChR subtypes 
α-Conotoxin is the largest class of conotoxins (113). Most of them have a size between 12 and 
19 amino acid residues (56). Because of their small size, they can be chemically synthesised 
relatively easily, and their selectivity and potency for important molecular targets make them 
interesting candidate drug leads. Most α-conotoxins share a conserved cysteine pattern (CC-C-
C, Figure 1.2). The length of the two loops existing between Cys II and Cys III (loop m) and 
between Cys III and Cys IV (loop n) is used to classify them into different classes noted m/n 
(Figure 1.2). The most common α-conotoxin classes are the 3/5, 3/6, 4/2, 4/3, 4/4, 4/5, 4/6, 4/7, 
4/8, 5/2, 5/5 and 5/8 (114,115). The four cysteine residues can theoretically form three disulfide 
connectivities (Figure 1.2), which are designated as the globular isomer (Cys I-III, Cys II-IV), 
ribbon isomer (Cys I-IV, Cys II-III) or bead isomer (Cys I-II, Cys III-IV). These disulfide 
connectivities play an important role in determining the activity of α-conotoxin against specific 
nAChR isoforms (112,116). The globular isomer is displayed by wild-type α-conotoxins, but 
the ribbon connectivity has been shown to also be active in some cases and to have interesting 
properties.  
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Figure 1.2 Three-dimensional nuclear magnetic resonance (NMR) solution structure of the 
three disulfide isomers of α-conotoxin GI. Cysteines are numbered with Roman numerals, and 
the disulfide bonds are shown as yellow sticks. A: the globular isomer (PDB: 1XGA); B: the 
ribbon isomer (PDB: 1XGB); C: the bead isomer (PDB: 1XGC). The structure shown for each 
isomer is the lowest energy conformer from an ensemble of the 35 (globular), 24 (ribbon) and 
25 (bead) NMR models. 
1.4.6.2 Studies on some representative globular α-conotoxins 
A number of comprehensive reviews have described the structure-activity relationship (SAR) 
of globular α-conotoxins (72,112). Several globular α-conotoxins, including LvIA, TxID, 
TxIB, BuIA, ImI, Vc1.1 and RgIA, have therapeutic potential arising from their high selectivity 
and potency for certain nAChR subtypes. Here, I give a brief overview of these α-conotoxins 
in their SAR studies.  
 
LvIA selectively and potently inhibits both human and rat α3β2 nAChR with IC50s of 17.5 nM 
and 8.67 nM, respectively (117). The Val111 of β2 subunit contributes to the binding of LvIA 
on α3β2 nAChR (118) and the crystal structure of Ac-AChBP in complex with LvIA suggested 
that Asn9 and Asp11 of LvIA were important for the selectivity on α3β2 nAChR (41). TxID 
selectively targets the rat α3β4 nAChR and alanine scanning results suggested that Gly1, His5, 
Pro6, Val7, Met11 and Pro13 are important for the biological activity of TxID, and the 
[S9K]TxID only targets α3β4 with IC50 of 6.9 nM (119-121). TxIB and [T5A; P6O]BuIA 
selectively blocks the α6/α3β2β3 and α6/α3β4 nAChR, respectively (122,123). ImI inhibits the 
rat α7 and α9 nAChRs (124) as well as the human α3β2 nAChR (125). SAR studies have shown 
that Asp5, Pro6, Arg7 and Trp10 of ImI are important for targeting the α7 nAChR (126,127). 
Vc1.1 and RgIA inhibit the α9α10 nAChR with IC50 values of 19 nM and 4.5 nM, respectively 
(27,128). SAR studies show that Ser4, Asp5, Pro6, Arg7, Asn9, Asp11, His12, Pro13, Glu14 
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and Ile15 of Vc1.1 are important for its activity and Asp5, Pro6, Arg7 and Arg9 are key residues 
for RgIA activity (129,130).  
1.4.6.3 Studies of ribbon and bead α-conotoxins 
Research on the ribbon and/or bead α-conotoxins is summarised below (Table 1.3):  
GI 
α-Conotoxin GI belongs to the 3/5 class and targets the muscle-type nAChR. The native 
globular isomer was shown to have 10-fold greater potency than the other two isomers in mice 
(131). Another study concluded that globular GI has an IC50 of 20 nM at rat α1β1δγ/ε nAChR 
expressed in Xenopus oocytes (Ach = 500 nM) (124). Gehrmann et al. studied the structures of 
the three isomers of GI, showing that the globular isomer has a well-defined and rigid structure, 
whereas the two non-native isomers have multiple conformers in solution (Figure 1.2) (132).  
ImII 
α-Conotoxin ImII belongs to the 4/3 class and inhibits the rat and human α7 nAChRs as well 
as the human muscle-type nAChR. Ellison et al. suggested that ImII inhibits the α7 nAChR 
subtype using a novel binding site differing from the binding site on the α7 nAChR targeted by 
ImI (125,133). It was demonstrated that both globular and ribbon isomers of ImII can target 
the human α7 nAChR , with IC50 = 1.5 µM and IC50 = 3 µM, respectively, and the muscle type 
nAChRs with IC50 = 9.5 ± 3.8 µM; IC50 = 2.6 ± 0.4 µM, respectively (134).  
BuIA 
α-Conotoxin BuIA belongs to the 4/4 class, and its globular isomer inhibits the rat α6/α3β2 and 
α6/α3β4 nAChR with IC50 = 258 pM and 1.54 nM, respectively (135). Interestingly, the 3D 
structure of the globular isomer showed that it has three conformations in solution, whereas the 
ribbon isomer only has a single well-defined structure (136). Globular BuIA also blocks α3β2 
and α3β4 nAChR, with IC50 of 4.8 ± 0.4 nM and 59.1 ± 2.3 nM, respectively, but the ribbon 
isomer does not have any activity at these subtypes (136). One potential explanation for this 
difference in potency is that Pro6 and Pro7 adopt a trans/trans conformation in conformer A 
of globular BuIA but are in a trans/cis conformation in the ribbon isomer (136). This different 
isomerisation of the Pro residues results in a different backbone conformation and therefore 
side chain presentation at the receptor (136). Additionally, the structure of globular BuIA 
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contains a two-turn helical motif associated with binding to α3-subunit of neuronal nAChRs 
(136). 
AuIB 
α-Conotoxin AuIB belongs to the 4/6 class and selectively inhibits α3β4 nAChR. Dutton et al. 
reported that the ribbon isomer of AuIB (IC50 = 0.1 nM) has 10-fold higher potency than the 
globular isomer (IC50 = 1.2 nM) in rat parasympathetic neurons (137). By contrast, another 
study showed that globular AuIB has more potency than the ribbon AuIB on α3β4 nAChR 
expressed in Xenopus oocytes (138). Grishin et al. suggested that these apparently conflicting 
results could be explained if the two isomers of AuIB have differential sensitivity to the two 
main stoichiometries of the α3β4 nAChR, i.e. if they have different activity at (α3)3(β4)2 and 
the (α3)2(β4)3 (139). A mutational study of globular AuIB was carried out, and Phe9 was shown 
to be the most critical residue for the activity (140). The mutational study of ribbon AuIB is 
reported in Chapter 3. 
TxIA 
α-Conotoxin TxIA belongs to the 4/7 class and selectively blocks α3β2 nAChR. The globular 
TxIA potently inhibited rat α3β2 nAChRs with an IC50 of 5.4 nM, whereas the ribbon TxIA 
has an IC50 of 430 nM (141). The bead isomer has little activity at the α3β2 nAChR at 5 µM. 
Globular TxIA was shown using circular dichroism to have an α-helical structure because the 
CD spectrum displayed two minima around 208 nm and 222 nm. The bead TxIA exhibited a 
minimum at around 200 nm, suggesting a random coil conformation and no α-helical or β-sheet 
structure. Interestingly, the CD spectrum of the ribbon isomer was between those of the 
globular and bead isomers (141).  
AusIA 
α-Conotoxin AusIA was isolated from Conus australis, and it was the first member of 5/5 α-
conotoxin class to be identified. Both globular and ribbon isomers of AusIA are antagonists of 
α7 nAChR with IC50 values of 11.68 ± 1.53 μM and 9.67 ± 0.01 μM, respectively (142). An 
NMR spectroscopy analysis of the two isomers concluded that they do not have a folded 
structure (142).  
 
GeXIVA 
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αO-Conotoxin GeXIVA was predicted to exist from transcriptome analysis of Conus generalis 
venom duct (143). The synthesised peptide inhibits both human and rat α9α10 nAChR and has 
potential in treating neuropathic pain in an animal model (143-145). Surprisingly, the three 
isomers of GeXIVA have similar activity, with the bead and ribbon being slightly more potent 
than the globular isomer (IC50: bead = 4.6 nM (rat), 20.3 nM (human); ribbon = 7 nM (rat), 
47.3 nM (human); globular = 22.7 nM (rat), 116 nM (human)) (143,145).  
α-Conotoxin isomers targeting calcium channels via GABAB receptor activation 
Recently, α-conotoxins Pn1.2 (4/6 class), Pu1.2 (4/7 class) and Vc1.1 (4/7 class) were reported 
to act on high voltage-activated calcium channels via GABAB receptor activation, and the non-
native isomers can be as potent as the globular peptides at this target. The 3D structures of three 
isomers of Pu1.2 were determined which showed that the globular and ribbon Pu1.2 had a well-
defined structure compared to that of the bead Pu1.2. The RMSD from Cys3-Pro8 of Pu1.2 
isomers was less than 1 Å which helped Carstens et al. to identify a simplified biologically 
active peptide motif (116). Likewise, globular α-conotoxin Lt1.3 (4/7 class) acts on the α3β2 
nAChR whereas the ribbon Lt1.3 inhibits GABAB receptor-coupled Cav2.2. The circular 
dichroism spectra results indicated the globular Lt1.3 has a helical structure whilst ribbon Lt1.3 
does not (146).  
Table 1.3 The sequence and cysteine framework folding class of ribbon or bead α-conotoxins  
Peptide Sequence 
Cysteine framework 
folding class 
GI ECCNPACGRHYSC-NH2 framework I 3/5 class 
ImII ACCSDRRCRWRC-NH2 framework I 4/3 class 
BuIA GCCSTPPCAVLYC-NH2 framework I 4/4 class 
AuIB GCCSYPPCFATNPDC-NH2 framework I 4/6 class 
Pu1.2 GGCCSYPPCIANNPLC-NH2 framework I 4/6 class 
TxIA GCCSRPPCIANNPDLC-NH2 framework I 4/7 class 
PnI.2 GCCSHPPCFLNNPDYC-NH2 framework I 4/7 class 
Vc1.1 GCCSDPRCNYDHPEIC-NH2 framework I 4/7 class 
Lt1.3 GCCSHPACSGNNPYFC-NH2 framework I 4/7 class 
AusIA SCCARNPACRHNHPCV framework I 5/5 class 
GeXIVA TCRSSGRYCRSPYDRRRRYCRRITDACV framework XIV 
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1.5 Aims and scope of this thesis 
So far, most studies on α-conotoxins have focused on the globular isomer, also called the 
“native isomer”, because it is typically displayed by the wild-type conotoxins. Nevertheless, it 
has been shown in one instance that the venom of a cone snail can contain the ribbon isomer 
of an α-conotoxin, albeit in much smaller quantity than the corresponding globular isomer 
(147). As noted already, recent studies have shown that ribbon and/or bead isomer of α-
conotoxins can be used in drug design application and can have potencies equal to or greater 
than the native isomer (116,137,143,146). This thesis focuses on investigating the SAR of the 
ribbon isomer of a range of α-conotoxins, providing the basis for using the α-conotoxin ribbon 
isomer as a scaffold in drug design to target nAChRs. The specific aims of this thesis are: 
Aim 1: To design analogues of the ribbon GeXIVA with the aim of improving its folding yield.  
Aim 2: To underdstand the interactions of ribbon α-conotoxin AuIB (rAuIB) to the α34 
nAChR.  
Aim 3: To identify the best energy calculation method that can be used in the design of α-
conotoxin analogues. 
Aim 4: To design stoichiometry-specific inhibitors of the nAChR stoichiometry based on a 
ribbon α-conotoxin scaffold. 
 
This thesis comprises six chapters, including four chapters containing new experimental data 
as well as an introduction chapter (Chapter 1) and a conclusion chapter (Chapter 6). The 
experimental chapters (2-5) are each focused on one of the specific aims. 
 
Aim 1 focused on the improvement of the oxidation yield of αO-conotoxin ribbon GeXIVA 
(Chapter 2). In Chapter 2, backbone cyclisation of αO-conotoxin GeXIVA facilitated direct 
folding of the ribbon isomer. This improved the folding yield by 17-fold higher than the 
uncyclised ribbon GeXIVA obtained by two-step oxidation. This study showed that ribbon α-
conotoxins can be engineered to have favourable properties to inhibt nAChRs. Therefore, it is 
necessary to investigate the binding mode of the ribbon α-conotoxin at nAChRs, which can be 
used to design ribbon α-conotoxins.   
 
Aim 2 explored the binding mode of the ribbon isomer at nAChRs (Chapter 3). In Chapter 3, 
the binding mode of rAuIB at α3β4 nAChR was built. Similar to globular α-conotoxins, the 
molecular model indicates that the first loop of rAuIB binds in the “aromatic box” of the 
Chapter 1: Introduction 
 
18 
 
acetylcholine orthosteric binding site. In contrast, the second loop and the termini of the ribbon 
isomer have different orientations and interactions in the binding sites to those of the globular 
α-conotoxins. 
 
Aim 3 identified the best energy prediction method (Chapter 4). In Chapter 4, four energy 
prediction methods were benchmarked. Foldx was the most reliable method. It successfully 
predicted which mutants would have increased and decreased affinities with the receptor. 
Therefore, it is a valuable computational tool to design ribbon α-conotoxin mutants.  
 
The findings from Aims 2 and 3 were applied in Aim 4 to design selective and potent α4β2 
nAChR inhibitors (Chapter 5).  In Chapter 5, the binding mode of ribbon [Gla4E]GID with 
(α4)3(β2)2 nAChR was built using information on the binding mode of rAuIB studied in Aim 
2. Foldx predicted mutational energies of ribbon [Gla4E]GID at (α4)3(β2)2 nAChR, and S7L, 
S7M, S7P, H17P and V18F mutants of ribbon [Gla4E]GID were suggested to have desirable 
properties to inhibit (α3)3(β4)2 nAChR.  
 
Overall, the design of ribbon α-conotoxins is an alternative strategy to develop specific nAChR 
inhibitors.  
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2.1 An overview of cyclisation of conotoxins 
In this Chapter, some general principles for the cyclisation of conotoxins are described and 
then the cyclisation of individual conotoxins is discussed in more detail. Knowledge of the 3D 
structure of a conotoxin can help in the design of a linker to cyclise its backbone, and thereby 
potentially improve its biopharmaceutical properties. Factors that influence successful 
cyclisation include the distance between the N- and C- termini, their flexibility, and the 
positions in the sequence of cysteine and other residues essential for activity. Too short a linker 
can strain the structure and too long a linker can result in difficult folding, increase degradation 
by endoproteases and reduce biological activity. In principle, any amino acid can be used to 
constitute a linker sequence (1) but Gly and Ala residues are often employed because they are 
small and their side chains cannot form hydrogen bonds, which could potentially disrupt the 
active fold. No more than two consecutive amino acid residues of the same type are used in the 
linker to avoid overlap in the NMR spectra (2,3).  
 
The primary method for cyclisation of peptides assembled using solid-phase peptide synthesis 
(SPPS) is native chemical ligation (NCL) (4). The NCL approach involves a reaction whereby 
an N-terminal cysteine residue and a C-terminal thioester undergo a thioester exchange 
followed by an intermolecular rearrangement to create a new amide bond. Any conotoxin 
containing both a N-terminal cysteine residue and a C-terminal thioester can potentially be 
cyclised using the NCL method. NCL has been successfully applied to cyclise a number of 
conotoxins, as illustrated in Figure 2.1 A, as well as other peptides (5-7). Recently, a 
straightforward in-solution cyclisation method has been developed to cyclise peptides ranging 
in size from 26 to 34 residues (Figure 2.1 B) (8). The NCL approach has also been 
complemented by semi biological approaches (Figure 2.1C and D). In particular, several 
enzymes have been reported to have the function of cyclisation (9-11). Enzyme-mediated 
cyclisation of synthetic linear peptides is fast and efficient, and so far has been applied to 
cyclise the backbone of three exemplary conotoxins, Vc1.1, MrIA and PVIIA.  
 
Overall, 10 conotoxins have been cyclised to date, using chemical or enzymatic approaches. 
Six of these conotoxins are globular or ribbon Framework I, and the other four toxins have a 
knottin fold and a Frameworks VI/VII or IX (Table 2.1; Figure 2.2).  
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Figure 2.1. Cyclisation of conotoxins. A: cyclisation using native chemical ligation; B: 
cyclisation using chemical amide coupling; C and D: cyclisation using enzymes. The use of 
Sortase A requires the incorporation of sortase recognition sequence (green) at the C-terminus 
and GG (blue) at the N-terminus. By contrast, only an Asn recognition residue (green) is needed 
for butelase-mediated cyclisation. 
 
Figure 2.2 The 3D solution structures of representative globular (Vc1.1; PDB: 2H8S), ribbon 
(MrIA; 2EW4) and knottin conotoxins (MVIIA; 1TTK). 
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Table 2.1 Summary of cyclic variants of conotoxins  
Name Target(s) Linker(s) 
Activity  
Cyclic vs. Linear 
% Improvement in stability 
of the cyclic variants Stability assays  
Globular Ribbon Globular Ribbon 
MII(2) α6* nAChR[a] GAGGAAG[b] NC[c] ND[d] 
~40%; 
~20% 
ND 
EndogluC (10 h) 
and human serum  
ImI(12) 
α3β2, α7 and α9 
nAChRs 
A/βA[e] ND ND ~75% NC Trypsin (5 h) 
Vc1.1(9,13) 
α9α10 nAChR & 
CaV via GABAB 
receptor 
GGAAGG 
Reduced ND 
~15%; 
~30%; 
~25% 
ND 
Simulated gastric 
fluid, simulated 
intestinal fluid and 
human serum  
Improved ND 
 GLPETG[f] ND ND ND ND ND 
RgIA(3) 
α9α10 nAChR GGAAGAG NC ND ~ 15% ND 
Human serum  
GABAB receptor GGAAGG NC ND ~ 10% ND 
AuIB(14,15) α3β4 nAChR 
AG Reduced NA[g] ~ 30% ~ 50% Chymotrypsin (48 
h) AGGG Reduced NA ND > 75% 
GGAA Reduced Reduced NC NC Human serum  
MrIA(6,11,16) 
Norepinephrine 
transporter 1 
AG ND NC ND ~ 40% Trypsin  
RGD ND NC ND ~ 50% Rat plasma  
LPX[h]TG[f] ND ND ND ND ND 
MVIIA(17) N-type Cav2.2 GGPG ND ND ND 
PVIIA(18) Shaker Kv  LPETGG[f] Reduced Reduced by ~ 50% Human serum 
Gm9a(19) ND GLP ND NC[i] Human serum  
Bru9a(19) ND GLP ND NC[i] Human serum  
[a] Nicotinic acetylcholine receptor. [b] There is a conflict between the linker sequence 
reported in the article and that reported in the supporting information and the NMR solution 
structure of cMII-7; the latter sequence shown here was confirmed by the authors (personal 
communication) [c] No changed. [d] Not determined. [e] Ala and Ala gave better yield for 
the ribbon and globular isomers, respectively. [f] Enzyme-mediated cyclisation. [g] No activity 
(IC50 > 300 µM). [h] Any amino acids. [i] Linear Gm9a and Bru9a are naturally highly stable. 
The incubation time of stability assay is specified in the brackets following the biological fluids 
or enzymes if different from 24 h. 
2.1.1 Framework I conotoxins (two disulfide bonds) 
As illustrated in Table 1.1 in Chapter 1, the primary sequences of Framework I conotoxins 
display the cysteine pattern CC-C-C, which has been found in more than 300 conotoxins to 
date. 
2.1.1.1 Globular isomers 
Most native Framework I α-conotoxins have the globular disulfide connectivity (Cys I-Cys III, 
Cys II-Cys IV). These conotoxins have been the most extensively studied substrate for 
cyclisation approaches. 
α-Conotoxin MII 
The first report on the cyclisation of a conotoxin was that of the 16-residue 4/7 α-conotoxin 
MII (2), which derives from Conus magus and is highly potent and specific at the α6* nAChR 
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subtype (20). The short distance between its N- and C- termini made MII an ideal conotoxin to 
be backbone cyclised (21). Three linkers, GGAAG, GGAAGG and GAGGAAG, were 
designed, and three corresponding cyclic MII variants, cMII-5, cMII-6 and cMII-7, were 
successfully synthesised using SPPS and cyclised using NCL. The yield of cMII-5 was <10%, 
whereas cMII-6 and cMII-7 folded with yields of around 50% and 90%, respectively. An 
analysis of Hα NMR secondary chemical shifts suggested that cMII-6 and cMII-7 had a similar 
structure to linear MII but cMII-5 did not. The solution NMR structures of cMII-6 and cMII-7 
are well defined with their backbone RMSD from the average structure is 0.41 and 0.43 Å, 
respectively. The structures were consistent with that of native MII, with a backbone RMSD 
of 0.5 Å from residues Gly1 to Cys16. 
 
Native MII and cyclic variants were tested for their ability to inhibit nicotinic-evoked currents 
in bovine chromaffin cells. cMII-7 had similar activity to native MII and cMII-6 was slightly 
less potent than native MII, whereas cMII-5 had no activity. This study demonstrates that the 
length of the cyclising linker can have a major influence on biological activity. The stability of 
MII and its analogues were tested for degradation by endoproteinase GluC (EndoGluC) and 
proteases in human serum. After 24 hours, cMII-6 and cMII-7 had 15-20% more peptide 
remaining than linear MII in human serum, indicating that cyclisation is indeed an effective 
strategy to improve the stability of MII with no loss of potency. 
α-Conotoxin ImI 
ImI selectively inhibits the α7 neuronal nAChR among all rat nAChR subtypes. But for human 
nAChR subtypes, it blocks the human α3β2 nAChR with 10-fold more potency than at the 
human α7 nAChR (22,23). The NMR solution structure shows that the distance between the 
N- and C- termini is ~9.5 Å (24), suggesting that only a short linker would be required for 
cyclisation. 
 
Armishaw et al.(12) designed four linkers (A, βA, AG and AGG) and used a one-pot oxidation 
method to form the disulfide bonds. For all cyclic variants, all three possible disulfide bond 
connectivities (globular, ribbon and bead) were observed. Wild-type ImI preferentially formed 
the globular isomer (96%), whereas the cyclic variants mainly folded into the ribbon isomer, 
with the exception of cImI-βA. The length of the cyclisation linker was found to impact the 
yield of ribbon isomer, with the yield of ribbon varying with the different lengths of linkers. 
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Interestingly, the yield of bead isomer was higher than that of the globular isomer for cImI-
AG. These results suggest that the length of the linker plays a crucial role in directing the 
disulfide bond connectivity. Overall, it can be concluded that the structure of the globular 
isomer of ImI with short linkers is highly constrained and disfavoured under normal folding 
conditions, as compared to the ribbon isomer. 
 
Stability assays were performed to test proteolytic susceptibility to trypsin. Overall, the results 
demonstrated that backbone cyclisation could make the native isomer of ImI more resistant to 
trypsin degradation. The globular isomers of cyclic ImI were the most resistant to proteolytic 
degradation, especially the globular of cImI-A, for which almost 95% peptide remained after a 
5-hour incubation with trypsin, whereas wild-type ImI only had 20% peptide remained. The 
stability of the cyclic variants of the ribbon isomers was not significantly improved compared 
to the wild-type ImI, indicating that cyclisation is not the only factor that leads to peptide 
stability for non-native disulfide isomers. For examples, the disulfide bonds can be reduced by 
glutathione.  
α-Conotoxin Vc1.1  
Conotoxin Vc1.1 targets the α9α10 nAChR and the N-type calcium channel via the GABAB 
receptor (25-27). In several animal models, this peptide has been shown to have potential as a 
treatment for neuropathic pain (28). However, Vc1.1 is susceptible to disulfide shuffling and 
degradation by proteases, and backbone cyclisation of this peptide was successfully applied to 
stabilise it against enzymatic proteolysis (13).  
 
Based on Vc1.1 NMR solution structure, the distance between the N- and C- termini is ~12 Å, 
which is similar to that of MII. Two linkers with five and six residues, respectively, were 
designed: GGAAG and GGAAGG. Under thermodynamic conditions, both globular and 
ribbon isomers formed in the proportions of 72:28 for cVc1.1-6 and 50:50 for cVc1.1-5. NMR 
chemical shift analysis suggested that the globular isomers of both cVc1.1-5 and -6 were 
similar to wild-type Vc1.1. The solution structure of cVc1.1-6 evidenced that the side chains 
and backbone had similar conformations to those of linear Vc1.1. Cartstens et al. investigated 
the effects of the composition of linker sequence of Vc1.1 on the structure, activity and 
stability, the results showed that non-neutral amino acids in the cyclising linker sequence can 
have a negative effect on biological activity but not for structure and stability (29). 
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cVc1.1-5 showed a substantial loss of activity in inhibiting the nAChR in adrenal chromaffin 
cells, whereas cVc1.1-6 retained the activity of linear Vc1.1. cVc1.1-6 was tested for inhibition 
of both rat α9α10 nAChR and high voltage-activated (HVA) calcium channels in rat DRG 
neurons. cVc1.1-6 was more potent at inhibiting the HVA calcium channels with full biological 
activity via the GABAB receptor than linear Vc1.1, with IC50 values of 0.3 and 1.7 nM, 
respectively. By contrast, the activity at the rat α9α10 nAChR dropped 10-fold, from IC50= 64 
nM (Vc1.1) to IC50= 765 nM (cVc1.1-6). The solution structure of cVc1.1-6 suggests that the 
linker might interfere with binding of Ser4 and Asp5, which have both been shown to be 
important for activity at nAChR. This same region of the sequence was recently reported to be 
crucial for activity on HVA calcium channels (30).  
 
Using the chronic constriction injury model of neuropathic pain in rats, cVc1.1-6 delivered 
orally was 120-fold more potent than gabapentin, which is in clinical use. By contrast, linear 
Vc1.1 had no effect in a similar assay, suggesting that cyclisation was responsible for 
introducing the oral activity. In a more recent study, cVc1.1-6 and its analogous, 
[C2H,C8F]cVc1.1 and [N9W]cVc1.1, showed to have the ability to inhibit colonic nociceptors 
and to reduce chronic abdominal pain in a mouse model (31). The stability of linear Vc1.1 and 
cVc1.1-6 in three different fluids was measured. Compared to Vc1.1, stability was only slightly 
improved in simulated gastric fluid, but remarkably improved in both simulated intestinal fluid 
and human serum. cVc1.1-6 was significantly more stable than Vc1.1, judged by increased 
amounts remaining after 24 hours in all three assays. Cyclisation also prevented the shuffling 
of disulfide bonds, which was suggested to occur for Vc1.1 in simulated intestinal fluid and 
human serum.  
 
Jia et al. (9) showed that Vc1.1 could be cyclised enzymatically using sortase A, a bacterial 
enzyme with transpeptidase activity. Sortase A recognises the “LPXTG” motif at the C-
terminus of a peptide, cleaving the amide bond between the Thr and Gly residues to form a 
thioacyl-linked intermediate, which in turn reacts with a N-terminal Gly residue to form a 
peptide bond. The linear substrate [G]Vc1.1[GLPETGGS] was synthesised and successfully 
cyclised by sortase A to yield cyclo-[G]Vc1.1[GLPET]. NMR Hα secondary chemical shift 
analysis suggested that there was no significant structural difference between cyclo-
[G]Vc1.1[GLPET] and cVc1.1-6. The biological activity and stability of cyclo-
[G]Vc1.1[GLPET] were not investigated. 
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α-Conotoxin RgIA 
RgIA inhibits the α9α10 nAChR and also blocks N-type calcium channels via activation of the 
GABAB receptor. Five linkers were designed to cyclise RgIA (3), with the longer ones 
(GAAGG, GGAAGG and GGAAGAG) resulting in similar structures to the parent globular 
isomer according to NMR Hα secondary chemical shifts. The shorter linkers (GAA and 
GAAG) resulted in peptides adopting a different conformation from RgIA, according to NMR 
chemical shifts, and were not further investigated. The NMR solution structure of cRgIA-6 
(with linker GGAAGG) was solved and revealed a well-defined structure, which is similar to 
RgIA. From an analysis of the NMR models, Loop 2 was suggested to be slightly more 
disordered than in RgIA. This difference in the resulting NMR models probably arose from 
broader NMR peaks and fewer NOEs near Tyr10 in cRgIA-6.  
 
cRgIA-7 was as potent as the parent peptide at inhibiting the hα9/rα10 nAChR expressed in 
Xenopus oocytes but the other four variants displayed reduced activity. Interestingly, the 
selectivity of cRgIA-6 for the calcium channel via the GABAB receptor was increased, as it has 
more than 10-fold higher inhibition of this pathway compared to its activity at hα9/rα10 nAChR 
whereas RgIA was equipotent at both target (3). Positions important for the activity of RgIA 
are not at the proximity of the termini in the sequence and therefore were a priori expected not 
to be affected by cyclisation. The unexpected higher flexibility of Loop 2 in cRgIA-6 could 
have affected the interaction of Arg9, which is important for binding to α9α10 nAChR, 
providing a possible explanation with the decreased activity at this receptor. 
 
The stability of linear RgIA and of all cyclic analogues was assayed in human serum. About 
8% of linear RgIA remained after 5 hours, whereas 57% and 46% of cRgIA-6 and cRgIA-7 
remained at the same time-point, respectively, showing the significantly improved stability 
brought about by backbone cyclisation.  
α-Conotoxin AuIB 
α-Conotoxin AuIB selectively inhibits the α3β4 nAChR (32, 33), which is implicated in the 
mediation of signalling in various physiological systems, including ganglionic transmission 
peripherally and nicotine-evoked neurotransmitter release centrally (34).  
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Armishaw et al.(14) designed seven linkers, varying in length from one to seven residues (A, 
AG, AGG, AGGG, GGAAG, GAGAAG and GGAGGAG), to cyclise AuIB. The cyclic 
peptides were folded using a one-pot oxidation procedure. Cyclic peptides using the short 
linkers A, AGG or AGGG preferentially formed the ribbon isomer, whereas other cyclic 
variants, ie using two-, five-, six- or seven-residue linkers, folded into both globular and ribbon 
isomers. All cyclic AuIB analogues lost their activity at the rat α3β4 nAChR except cAuIB-2 
globular isomer, which had only slightly reduced activity (three-fold) compared to AuIB. In a 
stability assay carried out in the same study, the parent peptide was >90% degraded after a 48-
hour incubation with chymotrypsin but ~40% of cAuIB-2 globular isomer remained and >90% 
of cAuIB-3, -4, -5, -6 and -7 ribbon isomers remained. 
 
In an independent study, Lovelace et al. (15) cyclised AuIB using four different linkers 
(GGAA, AGAGA, GGAAGG and GGAAAGG). A one-pot oxidation method was also used 
to form the disulfide bonds. Similarly to Armishaw et al., the four-residue linker cyclic peptide 
folded into a ribbon isomer, whereas cyclic peptides using longer linkers of five, six or seven 
residues resulted in a mixture of ribbon and globular isomers. In contrast to Armishaw et al., 
the preponderant isomer of five and six residue linker cyclic peptides was the globular isomer, 
indicating that the nature of the linker and its size affect disulfide connectivities. The NMR 
solution structures of globular cAuIB-4, -5 and -6 were solved, showing that these three 
globular isomers had a similar structure to their parent peptide. The structures of the ribbon 
isomers could not be determined because their NMR spectra contained few NOEs, suggesting 
that their structures were not well defined.  
 
All cyclic peptides showed decreased or no activity at the α3β4 nAChR expressed in oocytes 
compared to AuIB. The most active analogue active was globular cAuIB-4, which reduced 
65% of the current at 3 µM, compared to 50% reduction at the same concentration for globular 
AuIB. Ribbon cAuIB-4 was the most active cyclic ribbon isomer, with 65% current reduction 
at 10 µM compared to 50% for ribbon AuIB. A possible explanation for the decrease of activity 
of the cyclic variants is that the N-terminal Gly1 was shown to be important for activity, and 
the cyclisation linker might affect its interaction with nAChR.  
 
Overall, cyclisation of AuIB can improve, to some extent, its stability as less than 5% of the 
linear ribbon isomer remained after a 24-hour incubation in human serum, whereas >70% of 
the linear globular and all cyclic variants (both the globular and ribbon isomers) remained.  
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2.1.1.2 Ribbon isomers 
As noted earlier, ribbon isomers are much less common than globular isomers amongst native 
conotoxins but some interesting conotoxins adopt this fold. For example, MrIA, has been 
extensively studied and has been the subject of both chemical and chemo-enzymatic cyclisation 
approaches. 
χ-Conotoxin MrIA 
This 13-residue conotoxin was the first ribbon conotoxin to be cyclised. The analogue of MrIA 
that progressed to clinical trials as an inhibitor of the NET, Xen2174, has a modified N-
terminus, i.e. a pyroglutamic acid, which led to an increase in plasma stability. After a 6-hour 
incubation in plasma, ~70% of Xen2174 remained compared to ~50% for the parent peptide, 
ie the improvement in stability was of 20% (35).  
 
Chemical cyclisation rather than just N-terminal modification has been used as an alternative 
approach to further improve the stability of MrIA (6,16). MrIA has a β-hairpin structure, and 
the two termini are in spatial proximity. As a result, a short peptide linker of only two amino 
acid residues (AG) could be used to cyclise MrIA, resulting in a compound, cMrIA-AG, with 
a similar structure and activity to the parent peptide (16). The cyclic peptide was substantially 
more resistant to trypsin digestion than the parent peptide, with 97% of cMrIA-AG remaining 
compared to ~55% of linear MrIA after 24 hours of incubation with trypsin. Amide exchange 
rates monitored by NMR spectroscopy evidenced that cMrIA-AG was more rigid than the 
native peptide. The improved resistance toward endoproteases such as trypsin, of cMrIA-AG 
was suggested to originate from this backbone increased rigidity (16).  
 
In a recent study, cMrIA-AG was used as a scaffold to stabilise the RGD motif, which targets 
the integrin receptor αIIbβ3 and prevents platelet aggregation (6). This study aimed at 
incorporating two pharmacophores in the same peptide, which could then interact with two 
different targets. Because Gly6, Tyr7, Lys8, Leu9 and His11 of MrIA are important for binding 
to the NET, Asn1 and Ala14 of cMrIA-AG were replaced by Asp1 and Arg14, respectively, to 
form the RGD motif in the cyclisation linker. The NET inhibitory activity of cMrIA-RGD was 
similar to that of MrIA, and the grafted RGD peptide also prevented platelet aggregation. 
Interestingly, cMrIA-RGD displayed better plasma stability than cMrIA-AG, with >50% and 
~30% remaining after 24 hours of digestion, respectively. From mass spectrometry data, the 
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authors propose that Asn1 of cMrIA-AG can be deamidated in rat plasma but Asp1 of cMrIA-
RGD cannot, providing an explanation for the difference of stability (6).  
 
MrIA has also been recently cyclised enzymatically using butelase 1(11), a naturally occurring 
asparaginyl endopeptidase (AEP) from the butterfly pea plant (Clitoria ternatea) that is 
involved in the biosynthetic production of cyclotides (11). The enzyme requires an Asn or Asp 
residue followed by the dipeptide His-Val at the C-terminus of the linear substrate peptide to 
be cyclised (Figure 2.1 C). The dipeptide is ultimately cleaved off during the ligation reaction 
(11). The two residues His and Val were added to the C-terminus of synthetic linear MrIA-AG 
to create a substrate for butelase. The enzymatic reaction was very rapid (12 minutes) and the 
yield of cyclisation was >95% (11), demonstrating the value of chemoenzymatic cyclisation. 
However, biological assays and structure and stability assays were not performed, and further 
studies are required to confirm whether cyclic MrIA generated by butelase 1 can retain the 
native biological activity and improved stability. At the time of writing, butelase 1 had not been 
able to be produced recombinantly, but Harris et al.(36) recently reported recombinant 
production of an AEP from Oldenlandia affinis – a very efficient cyclising agent for a range of 
peptides. We anticipate that chemoenzymatic cyclisation of conotoxins and a variety of other 
peptides will be facilitated by this development. 
2.1.2 Framework VI/VII conotoxins (three disulfide bonds) 
As illustrated in Chapter Table 1.1, Framework VI/VII conotoxins contain the cysteine pattern 
C-C-CC-C-C, a very common pattern, found in more than 600 conotoxins to date. This is the 
pattern of MVIIA, a 25-residue conotoxin that has attracted significant attention for its 
therapeutic applications. 
ω-Conotoxin MVIIA  
MVIIA blocks N-type calcium channels and was the first conotoxin-based drug approved to 
treat neuropathic pain (37,38). It contains three disulfide bonds that are connected to form an 
inhibitor cystine knot (ICK) motif, which is a particular class of knottin (in practice, the term 
knottin and cystine knot are used interchangeably). MVIIA is administered to patients 
intrathecally, a route of administration that has limited the market of this drug to severe or 
intractable pain cases (39). Backbone cyclisation of MVIIA was reported in the early patent 
literature and more recently by Hemu et al. (17).  
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Tert-butoxycarbonyl (Boc) solid phase peptide synthesis is typically used to synthesise cyclic 
peptides because the thioesters used in NCL are not compatible with the repetitive piperidine 
deprotection steps and base solutions in fluorenymethoxycarbony (Fmoc) chemistry. HF acid 
treatment is required to deprotect side chains in Boc chemistry, but using such strong acid is 
inconvenient because it requires specialised equipment and is potentially hazardous. Thus, it is 
of interest that Hemu et al. succeeded in using Fmoc chemistry to synthesise cyclic conotoxins. 
Specifically, they developed an N-methyl Cys (MeCys) thioester surrogate, which they used to 
synthesise cyclic MVIIA with a four-residue linker (GGPG). The disulfide bonds with native 
connectivity (Cys I-Cys IV, Cys II-Cys V and Cys III-Cys VI) were formed after the cyclisation 
reaction.  
k-Conotoxin PVIIA  
PVIIA blocks the shaker Kv channel with an IC50 of 57 nM (40). This conotoxin exhibits 
cardio-protective properties in animal models and has clinical potential associated with cardiac 
reperfusion (41). As for MVIIA, it contains three disulfide bonds which form an ICK motif.  
Kwon et al. showed that the ICK PVIIA could also be cyclised enzymatically using sortase A, 
which was successfully applied to cyclise Vc1.1, as noted in the last section. The linear 
[GGG]PVIIA[LPETGG] was cyclised to cyclic PVIIA with the yield of 57 % after 8 h 
incubation in sortase A. Interestingly, the cyclic PVIIA reduced activity on shaker Kv channel 
with IC50 value of 824 ± 60 nM which was 10-folds higher than that of native PVIIA (IC50: 80 
± 5 nM), although the 3D structures and overall backbone conformations of the cyclic and 
acyclic PVIIA are high similar. Molecular modelling results indicated that the N-terminus of 
PVIIA was required for an interaction between PVIIA and the shaker Kv channel, which 
possibly resulted in the drop of the potency of cyclic PVIIA. The N-terminus acetylated PVIIA 
was synthesised and the activity decreased by 20-fold compared to PVIIA, which confirmed 
the hypothesis. Surprisingly, the PVIIA remained intact after 12 h incubation in human serum 
whereas only ~ 50 % of cyclic PVIIA was detected. But there is no accurate interpretation for 
this finding (18).  
2.1.3 Framework IX conotoxins (three disulfide bonds) 
Framework IX conotoxins have the cysteine pattern C-C-C-C-C-C and are relatively limited in 
number (Table 1.1 in Chapter 1) but two examples from this family have been cyclised recently, 
as described below.  
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Conotoxin gm9a and bru9a 
The conotoxins gm9a and bru9a have three disulfide bonds that form an ICK, similarly to other 
toxins displaying a Framework VI/VII. A cystine knot embedded within a cyclic backbone is 
referred to as a cyclic cystine knot framework, which is a structural motif that has been widely 
used in developing new treatments for a range of diseases, including pain, cancer, 
cardiovascular disease and multiple sclerosis (42). Thus, the cyclisation of Framework IX 
conotoxins provides a strong link to grafting studies of cyclotide, which share the same 
framework. As an illustration of this, a recent study reported the cyclisation of gm9a and bru9a, 
thereby transforming their ICK motif into a cyclic cystine knot motif (19). It should be noted 
that the biological target of these peptides is still unknown, but cyclisation was attempted as a 
proof-of-concept that conotoxins displaying an ICK motif could be cyclised. 
 
The primary purpose of cyclisation is typically to improve the stability of peptides, while 
maintaining their biological activity. The ICK motif is already highly stable and the aim in 
cyclising. Framework IX conotoxins were to prove that cyclisation can be applied to 
conotoxins with an ICK motif. Using a 3-residue Gly-Leu-Pro linker, which is present in the 
cyclisation loop of cyclotides, both gm9a and bru9a were successfully cyclised. The NMR 
solution structures of the two cyclic peptides were well-defined with mean backbone RMSD 
to the average structure of 0.16 Å for cyclic gm9a and 0.46 Å for cyclic bru9a. Both cyclic 
peptides had similar structures to their parent peptide.  
The linear and cyclic peptides were both very stable in human serum with ~90% peptide 
remaining after 24 hours(19). This result is consistent with a previous study that reported the 
cystine knot being more important than the cyclic backbone for stabilizing peptides against 
endo-proteases (43).  
2.2 Introduction 
The sequence of conotoxin GeXIVA was identified recently in a transcriptome analysis of the 
venom duct of Conus generalis (44). This 28-amino acid peptide has four cysteines (Cys I–IV) 
which can theoretically form three isomers depending on the disulfide connections: globular  
(Cys I-Cys III; Cys II-Cys IV); ribbon (Cys I-Cys IV; Cys II-Cys III) or bead (Cys I-Cys II; 
Cys III-Cys IV) as shown in Figure 2.3. The bead and ribbon isomers are slightly more potent 
than the globular on both human and rat α9α10 nAChR (44). NMR structure calculations have 
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shown that ribbon GeXIVA is flexible, while still having a more defined structure than the 
other two isomers (44). These isomers exhibit higher or similar potency at rat α9α10 nAChR 
compared with Vc1.1 (45) or RgIA (46). In addition, the ribbon and bead isomers of GeXIVA 
showed promise in relieving neuropathic pain in a chronic constriction injury model and also 
in a tail flick model of acute pain (47). 
Figure 2.3 The three isomers of α-conotoxin GeXIVA and the 3D NMR solution structure 
of ribbon GeXIVA (44). Cys residues are numbered with Roman numerals (I–IV) and the 
disulfide bonds are shown as yellow sticks; the structure shown for the ribbon GeXIVA is the 
lowest energy conformer from an ensemble of 10 NMR models.  
 
Despite significant therapeutic properties of α-conotoxins, one major challenge is that the 
delivery of the conotoxin-based drugs to their receptors is potentially hindered by their 
susceptibility to proteolytic degradation in a biological fluid (48-50). Backbone cyclisation of 
conotoxins is a robust and effective method to improve the stability of conotoxins and also can 
improve the activity of conotoxins (13,51). In this Chapter, we investigated whether a similar 
strategy could be used for αO-conotoxin GeXIVA. We used backbone cyclisation to control 
the selective formation of the ribbon isomer and investigated the effects of cyclisation on 
structure, activity and stability. The ribbon isomer is formed by the oxidation of two cysteine 
residues located near the N- and C-termini of the peptide, suggesting that backbone cyclisation 
could be used to direct the selective formation of the resultant disulfide bond. The three isomers 
of linear GeXIVA and a suite of cyclic ribbon GeXIVA analogs were synthesised, and their 
stabilities in human serum and biological activities at the human α9α10 (hα9α10) nAChR were 
tested.  
2.3 Methods and materials 
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2.3.1 Design of linkers 
Linkers were designed using molecular modelling. The structure of the ribbon isomer cyclised 
with linkers from one to five amino acid residues was modelled. Fifty models of the backbone 
cyclised ribbon GeXIVA were generated for each of the linkers using Modeller 6v13 (52), and 
the conservation of ribbon GeXIVA native conformation was measured by computing the mean 
Cα RMSD between the models and the 20 lowest-energy NMR structures (44). 
2.3.2 Peptide synthesis, cyclisation, oxidation and purification of peptides 
The three isomers of GeXIVA and the three cyclic analogs (cGeXIVA_G, cGeXIVA_GG and 
cGeXIVA_GAG) were synthesised using Fmoc-based solid phase peptide synthesis on an acid-
sensitive resin 2-chlorotrityl chloride. Side chains of Cys residues were protected in pairs with 
orthogonal protective groups that can be removed selectively under different oxidation 
conditions. The acid-labile trityl group was used to protect the side chains of Cys2 and Cys27, 
and acetamidomethyl group to protect Cys9 and Cys20 for the ribbon GeXIVA and its cyclic 
variants. The backbone cyclisation of cyclic variants was achieved using the protocol described 
recently (8). Briefly, a solution of 1% TFA in dichloromethane (v/v) was used to cleave the 
linear precursor peptides of the cyclic variants off the resin. The side chain protected precursor 
peptides were dried, cyclised in O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
hexafluorophosphate (5 mM) and N,N'-diisopropylethylamine (10 mM) in N,N -
dimethylformamide for 3 h and lyophilized. The protecting group on side chains was removed 
in TFA with 2% triisopropylsilane and 2% water (v/v) for 2 h.  
 
A two-step oxidative folding was used to form disulfide bonds: the first disulfide bond was 
formed in 0.1 M ammonium bicarbonate (NH4HCO3; pH 8.3) at room temperature (21-24C) 
for 24 h and the second disulfide bond was formed in 0.1 M iodine solution for 1 h. All peptides 
were purified by reversed-phase high-performance liquid chromatography (RP-HPLC) using 
Phenomenex C18 columns (Gemini
®: 5µM, 110Å, 250 × 10mm; Jupiter®: 5µM, 300Å, 250 × 
4.6mm) and the purification method is 15-25% buffer B within 40 minutes (increasing 1% 
buffer B per 4 minutes). Buffer A is 0.05 % TFA in water and buffer B is 0.045% TFA in 90% 
acetonitrile. 
2.3.3 NMR spectroscopy 
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Samples of peptide 2 and its cyclic analogs were prepared by dissolving peptide (~1mg) in 
90% H2O/10% D2O at a pH of ~3. Spectra were recorded on a Bruker Avance III 600 MHz 
NMR spectrometer at 298K and included TOCSY (mixing times of 80ms), NOESY (mixing 
times of 200ms), H-N HSQC and H-C HSQC. Chemical shifts were referenced to internal 2, 
2-dimethyl-2-silapentane-5-sulfonate (DSS) at 0 ppm. Spectra were processed with Topspin 
(Bruker Biospin) and analysed with CcpNMR analysis (version 2.4.1) (53). Secondary αH 
chemical shifts were calculated as the difference between the observed αH chemical shifts and 
that of the corresponding residues in a random coil peptide (54). Structure calculations were 
based upon distance restraints as derived from NOESY spectra, and on backbone φ and ψ 
dihedral angle restraints generated using TALOS+ (55). A family of structures consistent with 
the experimental restraints was calculated using CYANA (56). 
2.3.4 Relaxation measurements 
NMR relaxation measurements were carried out as described previously (57). Briefly, 13C T1 
(spin-lattice) relaxation times were measured using the Bruker pulse program hsqct1etgpsi3d.2. 
Spectra were acquired with a spectral width of 10 ppm over 2048 complex points in the 1H 
dimension and 22 ppm over 60 complex points in the 13C dimension. To determine T1 values, 
nine relaxation delays in the range of 0.01 to 1.0 s were used. A recycle delay of 3 s was used. 
13C NOEs were measured using the pulse program hsqcnoegpsi.2. Peak volumes were 
measured in CCPNMR. A recycle delay of 5 s was used. All experiments were carried out in 
triplicate. Order parameters were calculated by a model-free analysis using the same protocol 
and target function as described previously (57), but here the goodness-of-fit for the NOE 
values were given a 25% weighting compared to the T1 values to allow for the higher 
uncertainty in the experimental NOE measurements. 
2.3.5 Folding assays 
Ribbon GeXIVA and cGeXIVA_GG were reduced with 10 mM dithiothreitol and isolated 
using RP-HPLC. Reduced peptides were dissolved in 0.1 M NH4HCO3 buffer (pH 8.3) at 20 
µM and stirred at room temperature. An aliquot of peptide solution was removed after 0, 1, 4, 
8, 12, 16, 20 and 24 h and quenched with 2% TFA. All samples were analysed with ultra-
performance liquid chromatography using a gradient 11–18% buffer B within 28 min 
(increasing 1% buffer B per 4 min) in an analytical Vydac C18 column (201TP5415: 5µM, 
300Å, 150 × 4.6mm). 
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2.3.6 In vitro cRNA synthesis  
Plasmid pT7TS constructs of human α9 and α10 nAChR subunits were linearised with XbaI 
restriction enzymes (NEB, Ipswich, MA) for in vitro cRNA transcription using T7 mMessage 
mMachine® transcription kits (AMBION, Foster City, CA).  
2.3.7 Oocyte preparation and microinjection 
Stage V-VI oocytes were obtained from X. laevis, defolliculated with 1.5 mg/ml collagenase 
Type II (Worthington Biochemical Corp., Lakewood, NJ) at room temperature (21−23 °C) for 
1−2 h in OR-2 solution containing (in mM) 82.5 NaCl, 2 KCl, 1 MgCl2 and 5 HEPES at pH 
7.4. Oocytes were injected with 35 ng cRNA for hα9α10 nAChR (concentration confirmed 
spectrophotometrically and by gel electrophoresis) using glass pipettes pulled from glass 
capillaries (3-000-203 GX, Drummond Scientific Co., Broomall, PA). Oocytes were incubated 
at 18 ºC in sterile ND96 solution composed of (in mM) 96 NaCl, 2 KCl, 1 CaCl2, 1 MgCl2 and 
5 HEPES at pH 7.4, supplemented with 5% fetal bovine serum, 50 mg/L gentamicin (GIBCO, 
Grand Island, NY) and 10000 U/mL penicillin-streptomycin (GIBCO, Grand Island, NY).  
2.3.8 Oocyte two-electrode voltage clamp recording and data analysis 
Electrophysiological recordings were carried out 2–5 days post cRNA microinjection. Oocytes 
expressing hα9α10 nAChRs were incubated in 100 μM BAPTA-AM ~3 h before recording. 
Two-electrode voltage clamp recordings were performed at room temperature using a 
GeneClamp 500B amplifier and pClamp9 software interface (Molecular Devices, Sunnyvale, 
CA) at a holding potential 80 mV. Voltage-recording and current-injecting electrodes were 
pulled from GC150T-7.5 borosilicate glass (Harvard Apparatus, Holliston, MA) and filled with 
3 M KCl, giving resistances of 0.3–1 MΩ. Oocytes were perfused with ND115 solution 
containing (in mM): 115 NaCl, 2.5 KCl, 1.8 CaCl2, and 10 HEPES at pH 7.4, using a 
continuous Legato 270 push/pull syringe pump perfusion system (KD Scientific, Holliston, 
MA) at a rate of 2 mL/min.  
 
Initially, oocytes were briefly washed with ND115 solution followed by 3 applications of 
acetylcholine (ACh) at a half-maximal effective concentration (EC50) of 6 μM ACh for hα9α10 
nAChR. Washout with bath solution was done for 3 min between ACh applications. Oocytes 
were incubated with peptides for 5 min with the perfusion system turned off, followed by co-
application of ACh and peptide with flowing bath solution. All peptide solutions were prepared 
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in ND115 + 0.1% bovine serum albumin. Peak current amplitudes before (ACh alone) and after 
(ACh + peptide) peptide incubation were measured using Clampfit 10.7 software (Molecular 
Devices, Sunnyvale, CA), where the ratio of ACh + peptide-evoked current amplitude to ACh 
alone-evoked current amplitude was used to assess the activity of the peptides at human 
nAChRs.  
 
All electrophysiological data were pooled (n = 4 to 12) and represent means ± standard error 
of the mean (SEM). Concentration-response curves were obtained using GraphPad Prism 7 
nonlinear regression analysis (GraphPad Software, La Jolla, CA, USA). The IC50 was 
determined from the concentration-response curve and reported with an error of the fit.    
2.3.9 Stability assays 
Serum stability of peptides was carried out in 25% human serum (human male AB plasma, 
Sigma-Aldrich) over 4 h using a 20 μM final peptide concentration. Serum was prepared by 
centrifugation at 17,000 g for 15 min to remove the lipid component, and the supernatant was 
diluted 1 in 4 in phosphate buffered saline and incubated at 37°C for 15 min before the assay. 
Each peptide was incubated in 25% human serum at 37°C and aliquots were taken out at time 
points 0, 1, 2, 3 and 4 h, respectively. Serum proteins were denatured with 2 M urea and 
precipitated with 20% TFA. All samples were centrifuged at 17,000 g for 10 min, and the 
supernatant was analysed by analytical RP-HPLC. Remaining peptides were quantified using 
peak height with absorption at 214 nm. 
2.4 Results  
2.4.1 Cyclic GeXIVA ribbon isomer retains native structure 
NMR structure calculations for ribbon GeXIVA (44) showed that its N- and C- termini are 
maintained in close proximity (~6.4 Å) by a disulfide bridge between the first and last Cys 
residues (Figure 2.3). Five linkers (Figure 2.4) were designed using molecular modelling to 
bridge the termini, and all were geometrically compatible with the linear peptide structure, with 
the cyclic backbones maintained within 1 Å RMSD of the linear peptide. The data suggested 
that even a one-residue linker is sufficient to cyclise the backbone of ribbon GeXIVA without 
perturbing structure. Models of cyclic GeXIVA with minimum perturbation of the parent 
peptide backbone are shown in Figure 2.4. For experimental validation, we focused on three 
short linkers (G, GG and GAG) and the three corresponding cyclic variants: ribbon 
Chapter 2: Cyclisation improves selective folding of ribbon GeXIVA 
 
54 
 
cGeXIVA_G, ribbon cGeXIVA_GG and ribbon cGeXIVA_GAG. The three isomers of linear 
GeXIVA and the three cyclic ribbon analogs were synthesised using orthogonal protection of 
the cysteine side chains to orient the folding toward a unique disulfide isomer. The yields of 
three isomers of linear GeXIVA and cyclic ribbon GeXIVA were low (<1%) using a two-step 
oxidation method. Although we optimised the purification procedure, globular GeXIVA could 
not be completely purified. We therefore explored an alternative one-spot synthetic approach. 
Figure 2.4 Amino acid sequences and NMR structure of ribbon GeXIVA and cyclic ribbon 
isomers of GeXIVA. A: Amino acid sequences of ribbon GeXIVA and cyclic analogs. The 
backbone cyclisation of ribbon GeXIVA was carried out using differently sized linkers 
(highlighted in red) spanning its N- and C-termini (indicated by the black bracket and line). 
The black curved lines below the sequence show the ribbon disulfide connectivity. The α-
carbon (Cα) RMSD of the backbone for the parent peptide and molecular models of the cyclic 
peptides are shown in the last column. B: NMR solution structure of ribbon GeXIVA (green) 
and models of cyclic variants (backbones in blue and linkers in red). The disulfide bonds are 
represented by yellow sticks and the Cα are shown as balls.  
2.4.2 One-pot oxidative folding 
Fristly, linear peptides GeXIVA and cGeXIVA_GG were folded under thermodynamic 
oxidation conditions (NH4HCO3 (pH 8.3), room temperature) (Figure 2.5A). For the GeXIVA, 
three major products were formed within 20 h. The three major peaks were observed in the 
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Figure 2.5 Time course of the oxidative folding of GeXIVA and cGeXIVA_GG. A: HPLC 
traces of samples taken at various times during the random folding process. For GeXIVA, the 
black asterisk indicates that the peak occurring in the folding process of GeXIVA comprises 
intermediate forms with similar retention time to the globular isomer and the red asterisk 
indicates an impurity. The globular, bead and ribbon GeXIVA from two-step oxidations are 
shown as red, green and blue traces, respectively. For cGeXIVA_GG, the blue asterisk 
indicates the major intermediate occurring in the folding process of cGeXIVA_GG. The ribbon 
cGeXIVA_GG from two-step oxidation is shown as a blue trace. I1 represents the intermediate 
with one disulfide bond and I2 represents the intermediates with two disulfide bonds. B: Surface 
representations of ribbon GeXIVA and ribbon cGeXIVA_GG. Positively charged residues are 
shown in blue, negative residues are red, polar residues are white, and hydrophobic residues 
are green. Surface representations were created using program PYMOL. Cyclisation of ribbon 
GeXIVA resulted in an additional hydrophobic patch (circle) in cGeXIVA_GG. 
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ultra-performance liquid chromatography trace, accounting for ~25%, 45% and 30% of the 
total peptide, respectively. Analysis of each peak using a TripleTOF 5600 mass spectrometer 
(AB SCIEX, Ontario, Canada) with a nanoelectrospray ionization source revealed masses of 
3450.62, 3450.62 and 3450.63 Da, respectively, each corresponding to fully oxidised GeXIVA. 
The three peaks were unambiguously identified by co-elution with the globular GeXIVA, bead 
GeXIVA and ribbon GeXIVA isomers. The HPLC peaks of ribbon and bead GeXIVA partly 
overlapped and were difficult to separate (Figure 2.5A, 24 h). Interestingly, a single peak 
representing the majority of the oxidised forms transiently appeared from 1 to 4 h, and then 
disappeared from 4 to 8 h (Figure 2.5A; indicated by a black asterisk). This transient peak 
partly overlaps with the major final product (Figure 2.5A, 20 h), which was identified as 
globular GeXIVA. We hypothesized that the globular isomer might form within 4 h and then 
gradually convert into other isomers. We incubated globular GeXIVA in NH4HCO3 (pH 8.3) 
at room temperature at a final concentration of 20 μM and the globular GeXIVA was found to 
be very stable in the folding buffer for 24 h (data not shown), suggesting that the first major 
peak at 4 h mainly comprises intermediate forms with similar retention time to the globular 
isomer.  
The one-step oxidation of reduced cGeXIVA_GG was complete at 16 h, whereas some 
intermediates could still be seen at that time for the linear GeXIVA. Only three products were 
formed, all of mass 3546.66 Da, corresponding to that of the fully oxidised cGeXIVA_GG. 
The third major peak, accounted for 86% of the total peptide content, and was confirmed as 
being the ribbon isomer by co-elution. The two other peaks are presumably the globular and 
bead isomers. In contrast to linear GeXIVA, the retention time of globular, bead and ribbon 
isomers of the cGeXIVA_GG separate well (Figure 2.5A) as the linker engenders ribbon 
cGeXIVA_GG with a larger hydrophobic patch than ribbon GeXIVA (Figure 2.5B; shown in 
green), which could explain its later retention time. Four intermediate forms were identified 
over the time course. The major intermediate (Figure 2.5A; indicated by a blue asterisk and 
named I1) was the most abundant of the oxidised forms from 1 to 4 h. The major intermediate 
I1 of cGeXIVA_GG was isolated and its mass was 3548.66 Da, indicating that it has only one 
disulfide bond. The masses of the three minor intermediates were each 3546.65 Da, suggesting 
that they have two disulfide bonds (all designated as I2 in Figure 2.5A). 
2.4.3 NMR analyses of ribbon GeXIVA and oxidatively folded and cyclised ribbon 
cGeXIVA_GG 
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A comparison of the secondary αH chemical shifts of ribbon GeXIVA with those of ribbon 
cGeXIVA_GG suggested very little difference in structure between the linear and cyclic 
analogs (Figure 2.6A). The different chemical environment created by the presence of the 
cyclising linker can easily explain the minimal shift differences near the termini. Overlapping 
peaks in the 2D NMR spectra prevented the unambiguous assignment of the cGeXIVA_G and 
cGeXIVA_GAG spin systems. 
Figure 2.6 Structural characterisation of cGeXIVA_GG. A: Secondary αH chemical shifts of 
ribbon GeXIVA and ribbon cGeXIVA_GG (ΔδHα). The overall secondary structures of ribbon 
GeXIVA and ribbon cGeXIVA_GG are similar and both peptides display a 310-helix from 
Pro12 to Arg16. The black lines below the sequence show the ribbon disulfide connectivity. 
B: Ribbon diagram of the NMR solution structure of cGeXIVA_GG. Models were overlaid 
over the C9–C20 segment. Disulfide bonds are shown in yellow. 
 
The 3D structure of cGeXIVA_GG was calculated with a total of 171 distance restraints and 
found to contain a short 310-helix (from P12–R16; Figure 2.6B). The S11-P12 peptide bond 
was determined to adopt a trans configuration, similar to the configuration of this bond in the 
ribbon and bead isomers of linear GeXIVA (44). As shown for ribbon GeXIVA (44), the loop 
formed between C9 and C20 overlays reasonably well between NMR models (RMSD of 1.38 
± 0.56 Å across backbone atoms of residues 9–20, Table 2.2); although the remainder of the 
peptide is somewhat disordered, suggesting a degree of flexibility. We thus used NMR spin 
relaxation measurements to characterise the backbone dynamics of cGeXIVA_GG (Figure 2.7, 
Table 2.3). Heteronuclear T1 and NOEs were measured and used to derive order parameters 
reflective of motion of the Cα-Hα bonds. Due to spectral overlap, only 18 of the 22 residues 
could be analysed. Nevertheless, the order parameters (0.53–0.81; mean of 0.63) suggest that 
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cGeXIVA_GG is moderately flexible, which agrees with the geometric analysis of the lowest 
energy structures. The least flexible region is at the C-terminal end of the C9 to C20 loop. 
 
Table 2.2 Statistical analysis of cGeXIVA_GG structuresa 
cGeXIVA_GG Value 
Experimental restraints  
total no. distance restraints 171 
intraresidue 90 
sequential 73 
medium range, i-j<5 8 
long range, i-j≥5 0 
hydrogen bond restraints 2 
dihedral angle restraints 32 
NOE violations exceeding 0.3 Å 0 
Dihedral violations exceeding 2.0 Å 0 
Rms deviation from mean structure, Å  
backbone atoms (residues 9-20) 1.38 ± 0.56 
all heavy atoms (residues 9-20) 3.33 ± 0.98 
Stereochemical qualityb  
Residues in most favoured Ramachandran region, 
% 
77.9 ± 8.9 
Ramachandran outliers, % 1.4 ± 1.8 
Unfavourable sidechain rotamers, % 3.7 ± 2.6 
Clashscore, all atoms 0.1 ± 0.4 
Overall MolProbity score 1.6 ± 0.3 
aAll statistics are given as mean ± SD. 
bAccording to MolProbity (58). 
 
 
 
 
 
 
Chapter 2: Cyclisation improves selective folding of ribbon GeXIVA 
 
59 
 
Figure 2.7 Experimental relaxation data and derived order parameters for cGeXIVA_GG. T1 
(panel a) and heteronuclear NOE (panel b) values for the Cα nuclei were measured at 600 MHz. 
Errors are shown as the standard deviation of triplicate measurements. Only 18 of the residues 
could be analysed. A model-free analysis was used to derive order parameters (panel c). Models 
1 and 2 of model-free were used in the analysis. Errors, shown as standard deviation, were 
estimated using a Monte Carlo algorithm. 
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Table 2.3 Relaxation data, fitted parameters, and error estimates for cGeXIVA_GG 
Resa Datab T1 (s)c NOEc o errd i errd S2 errd RMSDe 
T1 Expf 0.36 1.51        
 m1 0.36 1.23 1.38 0.08    0.67 0.01  
 m2 1.51 1.39 1.39 0.02 49.17 27.53  0.56 0.07  
C2 Exp NAg NA        
R3 Exp NA NA 
S4 Exp 0.36 1.57        
 m1 0.36 1.23 1.38 0.08   0.68 0.03  0.64 
 m2 0.36 1.57 1.39 0.02 58.79 31.61 0.54 0.09 0.00 
S5 Exp 0.37 1.47        
 m1 0.37 1.23 1.38 0.08   0.65 0.01 0.29 
 m2 0.37 1.47 1.39 0.02 40.48 41.41 0.56 0.11 0.00 
G6 Exp NA NA 
R7 Exp NA NA 
Y8 Exp 0.35 1.27        
 m1 0.35 1.23 1.38 0.08   0.68 0.02 0.24 
 m2 0.35 1.27 1.39 0.02 8.30 12.68 0.67 0.02 0.00 
C9 Exp NA NA 
R10 Exp NA NA 
S11 Exp 0.34 1.48        
 m1 0.34 1.23 1.38 0.08   0.71 0.02 0.48 
 m2 0.34 1.48 1.39 0.02 50.50 36.54 0.60 0.09 0.00 
P12 Exp 0.40 1.33        
 m1 0.40 1.23 1.38 0.08   0.61 0.03 0.30 
 m2 0.40 1.33 1.39 0.02 15.00 16.53 0.57 0.04 0.00 
Y13 Exp 0.38 1.39        
 m1 0.38 1.23 1.38 0.08   0.64 0.02 0.23 
 m2 0.38 1.39 1.39 0.02 26.05 32.83 0.58 0.09 0.00 
D14 Exp 0.34 1.00        
 m1 0.34 1.23 1.38 0.08   0.72 0.03 0.43 
 m2 0.34 1.23 1.39 0.02 0.00 7.88 0.72 0.03 0.43 
R15 Exp 0.36 1.57        
 m1 0.36 1.23 1.38 0.08   0.66 0.01 0.62 
 m2 0.36 1.57 1.39 0.02 55.40 34.31 0.53 0.10 0.00 
R16 Exp    NA    NA 
R17 Exp 0.37 1.35        
 m1 0.37 1.23 1.38 0.08   0.65 0.03 0.24 
 m2 0.37 1.35 1.39 0.02 21.78 32.78 0.60 0.08 0.00 
R18 Exp 0.31 1.29        
 m1 0.31 1.23 1.38 0.08   0.77 0.02 0.06 
 m2 0.31 1.23 1.39 0.02 0.00 51.04 0.77 0.10 0.05 
Y19 Exp 0.30 1.20        
 m1 0.30 1.23 1.38 0.08   0.81 0.05 0.05 
 m2 0.30 1.23 1.39 0.02 0.00 44.45 0.81 0.07 0.05 
C20 Exp NA NA 
R21 Exp 0.34 1.17        
 m1 0.34 1.23 1.38 0.08   0.71 0.02 0.17 
 m2 0.34 1.23 1.39 0.02 0.00 21.77 0.72 0.05 0.16 
R22 Exp NA NA 
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I23 Exp 0.34 1.19        
 m1 0.34 1.23 1.38 0.08   0.71 0.03 0.10 
 m2 0.34 1.23 1.39 0.02 0.00 25.60 0.72 0.05 0.10 
T24 Exp 0.37 1.31        
 m1 0.36 1.23 1.38 0.08   0.66 0.04 0.18 
 m2 0.37 1.31 1.39 0.02 16.23 28.58 0.63 0.06 0.00 
D25 Exp 0.36 1.45        
 m1 0.36 1.23 1.38 0.08   0.68 0.04 0.58 
 m2 0.36 1.45 1.39 0.02 41.87 27.89 0.59 0.07 0.00 
A26 Exp 0.37 1.40        
 m1 0.37 1.23 1.38 0.08   0.66 0.03 0.21 
 m2 0.37 1.40 1.39 0.02 31.06 39.01 0.60 0.11 0.00 
C27 Exp    NA NA 
 m1 0.37 1.23 1.38 0.08   0.65 0.04 0.58 
 m2 0.37 1.48 1.39 0.02 40.22 23.05 0.56 0.08 0.00 
G29 Exp NA NA        
G30 Exp NA NA        
a Relaxation data shown  
b Two model-free models were analysed – m1 and m2 
c Relaxation data measured at 600.13 MHz  
d Errors obtained from 20 Monte Carlo simulations 
e RMSD is the root-mean-squared deviation between experimental and fitted T1 and NOE 
values. The NOE deviations were down-weighted to account for their intrinsically higher 
errors 𝑅𝑀𝑆𝐷 =  √∑
(𝑇1
𝑒𝑥𝑝
−𝑇1
𝑐𝑎𝑙𝑐)
2
𝜎𝑇1
2 + 0.25 ∑
(𝑁𝑂𝐸
𝑒𝑥𝑝
−𝑁𝑂𝐸𝑐𝑎𝑙𝑐)
2
𝜎𝑁𝑂𝐸2
 
f Exp, refers to the experimentally determined T1 and NOE values 
g NA, not assigned due to spectral overlap. 
2.4.4 Ribbon cGeXIVA_GG and ribbon GeXIVA are equipotent inhibitors of the human 
α9α10 nAChR subtype 
Linear GeXIVA isomers have been shown to selectively and potently inhibit the rat α9α10 
nAChR subtype (44). Here, globular, bead and ribbon isomers of linear GeXIVA, and cyclic 
constructs of ribbon GeXIVA (cGeXIVA_G, cGeXIVA_GG and ribbon cGeXIVA_GAG) 
were tested for their functional activity at the hα9α10 nAChR subtype heterologously 
expressed in Xenopus laevis oocytes. All three cyclic ribbon constructs tested at 100 nM, 
inhibited ACh-evoked currents mediated by hα9α10 nAChRs by ~60–70% (n = 4–6). 
Similarly, the bead (n = 5) and ribbon isomers (n = 8) of GeXIVA inhibited the hα9α10 ACh-
evoked current amplitude by ~60–70%. In contrast, the globular GeXIVA was less potent, 
inhibiting hα9α10 ACh-evoked currents by ~40% (n = 12) (Figure 2.8A).  
 
The concentration-dependent activity of globular and ribbon GeXIVA and ribbon 
cGeXIVA_GG at hα9α10 nAChRs were determined (Figure 2.8B). All peptides reversibly 
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inhibited ACh-evoked currents in a concentration-dependent manner, giving IC50 values of 
198.6 ± 18.9 nM (n = 4–12) for globular GeXIVA, 35.1 ± 2.7 nM (n = 4–8) for ribbon GeXIVA 
and 37.6 ± 4.9 nM (n = 4–11) for ribbon cGeXIVA_GG. Consistent with the previously 
reported potency of globular and ribbon GeXIVA at rat α9α10 nAChRs, the globular isomer 
of GeXIVA had lower potency at hα9α10 nAChRs than the ribbon analog. Ribbon GeXIVA 
and ribbon cGeXIVA_GG had similar IC50s, suggesting that backbone cyclisation had no 
impact on the potency of inhibition at hα9α10 nAChRs. 
Figure 2.8 Inhibition of human α9α10 nAChR by linear GeXIVA and ribbon cGeXIVA 
isomers. A: Bar graph of globular GeXIVA, bead GeXIVA, ribbon GeXIVA, and ribbon 
cGeXIVA_G, ribbon cGeXIVA_GG and ribbon cGeXIVA_GAG (100 nM) inhibition of ACh-
evoked peak current amplitude mediated by hα9α10 nAChRs. Whole-cell hα9α10 nAChR-
mediated currents were activated by 6 μM ACh. B: Concentration-response curves of globular 
and ribbon GeXIVA, and ribbon cGeXIVA_GG inhibition of ACh-evoked currents mediated 
by hα9α10 nAChRs (mean ± SEM, n = 4-12). 
2.4.5 Serum stability of linear GeXIVA and ribbon cGeXIVA isomers     
Stability assays for the ribbon isomer of GeXIVA and its three cyclic analogs were carried out 
in human serum. All four peptides degraded within 2 h but the ribbon cGeXIVA_GG was 
slightly more stable than the other peptides (data for cGeXIVA_G and GeXIVA_GAG not 
shown). Subsequently, the stability of the three isomers of linear GeXIVA and of ribbon 
cGeXIVA_GG was compared to that of α-conotoxin cVc1.1 (13) in 25% human serum. The 
positive control, cVc1.1, was highly stable, whereas only ~20% of the three isomers of 
GeXIVA remained after 4 h incubation. Ribbon cGeXIVA_GG was more stable than the three 
linear isomers of GeXIVA (p < 0.001) at 4 h time point, with 38% of cGeXIVA_GG remaining 
(Figure 2.9). 
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Figure 2.9 The stability of GeXIVA isomers, ribbon cGeXIVA_GG and cVc1.1 (positive 
control) in 25% human serum. The one-way ANOVA/Tukey test was used for comparing the 
remaining peptides at 4 h time point, and data were expressed as the mean ± SEM (*** p < 
0.001); all values (except cVc1.1) were compared with that of ribbon GeXIVA. 
2.5 Discussion 
The α9α10 nAChR mediates efferent olivocochlear innervations in outer hair cells and 
modulates immune responses in lymphocytes (59-61). It is also reported to be implicated in 
pain and cancer (62,63). Only a handful of α-conotoxins is currently known to selectively 
inhibit the α9α10 nAChR (44,64-66), so studies of new examples, such as GeXIVA are 
important for defining receptor specificity. Furthermore, previous studies have highlighted the 
value of backbone cyclisation to enhance the biopharmaceutical properties of α-conotoxins 
(3,13) and so here we attempted to apply this approach to GeXIVA.  
 
Molecular modelling was used to design linkers comprising only a small number of amino 
acids that would introduce minimal constraints into the peptide fold. A recent study highlighted 
the importance of the distance between the N- and C- termini in designing cyclizing linkers 
(1), but considering distances alone will not address limitations due to accessible conformations 
of backbones nor the orientation of the termini. Structural perturbations may be introduced 
unintentionally into a cyclic peptide when a linker is designed on the basis of distance only, 
ultimately decreasing biological activity (2,3). In the case of ribbon GeXIVA, modelling 
showed that the proximity of the termini would allow cyclisation with a single residue linker 
without affecting the structure. Since non-neutral amino acids in the cyclizing linker sequence 
can have a negative effect on biological activity (29), only Gly and Ala amino acids were used 
in the linkers in the current study. These residues are small, flexible and non-charged, and likely 
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to have minimal interference with biological activity. No more than two sequential Gly or Ala 
were used in any individual linker to avoid overlapping peaks in NMR spectra and thus avoid 
spectral assignment difficulties. Linkers composed of Gly and Ala residues have been 
successfully used to cyclise the α-conotoxins MII, RgIA and Vc1.1, without adversely affecting 
biological activity or structure (2,3,13).  
 
The linkers used in this study did not affect the activity and structure of ribbon GeXIVA. 
Indeed, all cyclic ribbon variants, i.e. cGeXIVA_G, cGeXIVA_GG and cGeXIVA_GAG, had 
similar activity to the linear ribbon form at the hα9α10 nAChR. Although no structural data 
from peptides cyclised with a G or GAG linker was obtained due to NMR spectral overlap, the 
GG linker did yield a cyclised peptide with a very similar conformation to the linear ribbon 
GeXIVA. Alignment of the lowest energy model generated from NMR data and an analysis of 
the backbone relaxation measurements suggests that the cyclic variant is most rigid in the C9-
C20 loop region but slightly more flexible in the remainder of the molecule. It has recently 
been shown that backbone cyclisation can enhance or retain backbone rigidity for three 
different classes of peptides, including for the conotoxin Vc1.1 (57). Cyclisation appears to 
have less of a rigidifying effect in GeXIVA. 
 
The non-directed oxidation of GeXIVA resulted in the preferential formation of the bead 
isomer, followed by the ribbon and globular forms, which interestingly parallels their 
biological activity (44). By contrast, two previous studies employing the one-step oxidation of 
α-conotoxins showed the preferential formation of the globular isomer under similar conditions 
(0.1 M NH4HCO3; pH 8; room temperature) (67,68). A possible explanation for this difference 
in isomer formation is that GeXIVA displays a Cys framework XIV (C-C-C-C) with 6, 10 and 
6 residues within the Cys I-Cys II, Cys II-Cys III and Cys III-Cys IV backbone segments, 
respectively, rather than the Cys framework I (CC-C-C) of most α-conotoxins with 0, 4 and 3–
7 residues between the cysteines.  
 
The one-step oxidation of cGeXIVA_GG was notably different from that of the linear parent 
peptide as it resulted in the preferential formation of the ribbon isomer. The use of short 
cyclising linkers has also been reported to drive oxidative folding towards the ribbon 
connectivity for three other conotoxins: α-conotoxins ImI and AuIB, and χ-conotoxin MrIA. 
Like GeXIVA, these peptides have four Cys residues, with Cys I and Cys IV being no more 
than three residues from the N- and C-termini, respectively. A short cyclising linker should 
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maintain these two Cys residues in spatial proximity in the reduced form and favour their cross-
linking by a disulfide bond during oxidation.  
 
During the oxidative folding of ribbon GeXIVA and ribbon cGeXIVA_GG, a major 
intermediate was identified. For GeXIVA, the amount of ribbon and globular isomers plateaued 
after 8 and 12 h incubation, respectively, whereas the bead form plateaued after 20 h. According 
to Wedemeyer et al., the rate of formation of disulfide bonds in an unstructured chain decreases 
with the number of residues between the two cysteines (69). Since 6, 10 and 6 residues exist 
between successive cysteines in GeXIVA we speculate that the major intermediate might 
involve a disulfide bond between Cys I and Cys II or between Cys III and Cys IV and that this 
intermediate subsequently translates into the bead isomer. For cGeXIVA_GG, there are only 
four residues between Cys I and Cys IV after backbone cyclisation, which may favour the 
formation of either a Cys I-Cys IV or Cys II-Cys III disulfide bond in the intermediate, thus 
leading to the ribbon isomer. Interestingly, three intermediates with two disulfide 
connectivities appeared during the course of folding of cGeXIVA_GG. The retention times of 
these three intermediates were different from the three stable isomers, suggesting that the 
intermediates have native-like connectivities but have meta-stable conformations. 
 
We hypothesize that the preferential formation of the ribbon isomer probably results from the 
destabilisation of the alternative connectivities rather than through stabilisation of the ribbon 
form (Figure 2.10). Backbone cyclisation of ribbon GeXIVA is likely to affect folding energy 
 
 
 
Figure 2.10 Schematic representation 
of the relative energy of the three linear 
isomers of GeXIVA (black) and their 
cGeXIVA_GG (dotted red) analogous. 
The energy difference between isomers 
of the same peptide was computed 
using a Boltzmann distribution of the 
isomers at equilibrium.  
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through an entropic effect, mainly impacting the unfolded state. Indeed, the linker has little 
interaction with the rest of the peptide in molecular models, suggesting that the termini are 
already maintained in proximity in the linear form and cyclisation does not result in structural 
perturbation to the core of the peptide. By contrast, the bead and globular isomers probably 
adopt a different set of conformations after being backbone cyclised because NMR 
characterisation of these isomers indicates that the globular form is disordered and the N- and 
C-termini of the bead isomer are uncoupled (44).  
 
A two-step oxidation strategy is often used to oxidise conotoxins containing two disulfide 
bonds because the yields are typically improved compared to undirected folding (70). 
However, the oxidation of GeXIVA using this strategy only produced small amounts of 
products, hindering high-throughput structure-activity relationship studies and therapeutic 
studies. The yield of folded ribbon GeXIVA calculated from the final weight of oxidised 
peptide divided by the weight of reduced peptide was 0.5%. Using the results of Cheneval et 
al., to extrapolate the yield for the synthesis of an unprotected peptide (8), the yield of cyclic 
ribbon cGeXIVA_GG through a one-step folding method should be 8.6% using Fmoc-based 
solid-phase peptide synthesis and considerably higher for a Boc-based approach. Additionally, 
the HPLC elution peaks of ribbon and bead isomers of GeXIVA overlapped, whereas the 
ribbon isomer of cGeXIVA_GG is distinct, and ribbon cGeXIVA_GG therefore can be 
produced in greater purity using one-step oxidation than the ribbon GeXIVA using the same 
strategy. 
 
An alternative strategy to increase the oxidative folding yield has been used in other cases of 
disulfide-rich peptides, including the widely used model system bovine pancreatic trypsin 
inhibitor (BPTI). Undirected folding of this protein results in the formation of two main 
species, one being native BPTI and the other a native-like two-disulfide intermediate (71). The 
addition of the N-terminal pro-region increased substantially the native BPTI formation, and it 
was identified that a cysteine residue in this region was responsible for this increased yield 
(72). Tethering a cysteine residue to the C-terminus with a flexible linker resulted in a similar 
effect, indicating that this residue acts as an internal catalyst. 
 
Backbone cyclisation typically improves the stability of disulfide-rich peptides against 
enzymatic degradation, as demonstrated for several conotoxins, chlorotoxin, and a spider toxin 
(6,14-16,73-75). However, it was recently reported that cyclisation of κ-conotoxin PVIIA 
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decreased its stability in human serum (76), without significantly perturbing the structure 
relative to the native form (77). Here, we show that the IC50 for cGeXIVA_GG inhibition of 
hα9α10 nAChR (37.7 ± 5.0 nM) is comparable to that for ribbon GeXIVA (35.1 ± 2.7 nM). 
The stability in human serum of ribbon cGeXIVA_GG is only slightly improved compared to 
linear GeXIVA, suggesting that the main routes of degradation of GeXIVA are by 
endoproteases or side chain denaturation, which are typically less affected by backbone 
cyclisation. A possible target for such endoproteases are the nine arginine residues in the 
sequence of GeXIVA (78). 
Using short linkers to enhance oxidative folding and other biopharmaceutical properties of 
bioactive peptides have broader applications than just for toxins, with perhaps a most striking 
example being for insulin. Insulin is an extremely important hormone but is difficult to 
synthesise owing to its two chains unique structure (79). In one study, the two peptide chains 
of human insulin were fused, increasing the production yield compared to native human 
proinsulin (80) while maintaining a native-like structure (81) but with an attendant loss of 
biological activity (82). In a later study, Hua et al. used a 6-residue linker, and the resulting 
insulin variant maintained biological activity and structure, and also had improved folding yield 
and stability (83). More recently, the nature of the linker region between the two insulin chains 
was further investigated, resulting in the identification of an insulin variant with the highest 
folding-efficiency to-date (79). In that study, it was shown that the linker region had a direct 
effect on folding yield by enhancing the formation of the native disulfide bond connectivity. 
The peptides in the current study have a direct analogy to single-chain insulin analogs: a 
suitable linker for cGeXIVA_GG, led to the preferential formation of the ribbon isomer, and 
significantly improved the product yield and stability whilst retaining the native-like structure 
and biological activity. The enhanced pharmaceutical properties deriving from a suitable linker 
provide an opportunity to develop GeXIVA as a potential therapeutic for the treatment of 
neuropathic pain, a condition with a huge unmet medical need (84). Treatment of neuropathic 
pain is challenging and alternative therapeutics are needed as currently available drugs such as 
morphine, gabapentin or antidepressants, are subject either to the development of tolerance or 
to significant side-effects (85,86).  
In summary, the head-to-tail backbone cyclisation via a short linker of ribbon GeXIVA had no 
impact on the potency of inhibition at hα9α10 nAChR and a rationally designed linker favoured 
the formation of the ribbon disulfide connectivity and improved stability in human serum.  
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3.1 Introduction 
The combinatorial nature of nAChR subtypes requires molecular probes to study their 
physiology. The existence of different stoichiometries adds another layer of complexity to the 
identification of nAChR subtypes but designing specific probes of a certain stoichiometry is 
exceptionally challenging. The α3β4 nAChR has two main stoichiometries:(α3)2(β4)3 and 
(α3)3(β4)2. The (α3)2(β4)3 nAChR subtype has α3(+)β4(-) functional binding sites (Figure 3.1 
A), and the (α3)3(β4)2 subtype has additional functional binding site(s) between two α3 
subunits, i.e. α3(+)α3(-) (1). In the current study, we focused on engineered α3-containing 
nAChRs of these compositions, but in native tissue, the ganglionic nAChRs are more complex 
and could include accessory subunits of α3, α5, α6, β2 or β4 (2). As the α3β4 nAChR subtype 
is involved in a range of drug addictions, (e.g. for morphine (3), methamphetamine (4) and 
nicotine (5-7)), and the β4 subunit is linked to anxiety behaviour (8), these receptors are of 
considerable pharmaceutical interest. Thus, high-affinity molecular probes are required to tease 
apart the neurological functions of the two α3β4 nAChR stoichiometries. 
 
α-Conotoxin AuIB (Figure 3.1 B) belongs to the 4/6 class of conotoxins (9), and the globular 
form (gAuIB) inhibits the rat α3β4 nAChR with an IC50 of 1-3 μM (10). rAuIB was the first 
ribbon isomer reported to have a higher potency than the globular isomer, with rAuIB 
displaying a 10-fold improved inhibition of Ach-evoked current in rat parasympathetic neurons 
compared to gAuIB, with IC50s of 0.1 nM and 1.2 nM, respectively (11). However, another 
study reported that gAuIB was more potent than rAuIB at inhibiting rat α3β4 nAChR expressed 
in Xenopus laevis oocytes (12). These apparently conflicting results were explained by a switch 
in the major stoichiometry of the α3β4 nAChR when expressed in mammalian cells compared 
to X. laevis oocytes (1). AuIB isomers were shown to have differential sensitivity to the two 
stoichiometries of the α3β4 nAChR: gAuIB inhibited the (α3)3(β4)2 nAChR (transfected at 
10:1 ratio) and (α3)2(β4)3 nAChR (1:10 ratio) with IC50s of 1.1 µM and 3.0 µM, respectively; 
whereas rAuIB inhibited the (α3)3(β4)2 nAChR with an IC50 of 0.86 µM and was inactive at 
the other stoichiometry (10). Therefore, rAuIB only inhibited the stoichiometry displaying an 
α3(+)α3(-) binding site, indicating that it binds at the interface between two α3 subunits. 
Conotoxin rAuIB can therefore potentially be used to identify a single subtype and 
stoichiometry among all α3β4 subtypes expressed in vivo. Here, we investigated the SAR and 
binding mode of rAuIB on the rat α3β4 nAChR putatively expressed as (α3)3(β4)2 
Chapter 3: Interaction between ribbon AuIB and α3β4 nAChR 
 
80 
 
stoichiometry from the injection of 10:1 α3:β4 RNA ratio. This is the first detailed SAR study 
of the binding mode of a ribbon α-conotoxin. 
Figure 3.1 Overview of the two possible stoichiometries of α3β4 nAChRs and the NMR 
spectroscopy solution structures of rAuIB and gAuIB. A: Illustration of the two possible 
stoichiometries of homopentameric α3β4 nAChRs and identification of the functional binding 
sites. The illustration represents the nAChR as seen from the extracellular side and parallel to 
the membrane; the pore is in the centre of the pentamer. The C-loop of each subunit is indicated 
by a curved line. The α3(+)β4(-) and α3(+)α3(-) agonist binding sites are indicated by orange 
and green discs, respectively. B: Three-dimensional NMR solution structures of gAuIB (PDB: 
1MXN) and rAuIB (PDB: 1MXP). 
3.2 Materials and methods 
3.2.1 Peptide synthesis and cleavage  
A suite of 13 AuIB peptides (gAuIB, rAuIB, 10 Ala variants of rAuIB and [P7A]gAuIB) was 
synthesised using Fmoc SPPS on a rink amide resin (Novabiochem®, Merck, Kenilworth, NJ, 
USA), with the side chains of Cys residues protected in pairs using orthogonal protective 
groups, which were then selectively removed in different oxidation solutions. For this purpose, 
we used the acid labile trityl (Trt) group to protect Cys II and Cys III, and the S-
acetamidomethyl (Acm) group to protect Cys I and Cys IV for rAuIB and its mutants. Likewise 
for gAuIB, the Trt group was used to protect Cys II and Cys IV, and the Acm group was used 
to protect Cys I and Cys III. All crude linear peptides were cleaved and deprotected in a 
cleavage cocktail comprising 96% trifluoroacetic acid (TFA, Auspep, VIC, Australia), 2% H2O 
and 2% triisopropylsilane (v/v) for 2 h. The crude peptides were purified by HPLC using a 
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gradient of 0−50% buffer B (0.045% TFA in 90% acetonitrile [Merck]) over 50 min and 
monitoring at 214/280 nm. The same method was also used in subsequent purifications. A two-
step oxidative folding was used to form the disulfide bonds; the first disulfide bond was formed 
by adding peptides (80 mg crude peptide dissolved in 100 mL water) into an equal volume of 
20 mM potassium ferricyanide, 0.1 M Tris, pH 7.5 for 1 h. The reaction mixture was frozen 
and lyophilized overnight, and the second disulfide bond was formed by adding 50 mL of 0.1 
M iodine solution for 1 h. All Fmoc-amino acids were from Chem-Impex International (Wood 
Dale, IL, USA). All organic reagents and solvents, unless stated otherwise, were purchased 
from Sigma-Aldrich (St Louis, MO, USA).  
3.2.2 NMR spectroscopy 
With a few exceptions, where crystallization has been possible (13), NMR is the preferred 
technique for conotoxin structural characterization. Two-dimensional total correlation TOCSY 
and NOESY spectra of rAuIB, gAuIB and the variants were acquired using an Avance-600 
MHz NMR spectrometer (Bruker) with mixing times of 80 ms and 200–300 ms, respectively. 
The α-proton (Hα) chemical shifts of synthetic peptides were assigned using CcpNmr analysis 
(version 2.4.1). Subsequently, the differences between the observed Hα chemical shifts and 
those of the corresponding residues in a random coil peptide (14), referred to as secondary Hα 
chemical shifts, were calculated to provide information on folding and secondary structure, as 
has been widely applied for other conotoxins (15). 
3.2.3 Electrophysiological assay of peptides 
RNA preparation, oocyte preparation, and expression of nAChR subunits in Xenopus were 
performed as described previously (10). Breifly, Plasmid constructs of rat α3 (pT7TS) and β4 
(pNKS2) nAChR subunits were linearised with the XbaI restriction enzyme (NEB, Ipswich, 
MA, USA) for in vitro cRNA transcription using the T7/SP6 mMessage mMachine® 
transcription kits (AMBION, Forster City, CA, USA). Oocytes were injected with 5 ng cRNA 
of rat α3β4 nAChR (α3:β4 = 10:1; concentration confirmed spectrophotometrically and by gel 
electrophoresis), and they were incubated at 18 °C in sterile ND96 solution (96 mM NaCl, 2 
mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES at pH 7.4), supplemented with 5% 
fetal bovine serum, 0.1 mg/mL gentamicin (Gibco, Grand Island, NY, USA) and 100 U/mL 
penicillin-streptomycin (Gibco, Grand Island, NY, USA) 2-5 days before recording. Two-
electrode voltage clamp recordings were performed at room temperature using a GeneClamp 
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500B amplifier and pClamp9 software interface (Molecular Devices, Sunnyvale, CA, USA) at 
a holding potential of 80 mV.  Voltage-recording and current-injecting electrodes were pulled 
from GC150T-7.5 borosilicate glass (Harvard Apparatus, Holliston, MA, USA) and filled with 
3 M KCl, giving resistances of 0.3–1 MΩ.  Initially, oocytes were briefly washed with ND96 
solution followed by three applications of 50 μM ACh for rat α3β4 nAChR (α3:β4 = 10:1) (10). 
Washout with bath solution was done for 3 min between ACh applications. Oocytes were 
incubated with peptides for 5 min with the perfusion system turned off, followed by co-
application of ACh and peptide with flowing bath solution. All peptide solutions were prepared 
in ND96 solution containing 0.1% bovine serum albumin. Peak current amplitudes before 
(ACh alone) and after (ACh + peptide) peptide incubation were measured using AxoGraph X 
software (Axograph Scientific, Berkeley, CA, USA), where the ratio of ACh + peptide-evoked 
current amplitude to ACh alone-evoked current amplitude was used to assess the activity of the 
peptides at the rat α3β4 nAChR.  
3.2.4 Molecular modelling 
Molecular models of the interaction between AuIB and the ECD of rat α3β4 nAChR were built 
by homology with Modeller 9v18 (16) using the following crystal structures as templates: [1] 
the complex between Aplysia californica AChBP and conotoxin PnIA variant (PDB: 2BR8), 
and [2] the human α4β2 nAChR (PDB: 5KXI). The complex between rAuIB and the ECD of 
(α3)3(β4)2 nAChR was modelled by assuming an interaction in the α3(+)α3(-) orthosteric 
binding site whereas the complex between gAuIB and the ECD of (α3)2(β4)3 nAChR was built 
by assuming an interaction in the α3(+)β4(-) orthosteric binding site. Similar to most other α-
conotoxins rAuIB is a competitive inhibitor of the α3β4 nAChR, suggesting that it binds in the 
orthosteric binding site (10). In contrast, α-conotoxin gAuIB inhibits non-competitively the 
α3β4 nAChR (10), but it was shown to nevertheless bind to the orthosteric binding site (17). 
This latter study unequivocally identified that gAuIB binds at the α3(+)β4(-) interface using 
the electrophysiological recording of nAChRs expressing β4 subunit mutants. As an 
explanation to the non-competitive nature of the inhibition, gAuIB was proposed to stabilise 
the desensitized state of α3β4 nAChR (17). It was previously demonstrated using single 
channel recording that another antagonist, DHβE, stabilised the desensitized state of a nAChR 
(18), despite binding in the orthosteric binding site (19).  
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The molecular models were refined by a 50 ns molecular dynamics simulation in explicit water 
using the GROMACS 5.1.4 package (20) and the Amber99SB-ILDN protein force field (21), 
as described previously (22,23). Briefly, the systems were gradually heated from 50 to 300 K 
at constant volume and then simulated with constant pressure while removing progressively 
the restraints imposed on the protein and peptide atoms. All bonds involving hydrogen atoms 
were constrained with the LINCS algorithm, allowing the use of a 2 fs time step. The particle-
mesh Ewald method was used to compute long-range electrostatic interactions. The models of 
complexes involving two rAuIB mutants, [S4A]rAuIB and [F9A]rAuIB, were initially 
generated by substituting residue side chains using Modeller 9v18 and then carrying out 
molecular dynamics simulations as described above. The backbone root-mean-square deviation 
from the starting conformation was stable over the last 20 ns of the simulations and this period 
was used for analysis. The solvent accessible surface area was calculated using the GROMACS 
package with a probe radius of 1.4 Å. Additional 200 ns molecular dynamics simulations were 
also carried out using a similar set-up for rAuIB and [P7A]rAuIB in the absence of the receptor. 
Secondary structure analyses of these simulations were computed using the DSSP program (24) 
and the GROMACS package.  
3.3 Results 
3.3.1 Peptide synthesis and oxidative folding  
We designed a suite of mutants in which all non-Cys residues of rAuIB were separately 
substituted by Ala to identify the positions that are crucial for the inhibition of the α3β4 nAChR 
(Table 3.1). All the Ala mutants of rAuIB as well as rAuIB, gAuIB and [P7A]gAuIB were 
successfully synthesised with orthogonal protection of the cysteine side chains to orient the 
folding toward a unique disulfide isomer. 
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Table 3.1 Amino acid sequences, yield and purity of gAuIB, rAuIB and variants in this study. 
Peptide Sequence 
Theoretical 
massa 
Observed 
massa 
Yield Purity 
gAuIB GCCSYPPCFATNPDC* 1572.8 1572.2 17.7% > 95% 
rAuIB GCCSYPPCFATNPDC* 1572.8 1572.4 15.1% > 95% 
[G1A]rAuIB ACCSYPPCFATNPDC* 1586.8 1586.6 12% > 95% 
[S4A]rAuIB GCCAYPPCFATNPDC* 1556.8 1556.6 12.6% > 95% 
[Y5A]rAuIB GCCSAPPCFATNPDC* 1480.7 1480.3 18.3% > 95% 
[P6A]rAuIB GCCSYAPCFATNPDC* 1546.7 1546.4 22% > 95% 
[P7A]rAuIB GCCSYPACFATNPDC* 1546.7 1546.4 26% > 95% 
[F9A]rAuIB GCCSYPPCAATNPDC* 1496.7 1496.3 23.3% > 95% 
[T11A]rAuIB GCCSYPPCFAANPDC* 1542.8 1542.4 6% > 95% 
[N12A]rAuIB GCCSYPPCFATAPDC* 1529.8 1529.4 19.3% > 95% 
[P13A]rAuIB GCCSYPPCFATNADC* 1546.8 1546.4 22% > 95% 
[D14A]rAuIB GCCSYPPCFATNPAC* 1528.8 1528.4 21.6% > 95% 
[P7A]gAuIB GCCSYPACFATNPDC* 1546.7 1546.2 21.6% > 95% 
a Average mass in Dalton; * C-terminal amidation 
 
3.3.2 [P7A]rAuIB has more similar secondary Hα chemical shifts to gAuIB 
 
Secondary Hα chemical shifts analysis, which is useful for deducing secondary structure 
elements, was conducted for gAuIB, rAuIB and all mutants (Figure 3.2). The Hα secondary 
chemical shifts of rAuIB synthesised in this study were in agreement with previously reported 
values (11), indicating that the fold of rAuIB is the same as in previous studies. Apart from 
some local changes in the chemical shift at the substitution site, all mutants displayed a similar 
pattern of shifts to the parent peptide except [P7A]rAuIB (Figure 3.2 C). Interestingly, residues 
from Pro6 to Phe9 of [P7A]rAuIB had negative secondary Hα chemical shifts (Figure 3.2 C), 
indicating that this segment adopts an α-helical structure, a motif that exists in the globular 
isomer but not in the ribbon isomer. The P7A substitution therefore seems to have improved 
the definition of the structure of rAuIB, with the parent peptide being devoid of stable regular 
secondary structure. The retention time and secondary Hα chemical shifts between [P7A]rAuIB 
and [P7A]gAuIB were different, excluding the possibility that [P7A]rAuIB converted into  
[P7A]gAuIB during the folding process (Figure 3.2D). To further substantiate this difference 
of conformation, we carried out two 200 ns molecular dynamics simulations: one simulation 
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starting from the NMR solution structure of rAuIB, and the second from a model of the P7A 
variant, which was created by simple side chain swaps in the NMR structure of rAuIB. 
Consistent with the NMR measurements, the simulation of [P7A]rAuIB suggested the 
existence of a stable α-helix from Pro6 to Phe9 (Figure 3.2 E). Interestingly, the P7A variant 
was more rigid than the parent peptide, as measured using the root-mean-square fluctuation 
(Figure 3.2 F). 
 
Figure 3.2 Secondary Hα chemical shifts (ΔδHα) of gAuIB, rAuIB and their variants (panels 
A, B and C) and analysis of the conformation of [P7A]rAuIB (panels D, E and F). A, B and C: 
Secondary Hα chemical shifts of gAuIB, [P7A]gAuIB, rAuIB, and the rAuIB variants. The 
sequence of AuIB is indicated at the bottom. The dashed lines at 0.1 ppm and -0.1 ppm indicate 
the cut-off considered for assessing regular secondary structure content (above 0.1 ppm is β-
strand and under -0.1 ppm is α-helix). D: Co-elution profile by reversed-phase HPLC of 
[P7A]rAuIB and [P7A]gAuIB monitored by absorbance at 214 nm. E: Secondary structure 
content of rAuIB and [P7A]rAuIB monitored over 200 ns molecular dynamics simulations. 
The positions in the sequence are on the y-axis. The secondary structure around position 7 is 
highlighted using a red dashed line. F: Root-mean-square fluctuation (RMSF) of the Cα of each 
position of rAuIB and [P7A]rAuIB over 200 ns molecular dynamics simulations. The RMSF 
was computed by fitting the Cα of the molecules to the first frame of each simulation. 
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3.3.3 Several rAuIB analogues have decreased potency at rat α3β4 nAChR 
All peptides were tested for inhibition of the rat α3β4 nAChR subtype heterologously expressed 
in X. laevis oocytes. In the first round of electrophysiological experiments, all rAuIB Ala 
mutants were tested at 1 µM (corresponding to the reported IC50 of rAuIB (10)) and gAuIB 
was tested at 3 µM, resulting in 30–40% inhibition of ACh-evoked currents of rat α3β4 
(α3:β4 = 10:1) nAChR (Figure 3.3 A). The rAuIB Ala mutants exhibited comparable activity   
Figure 3.3 Activity of gAuIB, rAuIB and alanine mutants of rAuIB at the rat α3β4 nAChR. A 
and B: Bar graphs showing relative ACh-evoked peak current inhibition of rat α3β4 nAChR 
(α3:β4 = 10:1) by rAuIB analogues and gAuIB compared with rAuIB. In A, the peptides were 
tested at 1 μM, except gAuIB (3 µΜ). In B, the peptides were tested at 100 μM. The dashed 
lines indicate relative current amplitude in the presence of rAuIB. C: Superimposed 
representative traces of ACh-evoked currents mediated by rat α3β4 nAChR in the absence 
(black) and presence (red) of 1 µM (left) or 100 µM (right) [S4A]rAuIB. D: Concentration-
response relationship of relative ACh-evoked current amplitude mediated by rat α3β4 nAChR 
(α3:β4 = 10:1) in the presence of [S4A]rAuIB (10 nM−100 μM) giving an IC50 of 441.8 ± 98.5 
nM. Whole-cell currents at rat α3β4 were activated by 50 μM ACh. Relative current amplitude 
values are mean ± standard error of the mean; n = 5-9. The difference between the relative 
current amplitude of rAuIB and each variant was evaluated using the unpaired Student’s t-test; 
* indicates a p < 0.05. 
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to the parent peptide except for [S4A] and [F9A]rAuIB, which caused 25% and 20% inhibition, 
respectively (Figure 3.3 A). Comparison of the rat α3β4 nAChR inhibition by [S4A] and 
[F9A]rAuIB indicates that the difference was not statistically significant. In the second round, 
all peptides were tested at 100 µM, inhibiting 35–55% of ACh-evoked currents of rat α3β4 
(α3:β4 = 10:1) nAChR (Figure 3.3 A). Mutation at S4, P6, F9, T11, N12 and D14 caused a 
decrease in activity, ca. 40% inhibition, whereas other peptides had higher activity, with 45–
55% inhibition (Figure 3.3 B and C). The efficacy (maximum inhibition of ACh-evoked 
currents) of rAuIB was ~55%, which is ~15% lower than reported previously (10). This 
difference may arise from variations in the relative levels of expression of α3 and β4 subunits 
in different batches of oocytes.  
 
In summary, none of the single position variants displayed a dramatic loss of activity compared 
to the parent peptide. The Ala substitution of six positions in rAuIB led to a decreased activity 
at high concentration, but only two substitutions, S4A and F9A, significantly impacted activity 
at a concentration similar to the IC50 of rAuIB, suggesting they are more critical for 
antagonizing the activity of rat α3β4 nAChR. To better quantify the loss of activity, we 
calculated the IC50 of [S4A]rAuIB at the α3β4 nAChR (α3:β4 = 10:1) to be 442 ± 99 nM 
(Figure 3.3 D); the IC50 of rAuIB was previously reported to be 860 nM at the same receptor 
stoichiometry (10). Considering the variability between different electrophysiological set-ups, 
we believe that inhibition by rAuIB and [S4A] rAuIB are of the same order of magnitude, i.e., 
the S4A substitution caused a less than 10-fold drop decrease in inhibition. 
 
3.3.4 rAuIB adopts a binding mode similar to that of globular α-conotoxins 
Since the functional data indicated that rAuIB inhibits the α3(+)α3(-) interface of the (α3)3(β4)2 
nAChR (10) we built molecular models of the interaction between the α3(+)α3(-) binding site 
and rAuIB. This model was refined using molecular dynamics simulations and used to propose 
explanations for the SAR data. A molecular model of the interaction between gAuIB and the 
α3(+)β4(-) binding site was built similarly to that of rAuIB for comparison purposes. The 
molecular interactions between the peptides and the receptors were monitored over the last 20 
ns of each 50 ns simulation. This period of 20 ns, during which the system reached equilibrium, 
is referred to as the “simulation time”. 
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3.3.4.1 Binding mode of gAuIB at the rat α3β4 nAChR 
The G1A, P6A and F9A mutants of gAuIB are reported to display decreased inhibitory activity 
at rat α3β4 nAChR compared to gAuIB (17). The molecular model of the complex between 
gAuIB and the α3(+)β4(-) binding site (Figure 3.4 A), which is very similar to a reported 
molecular model of the same system (17), can be used to suggest rational explanations to the 
consequence of these substitutions. The positively charged N-terminus (Gly1) is in the 
proximity of the negatively charged side chain oxygen atoms of D168 and D169 in the 
simulation, with an average distance of 3.9 Å and 2.8 Å. A stable salt bridge was established 
between D169 and the N-terminus during the simulation time and a similar interaction was 
transiently formed between D169 and the N-terminus. Therefore, substitution of this first 
residue of the toxin by Ala could change the peptide backbone conformation and prevent the 
establishment of these salt bridges.  
 
Pro6 is a highly conserved residue among α-conotoxins because it anchors the conotoxins into 
an aromatic pocket on the nAChR that is important for the interaction between nAChR and 
agonists (25). It is therefore not surprising that the substitution of Pro6 by Ala caused a decrease 
in activity. The side chain of Phe9 is embedded in a hydrophobic pocket formed by K57, E59, 
Q117 and L119 of the β4 subunit, and the backbone oxygen of Phe9 formed a hydrogen bond 
with the receptor Q117 during 85% of the simulation time. The substitution of the bulky Phe9 
by an Ala, which has a smaller side chain, would cause a change in shape complementarity at 
the interface, possibly resulting in a reorientation of the peptide in the binding pocket (similar 
to [F9A]rAuIB described below). 
3.3.4.2 Binding mode of rAuIB at the rat α3β4 nAChR 
Our molecular models suggest that the conformation adopted by rAuIB when bound to the rat 
α3β4 nAChR is similar to that of gAuIB except for the N- and C- termini (Figure 3.4 B). The 
interactions established by the first loop of AuIB are similar for the two isomers, and this loop 
sits deeply in the orthosteric binding site of the α3β4 nAChR. The first disulfide bond (i.e., Cys 
I-Cys III for gAuIB and Cys I-Cys IV for rAuIB) packs similarly against the vicinal disulfide 
bond of the C-loop, and this interaction is a conserved feature in the crystal structures of α-
conotoxins/AChBP. Because of this interaction, the different disulfide connectivities of the two 
isomers resulted in different peptide conformation and a different location of their N- and C- 
termini within the nAChR binding site. The charged N-terminus, (Gly1) interacts with the  
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Figure 3.4 Molecular models of complexes between α3β4 nAChR and gAuIB (A), rAuIB (B), 
[S4A]rAuIB (C), or [F9A]rAuIB (D). The evolution of a selection of distances indicative of 
hydrogen bonds between pairs of residues at the interface is shown at the bottom for each model. 
Hydrogen bonds monitored in the bottom panel are displayed as dotted black lines on the 
structure. Interactions between charged side chains are circled with a dotted red line. The label 
for each distance comprises the residue of the toxin followed by the residue of the receptor. A 
dashed line at 3.2 Å indicates the upper-limit between the donor and acceptor atoms involved 
in a hydrogen bond. Panel B inset shows an overlay of the binding modes of rAuIB (orange) 
and gAuIB (white). Panel D inset shows that the C-loop in the [F9A]rAuIB molecular model 
(orange) moves outward compared to the C-loop in the model of the rAuIB/α3β4 nAChR 
complex (white). 
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acidic residues of the F-loop of α3β4 nAChR in the gAuIB model (Figure 3.4 A) but not in the 
model of rAuIB (Figure 3.4 B). The location of the amidated C-terminus in the nAChR binding  
site is also different between the two isomers; this difference results from the different 
conformation of the second loop.  
 
We have shown the side chains of Ser4 and Phe9 in rAuIB are the most important for activity 
at the rat α3β4 nAChR. As shown in Figure 3.4B, Ser4 of rAuIB establishes a stable side chain-
side chain hydrogen bond with D169 (98% of the simulation time). Additionally, Ser4 forms 
transient hydrogen bonds with S36 and N166 (40% of the simulation time). Phe9 of rAuIB 
interacts with the α3(-) subunit: it creates a hydrogen bond with K57 through its backbone 
oxygen during 93% of the simulation and its side chain contacts the residues E34, S36, W55, 
K57 and I119. The distance between the heavy atoms of Phe9 and of the aforementioned 
residues of the α3(-) subunit was below 5.0 Å, the distance considered to define a contact.  
 
Positions 11, 12 and 14 of rAuIB caused a small drop of inhibition when mutated to Ala. These 
three residues are located at the interface with the receptor in the binding model but their side 
chains are also solvated, suggesting that their contribution to the electrostatic component of the 
binding energy is at best weak. Indeed, their involvement was only detected experimentally at 
the highest concentration (100 µM). By contrast, the impact of the substitutions S4A and F9A 
were detected at the lower concentration of 1 µM. We further studied the impact of these two 
substitutions on the binding mode by carrying out further molecular dynamics simulations.  
3.3.4.3 Binding mode of [S4A]rAuIB at the rat α3β4 nAChR 
The binding mode resulting from the 50 ns molecular dynamics simulation of [S4A]rAuIB 
displayed subtle variations from that of the parent peptide, with differences mainly located in 
the proximity of the modified position 4 (Figure 3.4 C). Besides position 4, all positions at the 
interface with the β4 subunit, such as Phe9, established similar molecular interactions in the 
S4A mutated model. The simulation suggests that the loss of the hydrogen bond between Ser4 
and D169 is compensated by the establishment of a hydrogen bond between the side chain of 
α3(-) K168 and the backbone oxygen of the toxin Cys2, which was stable for 89% of the 
simulation time. The conformation of the side chain of K168 of the receptor seems to be also 
stabilised by electrostatic interactions with the D169 side chain. This electrostatic interaction 
was not possible in the rAuIB model because D169 was engaged in a hydrogen bond with Ser4 
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and consequently maintained away from K168 (Figure 3.4 B and C). The transient hydrogen 
bonds between Ser4 and α3(-) S36/N166 established in the model of rAuIB were not 
compensated in the mutated model of [S4A]rAuIB. Therefore, we suggest that [S4A]rAuIB 
displays overall fewer hydrogen bonds with the receptor than the parent peptide. Based on 
electrophysiological measurements, we proposed that the decrease in activity was lower than 
10-fold, corresponding to a loss of less than 1.4 kcal/mol. This energy is typical of a weak 
hydrogen bond interaction, which is consistent with the 40% occurrence of the hydrogen bonds 
between Ser4 and S36/N166 during the molecular dynamics simulations. 
3.3.4.4 Binding mode of [F9A]rAuIB at the rat α3β4 nAChR 
According to the molecular model of rAuIB bound to the α3(+)α3(-) binding site, Phe9 is 
buried at the interface with the receptor. Its substitution by Ala creates a gap between the α3(-) 
subunit and the peptide in the initial step of the simulation. During this simulation, the peptide 
reoriented slightly in the binding site, resulting in several changes of pairwise interactions and 
a slight outward reorientation of the C-loop (Figure 3.4 D). Globally, the F9A variant had fewer 
contacts with the receptor than the parent peptide, as evidenced by a decrease in buried surface 
area from 1646 Å2 to 1452 Å2. As a result of the slight shift in orientation, the backbone oxygen 
of Ala9 only forms a transient hydrogen bond (42% of the simulation time) with the side chain 
of K57, whereas this interaction was present during 93% of the simulation time for the parent 
peptide. Similarly, the hydrogen bond between Ser4 (rAuIB) and D169 (α3 subunit) of the 
receptor was only observed during 75% of the simulation time compared to 98% for the parent 
peptide. We therefore propose that the F9A substitution caused a slight shift in the binding 
mode, resulting in fewer contacts and hydrogen bonds at the interface. 
3.4 Discussion 
The surprising discovery that the ribbon isomer of an α-conotoxin displays higher potency than 
the corresponding globular isomer (11) contrasts with the previously held assumption that 
native (globular) disulfide isomers have optimal activity. We carried out a complete Ala-scan 
of rAuIB, discovering the side chains of two positions, Ser4 and Phe9, were the most important 
for activity against the rat α3β4 nAChR. We have rationalized these data by proposing a binding 
mode between rAuIB and α3β4 nAChR. Molecular dynamics simulation suggested that rAuIB 
adopts a well-defined conformation when bound to its molecular target and that the binding 
mode is highly stable. A number of other SAR studies have been conducted on globular α-
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conotoxins (26), and we compared our results to these studies to further evaluate the molecular 
model of rAuIB binding mode.  
 
Position 1 was identified to be important for gAuIB activity at the α3β4 nAChR (17) but this 
was not the case for rAuIB (this study), paralleling the contrasting role of this position observed 
in several other studies on α-conotoxins. As for rAuIB, the G1A substitution had no impact on 
the inhibition of α7 nAChR by α-conotoxin ImI (27), and a minor impact on the affinity of α-
conotoxin MII for the α3β2 nAChR (< 5-fold difference) (28). A molecular model of the 
interaction between ImI and the α7 nAChR indeed suggested that ImI Gly1 does not interact 
with the receptor (23), similar to our model of the rAuIB/α3β4 nAChR complex. In contrast, 
the G1A mutation of α-conotoxin TxID resulted in a ~20-fold decreased activity at the α3β4 
nAChR (29), and the same substitution caused a significant decrease in activity for α-conotoxin 
gAuIB at the α3β4 nAChR (17). The molecular models of the corresponding complexes 
suggested that the N-terminus of these peptides potentially forms a salt bridge with negatively 
charged residues located in the F-loop of the receptor (17,29), as in our model of the 
gAuIB/α3β4 nAChR complex. 
 
The S4A substitution impacted the activity of rAuIB at the α3β4 nAChR, but it was reported 
not to affect that of gAuIB (17). As for gAuIB, this substitution had no effect on the activity or 
affinity of α-conotoxin RgIA at α9α10 (30), ImI at α7 (27,31), PeIA at α3β2 and α6/α3β2β3 
(32), BuIA at α6/α3β2β3 (33) and TxID at α3β4 nAChRs (29). Only a small decrease of 
inhibition of five- to eight-fold was reported after a substitution equivalent to S4A in GID* 
(S7A for GID*) and MII at the α4β2 and α3β2 nAChRs, respectively (28,34,35). TxID Ser4 
was suggested to have no interaction with the receptor using molecular modelling, explaining 
that its substitution to Ala was innocuous (29). In contrast, a molecular model of the complexes 
involving GID* and the α4β2 nAChR suggested that the Ser side chain potentially forms a 
hydrogen bond with an Asp residue in the F-loop of the receptor (36), similar to our model of 
the rAuIB/α3β4 nAChR complex.  
 
Pro6 is highly conserved among all α-conotoxins and typically interacts with the aromatic box, 
which is a conserved ACh interaction site in the nAChR and AChBP orthosteric binding sites 
(37-39). Pro6 is also essential for stabilizing the structure of globular α-conotoxins: replacing 
this Pro with Ala typically results in a change of conformation linked to a decrease or loss of 
activity. For example, the P6A substitution of α-conotoxin PeIA caused a 20-fold decrease of 
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inhibition of the α6/α3β2β3 nAChR compared to the parent peptide (32). The P6A substitution 
of α-conotoxins ImI and MI resulted in a 50–70 fold decrease in affinity for the α7 and muscle 
type nAChRs, respectively (27,31,40), whereas this substitution caused a >700-fold decrease 
in activity for α-conotoxin MII at the α3β2 nAChR (27,34). The same substitution resulted in 
a loss of helical content for globular Vc1.1 and a marked decrease in inhibitory activity of α-
conotoxin Vc1.1 (41). Similarly, the P6A substitution of gAuIB resulted in a decrease in 
secondary structure content as well as a complete loss of inhibitory activity (17). In contrast, 
[P6A]rAuIB showed only a small decrease in activity compared to the parent peptide. Our 
molecular models suggest that Pro6 of rAuIB and gAuIB should make similar interactions with 
the receptor and we propose that the different impact that P6A substitution had on the activity 
of the two peptides arises from its differential effect on the peptide structures. Indeed, P6A 
substitution destabilises the small α-helical motif required for the activity of gAuIB. In contrast, 
as rAuIB already lacks regular secondary structure, P6A does not further impact its propensity 
to adopt the α-helical content required for binding to the receptor. The substantial decrease in 
inhibitory activity of gAuIB resulting from P6A substitution appears therefore to result 
primarily from the change of conformation of the peptide rather than decreased interactions of 
the position 6 side chain at the interface. 
 
The only rAuIB variant that displayed different Hα secondary chemical shifts from the parent 
peptide was [P7A]rAuIB, indicating that this variant adopts a different fold in solution. NMR 
spectroscopy data suggest that [P7A]rAuIB adopts a helical structure, whereas rAuIB lacked 
regular secondary structure and was globally less structured. A possible explanation for this 
change of conformation is that Ala residues promote the formation of α-helices, whereas Pro 
residues typically destabilise regular secondary structure elements. BuIA is the only other α-
conotoxin that has a similar cysteine scaffold to AuIB and had its ribbon isomer studied by 
NMR spectroscopy (42). As for ribbon AuIB, ribbon BuIA displays Pro residues at positions 6 
and 7. The ribbon isomer of BuIA also has a more flexible backbone than the globular isomer 
and does not form the α-helix that is a conserved feature of α-conotoxin globular isomers. It 
would be interesting to study the influence of the P7A substitution on the structure of ribbon 
BuIA because this substitution could increase the helical content similarly to rAuIB. In our 
molecular models, rAuIB interacts with the receptor using a conformation that is stabilised by 
the P7A substitution, suggesting that the binding energy of the variant would benefit from a 
more favourable entropy term than the parent peptide. Nevertheless, the activity of the mutant 
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was not experimentally different from the parent peptide, which could be interpreted by the 
loss of a number of contacts between the Pro side chain and the receptor. 
 
The substitution of position 9 with Ala caused a decrease in affinity for both gAuIB (17) and 
rAuIB (this work). Position 9 of globular α-conotoxins is buried at the interface with the 
complementary subunit and has been identified as important for modulating the activity of a 
range of globular α-conotoxins (17,29,30,33,35,41). For example, Ala mutation at this position 
caused a 50-fold decrease in activity of α-conotoxin GI at the muscle-type nAChR (43), a 20–
30 fold decrease in affinity of α-conotoxin MII at α3β2 nAChR (28,34), and a >17-fold 
decrease in activity of α-conotoxin GID* at α4β2 nAChR (35). In addition, the R9A 
substitution resulted in a 1500-fold decrease in activity of RgIA at α9α10 nAChR (30). 
Substitution of position 9 can also enhance activity, with the [S9A]PeIA displaying three-fold 
lower IC50 than the parent peptide at the α3β2 nAChR (32) and the [N9W]Vc1.1 and 
[N9A]Vc1.1 increasing activity by 20- and 30-fold at the human α9α10 nAChR compared to 
Vc1.1, respectively (22,42). Several molecular models have been built to explain the ability of 
α-conotoxin position 9 to modulate nAChR inhibition, which suggests this residue interacts 
with various positions of the complementary subunit depending on the conotoxin and nAChR 
subtype (22,36,44). In the proposed binding mode of rAuIB, Phe9 mainly interacts with β4 
K57, whereas GID* Arg12 was proposed to interact with β2 position 59 (36), [N9W]Vc1.1 
Trp9 with α10 W118 (22) and RgIA Arg9 with α10 W81 (44). 
 
In summary, we have identified a number of positions crucial for the activity of the ribbon 
isomer of AuIB that are also important for the activity of gAuIB and/or other globular α-
conotoxins, indicating rAuIB has a globally similar binding mode to the globular isomers of α-
conotoxins. According to our models, the main difference between the ribbon and globular 
AuIB at the interface with α3β4 nAChR is at their N- and C- termini. Changing the disulfide 
connectivity of α-conotoxins from a globular to ribbon isomer therefore does not introduce a 
dramatic change of binding mode at the interface with the receptor but it does create some 
different interactions that can have a substantial impact on the selectivity, as is the case for 
AuIB. Ribbon isomers should therefore be more systematically considered in the design of 
molecular probes and specific inhibitors of nAChR subtypes based on α-conotoxins. 
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4.1 Introduction 
As mentioned in Chapter 1, α-conotoxins have potential in the development of novel drugs to 
treat diseases such as neuropathic pain, nicotine addiction, and Alzheimer's disease (1-5). 
However, two main challenges currently limit their translational application. The first 
challenge is that some α-conotoxins have less potency at human compared to rat nAChR 
subtypes (6-10). Species-level differences in the amino acid sequences of target nAChRs can 
have substantial effects on ligand activity. For example, the α-conotoxin Vc1.1 can potently 
inhibit α9α10 nAChR, which is involved in chronic pain (11). Vc1.1 was discontinued in 
clinical trial phase II for the treatment of pain because it was discovered that this peptide’s 
behaviour at the human receptor was different from the rat receptor (12). A recent study 
suggested that a single amino acid difference between human and rat α9 nAChR subunits 
causes globular α-conotoxin Vc1.1 to inhibit rat α9α10 nAChR two orders of magnitude more 
potently than human α9α10 nAChR (7). More broadly, designing α-conotoxins to be selective 
for a particular nAChR subtype is challenging (13-16). For example, α-conotoxin RegIIA 
inhibits the α3β2, α3β4 and α7 nAChRs with an IC50 of 33, 97 and 103 nM, respectively (16). 
Since it is relatively unselective, designing RegIIA as a selective and potent probe of one 
subtype has been challenging (17).  
 
The design of α-conotoxins selective and potent for human nAChR subtypes has been carried 
out by synthesising large libraries of α-conotoxin mutants (18,19). For example, Romero et al. 
discovered a globular RgIA mutant that inhibits the human and rat α9α10 nAChR with the 
same order of magnitude, improving the activity from > 10,000 nM to 1.5 nM at human α9α10 
nAChR (18). A globular PeIA mutant was shown to be > 15,000-fold more potent at blocking 
α6β2* over α3β2 nAChRs, whereas the parent peptides had IC50s of 17.2 nM and 19.2 nM at 
these two receptors, respectively (19). However, large SAR studies are costly and time-
consuming, and computational methods could be used to focus these studies on the most 
interesting variants (7). Recently, our laboratory has designed two Vc1.1 mutants informed by 
a combination of molecular modelling and energy calculation methods. One of these variants, 
[N9W]Vc1.1, has improved activity by ~30-fold on human α9α10 nAChR compared to the 
parent peptide with the IC50 value of 33 nM (7). This suggests computational methods have 
potential to guide design of selective nAChR subtypes inhibitors based on α-conotoxins. This 
variant was shown to be an effective analgesic in a mouse model of chronic abdominal pain 
(20). 
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Binding free energy computations are potentially important tools for designing selective 
inhibitors based on α-conotoxins. Nevertheless, these methods need to be benchmarked to 
assess their accuracy in the context of nAChR/α-conotoxin systems because they are especially 
sensitive to the accuracy of the structural models. Ideally, these methods should be employed 
with high-resolution experimental structures. Unfortunately, there is so far no crystal structure 
of any nAChR in complex with α-conotoxin. The acetylcholine binding proteins (AChBPs), 
which are structurally homologous to the extracellular domains (ECDs) of the nAChRs, can be 
relatively easily crystallised and studied using X-ray crystallography. AChBPs have been co-
crystallised in complex with several α-conotoxins (21-26), providing relatively accurate 
information on the binding mode of α-conotoxins. In this study, we benchmarked four 
mutational energy prediction methods using the recently published crystal structures of the 
AChBP/α-conotoxin LsIA (PDB: 5T90) and AChBP/α-conotoxin LvIA complexes (PDB: 
5XGL). In addition, we used the associated experimental affinity of LsIA mutants for AChBP 
with results from a competitive radioligand binding assay with 3H-epibatidine and LvIA 
mutants for AChBP measured using surface plasmon resonance (24,26).  
4.2 Materials and Methods 
4.2.1 Binding free energy predictors 
We have compared four methods: BeAtMuSic (27), Foldx (28,29), coarse-grained umbrella-
sampling (CG_US) (30,31), and MMGBSA/MMPBSA (32). BeAtMuSiC predicts the change 
in binding affinity upon mutation. It relies on a set of statistical potentials derived from coarse-
grained representation of protein structures. It is used to predict the effect of the mutations on 
the overall stability of a complex and the strength of interactions at the interface (27). Foldx 
uses an empirical energy function that was optimised using experimental data to predict 
unfolding free energy upon mutations (28,29). The umbrella sampling (US) method predicts 
the binding free energy by computing the potential of mean force (PMF) derived from a series 
of simulations of unbinding of the ligand from the receptor (30). This method is considered too 
computationally intensive to be applied systematically to study a large number of mutations of 
α-conotoxin/nAChR systems (33-35), but we will benchmark a recent method that applies US 
to a coarse-grained simplified representation of the system, dramatically speeding the 
computations (31). Finally, MM/PBSA computes free energies by combining three energies: 
1) internal energy of the solute using a molecular mechanics force field (MM), 2) electrostatic 
component of solute/solvent interaction using the Poisson-Boltzmann equation (PB) and 3) 
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non-polar component of solute/solvent interaction using an equation depending on the surface 
area (SA) (32). The MM/GBSA variant employs the Generalized Born approximation instead 
of PB, which is faster and in some instance more accurate than PB when the accuracy of the 
system is low. 
4.2.2 Experimental data 
Experimental data from two recently published papers was used to guide the computations in 
this study (24,26). Specifically, Abraham et al. (26) calculated the crystal structure of the Ls-
AChBP/LsIA complex, synthesised 10 LsIA variants, and measured their competitive affinity 
at AChBP. The IC50 values were calculated for only six of the LsIA variants. For the remaining 
four mutants, the IC50 values were reported as greater than 10 µM (26). Xu et al. (24) calculated 
the crystal structure of the Ac-AChBP/LvIA complex, and the competitive binding of seven 
LvIA variants were measured at AChBP. Another four variants were reported to lose their 
binding capacity for Ac-AChBP, but the maximal concentration of the peptide used to test for 
these four variants were not provided (24). Because of these missing values, we used the 
confusion matrix to analyse the performance of energy prediction methods (described below). 
Some regions of the flexible loops were not resolved in the 5T90 structure, and these loops 
were modelled using Modeller 9v18.  
4.2.3 Molecular dynamics simulation 
Refinement. The two crystal structures were refined by a 10 ns molecular dynamics simulation 
in explicit water using the AMBER 16 package and the ff14SB protein force field. Briefly, the 
receptor complexes were solvated in a truncated octahedral TIP3P water box simulation. 
Sodium ions were added to neutralise the systems. 2,000 steps of steepest descent minimisation 
and then 10,000 steps of conjugate gradient minimisation were performed to ensure that the 
systems have no steric clashes or inappropriate geometry. The systems were then gradually 
heated up from 50 to 300 K in the NVT ensemble over 100 ps with the solute restrained to their 
position by a harmonic force of 100 kcal/mol·Å2. MD simulations were then carried out in the 
NPT ensemble, and the position restraints were gradually removed over 100 ps. All bonds 
involving hydrogen atoms were constrained with the SHAKE algorithm, allowing the use of a 
2 fs time step and the Particle-mesh Ewald method was used to compute long-range 
electrostatic interactions. The systems were mutated by substituting residue side chains using 
Modeller 9v18 and then molecular dynamics simulations were carried out as above. 
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Coarse-grained simulations. All coarse-grained molecular dynamics simulations (500 ns) in 
explicit water were performed using the GROMACS 5.2 package (36) and the SIRAH force 
field (http://www.sirahff.com/) (37). Protonation state of each residue was assigned at pH 7 
using PROPKA (38) and the PDB2PQR server (http://nbcr-222.ucsd.edu/pdb2pqr_2.0.0/) with 
the output naming scheme set to AMBER. The protein complexes were placed in a box of 8 
nm × 20 nm × 8 nm, which is large enough to have the conotoxin and the receptor at a distance 
along the Y-axis during unbinding. Each system was firstly minimised with 10,000 steps using 
the steepest descent. Each system was then gradually heated up from 50 to 300 K in the NVT 
ensemble over 2 ns. Position restraints were gradually removed from 1,000 kJ mol-1 nm-2 to 0 
kJ mol-1 nm-2 over 1 ns, followed by an unrestrained 500 ns simulation. The Particle-mesh 
Ewald method (39) was used to compute long-range electrostatic interactions with a cutoff of 
1.2 nm and a grid spacing of 0.33 nm. A 1.2 nm cutoff was used for van der Waals interactions. 
The models of complexes involving mutant peptides were initially generated by substituting 
residue side chains using Modeller 9v18 and then coarse-grained umbrella simulations were 
carried out as described above. The backbone RMSD from the starting conformation was stable 
over the last 100 ns of the 500 ns simulations and this period was used for analysis. After this 
initial simulation, the α-conotoxin was pulled away from the receptor using an umbrella pulling 
force with a harmonic force constant of 2,000 kJ/mol/nm2 over 500 ps of MD simulation along 
the Y-axis. 500 frames were extracted from the pulling trajectory, and the center of mass 
(COM) distance of each frame from the starting position was measured between the ligand and 
receptor. A total of 30 frames with a COM spaced by 0.15 nm were chosen and used to carry 
out US. The selected 30 frames from each system were run in the independent US. The PMF 
was calculated with the weighted histogram analysis method (WHAM) (30), which is 
implemented in the wham module of GROMACS. PMF value of each peptide was an average 
value calculated from last 30 ns using the WHAM. Each system was simulated until the PMF 
converges. The PMF values were used to compute the relative binding free energies. 
4.2.4 Analysis of energy prediction data using confusion matrix 
The experimental data and predicted ΔΔGs were divided into three classes as below: For 
experimental data, 1) decreased in activity (IC50 of mutant is at least 8-fold higher than the IC50 
of wild type); 2) similar activity (IC50s value of wild type and mutant are within 8-fold); 3) 
increased in activity (IC50 of mutant is at least 8-fold lower than the IC50 of the wild type). The 
predicted ΔΔG were binned into three classes: 1) decreased in affinity (ΔΔG ≥ 1 kcal/mol for 
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BeAtMuSiC, Foldx and CG_US; ΔΔG ≥ 13 kcal/mol for MMPBSA/MMGBSA); 2) similar 
affinity (-1 kcal/mol < ΔΔG < 1 kcal/mol for BeAtMuSiC, Foldx and CG_US; -13 kcal/mol < 
ΔΔG < 13 kcal/mol for MMPBSA/MMGBSA); increased in affinity (ΔΔG ≤ -1 kcal/mol for 
BeAtMuSiC, Foldx and CG_US; ΔΔG ≤ -13 kcal/mol for MMPBSA/MMGBSA).  
 
The confusion matrix was used to analyse for energy prediction data. The terms of Positive (P), 
Negative (N), True (T) and False (F) were defined as follow: 1) Positive: IC50 decreased or no 
change in experimental data; 2) Negative: IC50 increased in experimental data; 3) True: 
predicted ΔΔG class is consistent with experimental data; 4) False: predicted ΔΔG class is not 
consistent with experimental data. The ΔΔG results were classified as true positives (TP), false 
positives (FP), true negatives (TN) and false positives (FP). On the basis of these four values, 
the accuracy and Matthews Correlation Coefficient (MCC) were calculated using the equations 
as below:  
Accuracy =
𝐓𝐏 + 𝐓𝐍
𝐓𝐏 + 𝐓𝐍 + 𝐅𝐏 + 𝐅𝐍
 × 100% 
MCC=
𝐓𝐏×𝐓𝐍−𝐅𝐏×𝐅𝐍 
√(𝑻𝑷+𝑭𝑷)(𝑻𝑷+𝑭𝑵)(𝑻𝑵+𝑭𝑷)(𝑻𝑵+𝑭𝑵)
 
4.3 Results 
4.3.1 BeAtMuSic  
The crystal structures of AChBP/LvIA and AChBP/LsIA were firstly used to predict the 
mutational energies for all site-directed mutants. Then refinements were put on these structures 
using either the energy minimisation (EM) or the molecular dynamics simulation (MD), and 
the refined structures were used as inputs to calculate ΔΔGs (Table 4.1). The accuracies and 
MCCs of the predicted ΔΔGs based on published IC50s were calculated using the confusion 
matrix, and the results are shown in Table 4.1.  
 
According to our tests, BeAtMuSic can make accurate ΔΔG predictions for mutants displaying 
a decreased in IC50 (Table 4.1). Interestingly, the EM and MD refinement approaches were 
unable to improve the performance of BeAtMuSic in mutational energy calculation. The 
predicted ΔΔGs of [S4A]LvIA, [N12L]LsIA and LsIA-[Q55K]AChBP do not agree with the 
experimental affinity data (highlighted in red in Table 4.1) and were the main data points 
lowering the accuracy and MCC values.  
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Table 4.1 Fold change in IC50 of mutants versus wild type for the LvIA/AChBP and 
LsIA/AChBP systems, and ΔΔGs computed using BeAtMuSic. IC50s were taken from Xu et 
al. (24) and Abraham et al.(26). TP: True Positive; TN: True Negative; FP: False Positive; FN: 
False Negative.  
Position 
Experimental 
fold change 
Crystal structure 
Energy 
minimisation 
Molecular 
simulationa 
BeAtMuSic  BeAtMuSic  BeAtMuSic  
[S4A]LvIA 0.18 1.3 FN 1.2 FN 1.1 FN 
[H5A]LvIA No activity 2.1 TN 2.2 TN 2.2 TN 
[P6A]LvIA No activity 2.4 TN 2.3 TN 2.2 TN 
[A7G]LvIA No activity 1 TN 1.1 TN 1 TN 
[N9A]LvIA 0.63 0.4 TP 0.7 TP 1 FN 
[D11A]LvIA 0.13 0.8 TP 0.7 TP 0.8 TP 
[H12A]LvIA No activity 1.7 TN 1.5 TN 1.3 TN 
[R10M]LsIA 2.4 0.3 TP 0.3 TP 0.3 TP 
[R10D]LsIA > 47.6 2.1 TN 1.9 TN 2 TN 
[R10F]LsIA 0.52 -0.1 TP 0 TP 0 TP 
[N12Q]LsIA 11.62 1.1 TN 1.3 TN 0.9 FP 
[N12D]LsIA > 47.6 1.6 TN 1.7 TN 1.4 TN 
[N12L]LsIA > 47.6 0.5 FP 0.4 FP 0.6 FP 
LsIA-
[Q55K]AChBP 
82.86 0.7 FP 0.9 FP 0.8 FP 
[R10M]LsIA -
[Q55K]AChBP 
0.41 0.1 TP 0.1 TP 0.2 TP 
[R10F]LsIA -
[Q55K]AChBP 
0.05 -0.1 TP -0.2 TP -0.1 TP 
Accuracy 81.3% 81.3% 68.8% 
MCC 0.63 0.63 0.38 
a the ΔΔGs values were averaged on five frames (2ns, 4ns, 6ns, 8ns, and 10ns) extracted from 
the MD simulation. 
 
4.3.2 Foldx 
In our hands, Foldx had 75% accuracy and an MCC score of 0.52 when performed using the 
crystal structure. The predictions were improved to 87.5% accuracy and 0.75 MCC when using 
EM structures, mainly because the effects of mutations were better accounted for the 
[N12L]LsIA and [Q55K]AChBP variants (highlighted in blue, Table 4.2). MD refinement did 
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Table 4.2 Fold change in IC50 of mutants versus wild type for the LvIA/AChBP and 
LsIA/AChBP systems, and ΔΔGs computed using Foldx. IC50s were taken from Xu et al.(24) 
and Abraham et al.(26). TP: True Positive; TN: True Negative; FP: False Positive; FN: False 
Negative. 
Position 
Experimental 
fold change  
Crystal structure Energy minimisation 
Molecular 
simulationa 
Foldx  Foldx  Foldx  
[S4A]LvIA 0.18 -0.3 TP 0 TP 0.3 TP 
[H5A]LvIA No activity 1.2 TN 1.9 TN 1.3 TN 
[P6A]LvIA No activity 1.7 TN 1.8 TN 1.4 TN 
[A7G]LvIA No activity 0.7 FP 0.9 FP 0.9 FP 
[N9A]LvIA 0.63 -0.1 TP 0.2 TP 0.1 TP 
[D11A]LvIA 0.13 -1.6 TP -1.7 TP -0.9 TP 
[H12A]LvIA No activity 1.9 TN 2.5 TN 0.9 FP 
[R10M]LsIA 2.4 0.6 TP -0.2 TP 1.1 FN 
[R10D]LsIA > 47.6 3.1 TN 2.3 TN 3.6 TN 
[R10F]LsIA 0.52 2.5 FN 2 FN 3 FN 
[N12Q]LsIA 11.62 1.9 TN 1.5 TN 2.9 TN 
[N12D]LsIA > 47.6 2.1 TN 3.5 TN 2.9 TN 
[N12L]LsIA > 47.6 0.5 FP 1.4 TN 2.8 TN 
LsIA-
[Q55K]AChBP 
82.86 0.9 FP 1.2 TN 2.2 TN 
[R10M]LsIA -
[Q55K]AChBP 
0.41 -2.2 TP -1.1 TP -1.4 TP 
[R10F]LsIA -
[Q55K]AChBP 
0.05 -1 TP -1 TP -0.1 TP 
Accuracy 75% 87.5% 75% 
MCC 0.52 0.75 0.49 
a the ΔΔGs values were averaged on five frames (2ns, 4ns, 6ns, 8ns, and 10ns) extracted from 
the MD simulation. 
 
not improve performance, probably because this type of refinement requires longer sampling 
times and increased number of data points along the trajectory (40). Interestingly, Foldx failed 
to achieve accurate predictions for the [A7G]LvIA and [R10F]LsIA mutants, regardless of 
refinement procedure. 
4.3.3 Coarse-grained umbrella-sampling (CG_US)  
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All LvIA and LsIA mutants reached PMF convergence using the last 30 ns period of each US 
simulation (Figure 4.1 and 4.2). Nevertheless, the calculated ΔΔG values of LvIA and LsIA 
mutants were all < -1 kcal/mol with the exception of [N9A]LvIA, indicating all mutated 
peptides had an improved affinity compared to parent peptide (Table 4.3). This was not in 
agreement with experimental affinity data. For LvIA, the computed ΔΔGs of H5A, A7G and 
H12A are -22.5 kcal/mol, -26.8 kcal/mol and -35.7 kcal/mol, respectively, but these mutants 
had no affinity for AChBP experimentally. The R10D, N12Q, N12D, and N12L substitutions 
of LsIA caused a significant decrease in affinity (> 8-fold) according to the simulations. In 
contrast, experimentally the IC50 of LsIA decreased from 0.21 µM to 17.4 µM when AChBP 
Gln55 was substituted by a Lys residue. The accuracy and MCC of the calculated ΔΔGs are 
47% and 0 respectively, demonstrating this energy prediction method is not suitable for α-
conotoxin/AChBP complexes. 
Figure 4.1 PMF profiles (kcal/mol) for AChBP in complex with LvIA and its mutants as a 
function of separation distance (nm). 
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Figure 4.2 PMF profiles (kcal/mol) for AChBP in complex with LsIA and its mutants as a 
function of separation distance (nm). 
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Table 4.3 Fold change in IC50 of mutants versus wild type for the LvIA/AChBP and 
LsIA/AChBP systems, and ΔΔGs computed using CG_US, MMGBSA and MMPBSA. IC50s 
were taken from Xu et al. (24) and Abraham et al.(26). TP: True Positive; TN: True Negative; 
FP: False Positive; FN: False Negative. 
position 
Experimental 
fold change  
CG_US 
 
MMGBSA 
 
MMPBSA 
 
[S4A]LvIA 0.18 -39.7 TP 10.1 TP -1.4 TP 
[H5A]LvIA No activity -22.5 FP 15.7 TN -3.3 FP 
[P6A]LvIA No activity   19.6 TN 8.6 FP 
[A7G]LvIA No activity -26.8 FP 5 FP -3.9 FP 
[N9A]LvIA 0.63 -0.9 TP 4.6 TN 4 TP 
[D11A]LvIA 0.13 -16.8 TP 17.4 FN -6.2 TP 
[H12A]LvIA No activity -35.7 FP 20.4 TN 6.6 FP 
[R10M]LsIA 2.4 -22.2 TP 8.9 TP 7.9 TP 
[R10D]LsIA > 47.6 -6.3 FP 6.7 FP 21.1 TN 
[R10F]LsIA 0.52 -4 TP 10.8 TP 12.3 TP 
[N12Q]LsIA 11.62 -4.5 FP 7.6 FP 6.4 FP 
[N12D]LsIA > 47.6 -3.8 FP 11.1 FP 19.2 TN 
[N12L]LsIA > 47.6 -1.6 FP 8.7 FP 8.2 FP 
LsIA-[Q55K]AChBP 82.86 -1.2 FP 15.6 TN 12.6 FP 
[R10M]LsIA -
[Q55K]AChBP 
0.41 -10.9 TP 14 FN 8.1 TP 
[R10F]LsIA -[Q55K]AChBP 0.05 -2.9 TP 6.5 TP 7 TP 
Accuracy 47% 56.3% 56.3% 
MCC 0 0.16 0.33 
a The [P6A]_LvIA moved away from the binding site of the AChBP after 500 ns molecular dynamics simulation. 
Therefore the ΔΔG of [P6A]LvIA was not calculated. 
 
4.3.4 MMGBSA and MMPBSA 
Each model was refined using 10 ns molecular dynamics simulations in triplicate with all atoms 
of the receptor located more than 5 Å from α-conotoxins restrained to their starting position. 
The mutational energies of peptides were calculated using MMGBSA and MMPBSA (Table 
4.3). The predictions had an Accuracy and MCC results of 56.3% and 0.16 for MMGBSA, 
respectively, and 56.3% and 0.33 of MMPBSA, respectively, suggesting that these two energy 
methods are not highly accurate. Interestingly, incorrect predictions of MMGBSA and 
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MMPBSA were made for mutants with decreased IC50s (five mutants for MMGBSA and seven 
mutants for MMPBSA). 
4.4 Discussion 
Computational protein design method could be potentially used for increasing the selectivity 
of α-conotoxins on human nAChRs. Binding free energy prediction has been successfully 
applied in peptide design (7). We here benchmarked four binding free energy computation 
methods using experimental structures of complexes between α-conotoxins and AChBP. 
 
Most predicted mutational energies made by BeAtMuSiC were consistent with experimental 
data. Incorrect predictions were made for three LvIA mutants: [S4A]LvIA, [N12L]LsIA and 
LsIA/[Q55K]AChBP. The [S4A]LvIA, has comparable affinity to the parent peptide according 
to experimental data, but our models predicted decreased affinity compared to the parent 
peptide (Table 4.1). In the crystal structure of the AChBP/LvIA complex, the S4 of LvIA forms 
a hydrogen bond with Ser166 of the complementary subunit (Figure 4.3A) (24). In the 
molecular model of [S4A]LvIA/AChBP complex after MD refinement (Figure 4.3B), the 
substitution of S4 to Ala resulted in a small change of conformation of the second loop, 
resulting in the creation of a hydrogen bond between LvIA Asn9 and AChBP Gln55 
(complementary subunit). BeAtMuSic likely cannot provide an accurate prediction for 
[S4A]LvIA because it does not account for change of backbone conformation (27). The 
experimental data showed reduced activity for [N12L]LsIA and LsIA/[Q55K]AChBP, but 
predicted ΔΔGs suggested these two mutants had comparable affinity compared to parent 
peptide. In the molecular models of AChBP/[N12L]LsIA and [Q55K]AChBP/LsIA complexes 
after MD refinement (data not shown here), these two peptides also have a small conformation 
change in the second loop at the binding site. Thus, BeAtMuSic made incorrect predictions for 
these two mutants. A previous study showed that BeAtMuSic only performs well in predicting 
large decrease in affinity (41). Our results confirm this, noting that BeAtMuSic was not able to 
correctly predict any increase in affinity. The EM and MD refinements had no impact on the 
performance of BeAtMuSic, probably because the coarse-grained treatment of side chains of 
BeAtMuSiC is insensitive to the quality of the structure (27,42). BeAtMusic could be used to 
predict mutants that would have decreased activity using a low resolution molecular model of 
α-conotxin/nAChR. 
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Figure 4.3 Interactions between AChBP and LvIA, [S4A]LvIA, LsIA or [R10F]LsIA. A: 
Crystal structure of the AChBP/LvIA complex (PDB: 5XGL); B: Overlay of the crystal 
structure of the AChBP/LvIA (orange) complex and MD structure of the AChBP/[S4A]LvIA 
(magenta) complex; C: The crystal structure of the AChBP/LsIA complex (PDB: 5T90); D: 
Overlay of the crystal structure of the AChBP/LsIA (orange) complex and MD structure of the 
AChBP/[R10F]LsIA (magenta) complex. The hydrogen bonds are displayed as dotted black 
lines and interactions between charged side chains are circled with a dotted red line.  
 
 
The performance of Foldx was significantly improved on EM structures, increasing the 
accuracy and MCC values from 75% and 0.52 to 87.5% and 0.75, respectively. The MCC of 
0.75 is the best recorded among all methods tested here, suggesting that Foldx is the best 
method for predicting the mutational effect if the model is refined by EM. Because Foldx is 
highly sensitive to the quality of the structure (43,44), EM is likely to improve the quality of 
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the structure. EM refinement allowed the program to have accurate ΔΔG predictions for 
[N12L]LsIA and LsIA-[Q55K]AChBP but still not enough for a correct prediction for 
[A7G]LvIA. In contrast, MD did not improve the performance of Foldx in ΔΔG prediction, 
possibly because 10 ns simulation time is insufficient for the α-conotoxin/AChBP systems to 
reach equilibrium. [R10F]LsIA was inaccurately predicted by Foldx using the crystal structure, 
EM structure and MD structure. LvIA Arg10 is buried at the interface with the complementary 
subunit in the crystal structure (PDB: 5XGL). It forms a salt bridge with Asp160 and has a 
repulsive force with Lys34 (Figure 4.3C), and its side chain makes contact with Lys34, Gln55, 
Met114 and Tyr164 of AChBP (26). The substitution of the charged residue (equivalent to 
position 9 of other α-conotoxins) to a hydrophobic Phe could cause the change of binding mode 
of LsIA at the binding site, discussed in Chapter 3. However, Foldx does not consider change 
of binding mode upon mutations as it only computes change in the conformation of side chains 
(45). During the MD simulation of the complex between [R10F]LsIA and AChBP (Figure 
4.3D), the backbone of [R10F]LsIA shifted, suggesting that the [R10F] mutation indeed 
resulted in a small change of binding mode. A previous study showed that the correlation (R2) 
value between the Foldx calculated ΔΔGs and the experimentally derived ΔΔGs was 0.7 for 
the α-conotoxin ImI/human αnAChR system (35), suggesting that Foldx is a reliable energy 
prediction tool for α-conotoxin/nAChR systems. A recent review summarised the use of Foldx 
in protein engineering applications and concluded that Foldx is better than random and is useful 
for protein design applications (46). Accordingly, we here suggest that Foldx could be used to 
design α-conotoxins with improved selectivity and potency for nAChR subtypes.  
  
The mutational energies obtained from CG_US were all negative, which does not correlate 
with the experimental affinity data. In contrast, the CG_US was successfully applied to 
calculate ΔΔGs in three different protein-protein complexes from the SKEMPI database. The 
R2 with experimental values reached 0.88, 0.92 and 0.5 for the three complexes, and it clearly 
outperformed Foldx (47). Additionally, the umbrella sampling has accurately calculated PMFs 
of disassociation for a range of conotoxins complexed with different ion channels and 
receptors. For example, the PMFs of α-conotoxins [A10L,D14K]PnIA and ImI from AChBP 
were -24.2 kcal/mol and -20.3 kcal/mol, in agreement with experimental values (33). The PMFs 
of [γ4E]GID from α7 and α4β2 nAChR were also in accordance with their experimental data 
(35). Similarly, the PMFs of µ-conotoxin PIIIA from Nav1.1 to Nav1.9 were calculated, and 
the R2 between PMFs and experimentally derived energies was 0.68 (48). The PMFs of ω-
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conotoxin GVIA from Cav2.2 were calculated, and the IC50s obtained from PMFs were similar 
to the experimental IC50 of ω-conotoxin GVIA (~1 nM) (49). These successful examples show 
that US could predict mutational energies for the α-conotoxin/nAChR systems with reasonable 
accuracy. However, in our study, we found that CG_US method did not result in correct 
predictions. Therefore we suggest that the SIRAH force field is not suitable for simulating the 
α-conotoxin/AChBP systems.  
 
Surprisingly, the mutational energies calculated using MMGBSA and MMPBSA did not 
perform as expected in this study. Our results contrast with previous report in which MMGBSA 
was shown to correctly predict ΔΔG (40). Initially, the MMGBSA performed well, predicting 
mutational energies of α-conotoxin ImI correlating with experimental data (R2 = 0.74) (40). In 
a subsequent study, this method was used to pinpoint the binding site of α-conotoxin Vc1.1 on 
the α9α10 nAChR. The mutational energy prediction by MMGBSA successfully helped design 
an α-conotoxin Vc1.1 mutant, [N9W]Vc1.1, with improved activity on human α9α10 nAChR 
α10(+)α9(-) binding pocket (7). Recently, α9α10 nAChR has been reported to have two 
stoichiometries: (α9)2(α10)3 and (α9)3(α10)2 (50). The MMGBSA method assisted in the 
elucidation of structural characterisitcs which affect Vc1.1 binding to the α10(+)α9(-) binding 
pocket of the (α9)2(α10)3 stoichiometry and the α9(+)α9(-) binding pocket of the (α9)3(α10)2 
stoichiometry (51). Two main approaches are likely to improve the performance of MMGBSA 
or MMPBSA in our study: 1) predicting the mutational energy using energy minimisation 
structures, which has been reported by Yu et al.(40); 2) prolonging the simulation time, because 
the α-conotoxin/AChBP systems might not reach equilibrium by 10 ns. 
 
In summary, we have benchmarked a series of mutational energy prediction methods and 
identified that Foldx is the most reliable method. Notably, this method successfully predicted 
which mutated peptides would exhibit increased and decreased affinities with the receptor. 
Foldx therefore is useful for designing selective inhibitors of nAChR subtypes based on α-
conotoxins. 
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5.1 Introduction 
The α4β2 nAChR is the most abundant and widely distributed neuronal nAChR, and is a 
potential target for a range of neurological conditions and disorders, such as nicotine addiction 
(1,2), epilepsy (3), Parkinson’s, and Alzheimer’s disease (4). The heteromeric α4β2 nAChR 
has two major stoichiometries with distinct functional properties: (α4)2(β2)3 (a pentamer with 
two α4 subunits and three β2 subunits) and (α4)3(β2)2 nAChR (5,6). The two subtypes differ 
in sensitivity to agonists, antagonists and allosteric modulators. Each subtype also has distinct 
single-channel conductance, mean open lifetime, and activation-deactivation kinetics (7). 
Interestingly, both stoichiometries are associated with nicotine addiction and congenital 
epilepsy (8,9). Previous studies showed that chronic inactivation of α4β2 nAChR could result 
in a significant impairment in spatial memory (10), indicating that understanding α4β2 nAChR 
antagonists could assist in designing drugs to treat memory impairment.  
 
To date, no conotoxin that can selectively and potently block the α4β2 subtypes has been 
discovered (11). Some globular α-conotoxins have shown low inhibition of the α4β2 receptor, 
suggesting that it is possible to target it with a peptide (12-15). These conotoxins are 
nevertheless more active at other nAChR subtypes, and they need modification to generate 
selective compounds for the α4β2 nAChR. α-Conotoxin GID was discovered from C. 
geographus. It has a four-residue N-terminal tail and residues with post-translational 
modifications in positions 4 and 16 (Figure 5.1) (13). Globular α-conotoxin GID (gGID) 
inhibits the rat α3β2, α4β2 and α7 nAChRs with IC50s of 3.4 nM, 128.6 nM and 5.1 nM, 
respectively (16). An alanine scan of non-cysteine residues showed that most of the gGID Ala 
mutants had at least a 10-fold decrease in activity at the α4β2 nAChR (Table 5.1) (16).  
Figure 5.1 Amino acid sequence of globular and ribbon GID and the 3D NMR solution 
structure of gGID (PDB: 1MTQ). Gla:γ-carboxyglutamate acid, O: hydroxyproline; The 
connectivities of disulfide bonds are shown as orange lines and the disulfide bonds are shown 
as orange sticks in the 3D structure; “C” and “N” stand for the C-terminus and N-terminus, 
respectively.  
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Table 5.1 Electrophysiology results for gGID and its analogues (16).  
Peptide name 
IC50 values (mean_S.E.) (nM) 
α4β2 nAChR α3β2 nAChR α7 nAChR 
gGID 128.6 ± 13.1 3.4 ± 0.5 5.1 ± 1.3 
[Gla4E]gGID 56.8 ± 13.2 2.9 ± 0.6 5.9 ± 0.6 
[Gla4E,I1A]gGID 255.9 ± 57.2 15.5 ± 2.2 5.9 ± 1.6 
[Gla4E,R2A]gGID NA 97.6 ± 28.4 12.5 ± 4.4 
[Gla4E,D3A]gGID NA 69.8 ± 16.5 42.1 ± 10.9 
[Gla4A]gGID 52 ± 16.5 3.0 ± 0.6 6.1 ± 2.8 
[Gla4E,S7A]gGID 429.9 ± 82.6 2.5 ± 0.3 12.8 ± 1.5 
[Gla4E,N8A]gGID NA 4.1 ± 1.6 >30a 
[Gla4E,P9A]gGID NA 172.6 ± 50.1 90.5 ± 22.6 
[Gla4E,R12A]gGID NA 10.4 ± 0.7 48.8 ± 4.2 
[Gla4E,V13A]gGID 112.5 ± 32.1 0.6 ± 0.1 11.2 ± 4.0 
[Gla4E,N14A]gGID NA 1.3 ± 0.5 51.4 ± 6.8 
[Gla4E,N15A]gGID NA 3.3 ± 0.2 6.0 ± 1.0 
[Gla4E,O16A]gGID NA 13.5 ± 2.1 13.0 ± 4.4 
[Gla4E,H17A]gGID 571.7 ± 59.6 2.7 ± 0.2 5.0 ± 1.9 
[Gla4E,V18A]gGID 602 ± 75.1 40.8 ± 8.0 7.9 ± 2.9 
a Where IC50 values were unable to be determined, estimations are represented as > the highest 
concentration tested. NA denotes a nonactive analogue at concentrations ≤ 1µM.  
 
Banerjee et al. built a binding mode of the gGID with α4(+)β2(-) interface using the crystal 
structure of acetylcholine binding protein (AChBP) in complex with [A10L, D14K]PnIA as a 
template, which was used to design new mutants to selectively and potently inhibit α4β2 
nAChR. Out of 22 mutants that have been designed and tested, [V18N]gGID maintained a 
comparable activity at rat α4β2 nAChR but had no biological activity at the rat α3β2 nAChR, 
suggesting that the selectivity against different subtypes of this molecule can be improved using 
a de novo design approach (17). Likewise, Leffler et al. built the molecular model of gGID 
interacting with the α4(+)β2(-) binding site based on the crystal structures of AChBPs in 
complex with α-conotoxins [A10L, D14K]PnIA, ImI, BuIA, and [A10L]TxIA, which was 
refined using a newly developed docking algorithm ToxDock based on the Rosetta modeling 
framework (18). The refined molecular model was then used to screen virtually some predicted 
bioactive peptides that were selected to evaluate their activities against a range of nAChRs. 
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The [V13Y]gGID displayed reduced activity at the human α7 nAChR from 0.1 µM to 4 µM 
while maintaining same activity at the α4β2 nAChR (3 µM), but demonstrated increased 
activity at the α3β2 nAChR from 10 nM to 2 nM (18).  
 
The modification of gGID to selectively and potently block α4β2 nAChRs has been attempted 
but did not succeed, possibly resulting from imperfect GID/α4β2 complex molecular models. 
Although the AChBP is a structural homologue to nAChR and is typically considered as a 
structural surrogate of nAChR ligand binding domain, the low sequence identity (< 30%) 
possibly prevents from constructing a reliable α4β2 nAChR molecular model using homology 
modelling only. Recently, the high-resolution 3D crystal structures of (α4)2(β2)3 and (α4)3(β2)2 
nAChR have been released (19,20), which provide an opportunity to build a more accurate 
molecular model of the complex between GID and α4β2 nAChR. The globular [Gla4E]GID 
([Gla4E]gGID) mutant was reported to have comparable activity at rat α3β2, α4β2 and α7 
nAChR to gGID (Table 5.1), and this variant was used to build the molecular models described 
below. The [Gla4E]gGID is referred to as the “ gGID*” in the literature and this study. 
Likewise, the ribbon [Gla4E]GID is referred to as the “ rGID*”. 
In this chapter, we report on the development of selective and potent α4β2 nAChR inhibitors 
based on the globular and ribbon GID, and guided by molecular modelling and energy 
calculation method. The binding modes of gGID* at α3β2, α4β2 and α7 nAChRs were built by 
assuming interactions at the α3(+)β2(-), α4(+)β2(-) and α7(+)α7(-) interface. As noted in 
Chapter 3, the ribbon α-conotoxin can bind at the α(+)α(-) interface, suggesting that the ribbon 
GID (rGID) could bind the (α4)3(β2)2 nAChR at the α4(+)α4(-) interface. We therefore built a 
molecular model of the interaction between rGID* and (α4)3(β2)2 nAChR at the interface 
between two a4 subunits, with the aim of modifying the peptide to selectively and potently 
inhibit (α4)3(β2)2 nAChR. These molecular models were used to calculate the mutational 
energies (ΔΔG) of GID* mutants, and this analysis was used to suggest potential α4β2 nAChR 
inhibitors. 
5.2 Materials and methods  
5.2.1 Homology modelling and molecular dynamics simulation 
Molecular models of the interaction between gGID* and the ECD of rat α3β2, α4β2 and α7 
nAChRs were built by homology using Modeller 9v18 (21) and the following crystal structures 
as templates: the complex between Aplysia californica acetylcholine-binding protein (AChBP) 
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and conotoxin PnIA variant (PDB ID: 2BR8), and the human α4β2 nAChR (PDB ID: 5KXI; 
6CNK; 6CNJ). The complexes between gGID* and the ECD of (α3)2(β2)3, (α4)2(β2)3 and (α7)5 
nAChR were modelled by assuming an interaction at the α3(+)β2(), α4(+)β2() and 
α7(+)α7() orthosteric binding sites. The complex between rGID* and the ECD of (α4)3(β2)2 
nAChR was built by assuming an interaction at the α4(+)α4() orthosteric binding site. 
Modeller 9v18 was set up to create 100 models, and the best model was selected according to 
the lowest DOPE score (22). 
 
The models were refined by a 50-100 ns molecular dynamics simulation in a solution of 
discrete water using the GROMACS 5.1.4 package (23) and the Amber99SB-ILDN protein 
force field (24) using the same methods described in “Material and methods” section in Chapter 
3. MD simulations were finished until the last 20 ns of the simulations was stable (60 ns for 
gGID*/α4β2 complex, 100 ns for gGID*/α3β2, 70 ns for gGID*/α7 complex and 50 ns for 
rGID*/α4β2 complex). All bonds involving hydrogen atoms were constrained with the LINCS 
algorithm (25) and the particle-mesh Ewald method (26) was used to compute long-range 
electrostatic interactions. 
5.2.2 Mutational energy calculation  
For energy calculation, 100 frames were extracted from each MD simulation, and the resulting 
structures were optimised using Foldx (http://foldx.crg.es/) RepairPDB. The Buildmodel 
command of Foldx was used to mutate the residues and build mutation models. The interaction 
energy and mutational energy of the complex between GID* and α3β2, α4β2 or α7 nAChR 
were calculated by the following equations: ΔGbinding = Gcomplex − (Greceptor + Gligand) and 
ΔΔGbinding = ΔGbinding (mutant) – ΔGbinding (wildtype), which was conducted by the command 
Positionscan. The ΔΔG of each mutation is an automatic output in Foldx and generated in a 
separate file.  
5.2.3 Analysis of energy prediction data 
The experimental data and predicted ΔΔGs were divided into three classes. For experimental 
data, 1) decreased in activity (IC50 value of the mutant ≥ 8-fold of IC50 value of the wildtype); 
2) similar activity (affinity value of the wildtype versus affinity value of a mutant is within 8-
fold); 3) improved in activity (8-fold IC50 value of the wildtype ≤ IC50 value of the mutant). For 
the predicted ΔΔG, we binned the ΔΔG into three classes: 1) decreased in activity (ΔΔG ≥ 1 
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kcal/mol); 2) similar activity (-1 kcal/mol < ΔΔG < 1 kcal/mol); improved in activity (ΔΔG ≤ 
-1 kcal/mol).  
 
A confusion matrix was used to analyse energy prediction data. The terms of Positive (P), 
Negative (N), True (T) and False (F) were defined as follow: 1) Positive: IC50 value of peptides 
decreased or showed no change in experimental data; 2) Negative: IC50 value of peptides 
increased in experimental data; 3) True: predicted mutational energies are consistent with 
experimental data; 4) False: predicted mutational energies are not consistent with experimental 
data. The mutational energy results were classified as true positives (TP), false positives (FP), 
true negatives (TN) and false positives (FP). By these four values, the accuracy and Matthews 
correlation coefficient (MCC) were calculated using the equations as below:  
Accuracy =
𝐓𝐏 + 𝐓𝐍
𝐓𝐏 + 𝐓𝐍 + 𝐅𝐏 + 𝐅𝐍
 × 100% 
MCC=
𝐓𝐏×𝐓𝐍−𝐅𝐏×𝐅𝐍 
√(𝑻𝑷+𝑭𝑷)(𝑻𝑷+𝑭𝑵)(𝑻𝑵+𝑭𝑷)(𝑻𝑵+𝑭𝑵)
 
5.3 Results 
5.3.1 Binding modes of GID*  
We here built molecular models of the interaction between the α4(+)2(), α3(+)2(), and 
α7(+)α7() binding sites and gGID* as well as interaction between the α4(+)α4() binding site 
and rGID*. These models were refined using molecular dynamics simulations and used to 
propose explanations for the SAR data previously published by Millard et al. (16). The 
backbone RMSD from the starting conformation was stable over the last 20 ns of the 
simulations and this period was referred to ‘simulation time’ and was used for analysis. 
5.3.1.1 Binding mode of gGID* at the rat α4(+)β2() interface 
In the previous study, the SAR experimental data of gGID* (Table 5.1) showed that R2A, D3A, 
N8A, P9A, R12A, N14A, N15A, O16A, H17A and V18A mutants lost activity at α4β2 nAChR 
by more than 8-fold (16). The molecular model of the complex between gGID* and α4(+)β2() 
binding site can be used to provide rational explanations of these data (Figure 5.2). 
 
In the proposed model, Arg2 and Asp3 form salt bridges with α4 (+)-E191 and α4(+)-R188, 
respectively. Therefore, substitution of these two residues by Ala could prevent the 
establishment of the salt bridges, potentially resulting in a change of conformation of the tail, 
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which could explain why the substitution of these two residues by Ala caused a decrease in 
activity > 18-fold (Table 5.1). Pro9 (Corresponding to Pro 6 in most other α-conotoxins) is 
highly conserved among all α-conotoxins, and it is crucial for stabilising the structure of 
globular α-conotoxins; Substitution of Pro by an Ala typically results in a dramatic decrease in 
activity (27-35). In the molecular model, Arg12 is buried at the interface with the receptor and 
forms a salt bridge with β2 ()-E61. Its side chain interacts within 5 Å of the M36, T59, E61, 
F119 and L121 of β2 () subunit (Distance < 5 Å is considered to be a certain contact in this 
study). It is therefore not surprising that the substitution of Arg by Ala caused a decrease in 
activity by > 18-fold (Table 5.1). Residues Asn8, Asn14 and Hyp16 established hydrogen 
bonds with β2 ()-D171, α4 (+)-T150 and β2 ()-K79, respectively. These interactions were 
present in 85%, 94% and 71% of the molecular dynamics simulation time, respectively. These 
hydrogen bonds seem to be crucial for the activity of the peptide as experimental data showed 
that the loss of any of these hydrogen bonds caused a significant drop in activity (Table 5.1). 
In the molecular model, Asn15 interacts with the C-loop disulfide bond (formed by α4 (+)-
C192, and α4 (+)-C193), Glu195 and Y197. His17 contact with the C-loop disulfide bond. The 
sidechain of Val18 is embedded into a pocket formed by Cys5, Cys6, Arg12, Asn15, Hyp16 
and His17 of gGID* as well as the C-loop disulfide bond. Substitution of Asn15, His17 and 
Val18 by Ala could reduce interaction between the peptide and nAChR, resulting in a decrease  
Figure 5.2 Molecular model of the complex between gGID* and α4(+)β2(-) interface. A: 
Interactions between the receptor and R2, D3, N8, P9, R12, H17, and V18 of gGID*; B: 
Interactions between the receptor and V13 (inserted figure), N14, N15 and O16 of the gGID*. 
Hydrogen bonds are displayed as dotted black lines. Interactions between charged side chains 
are circled with a dotted red line. 
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in activity. It is in agreement with the experimental data that N15A, H17A and V18A mutants 
demonstrated reduced activity compared to the parent peptide (Table 5.1). In the molecular 
model, the side chain of Val13 contacts α4 (+)-W149, α3 (+)-T150, β2 ()-F119 and β2 ()-
L121, and the substitution of Val13 by Ala should result in less contact between the peptide 
and α4β2 nAChR, negatively impacting the activity. By contrast, the experimental data showed 
that the V13A mutant had comparable activity to the gGID*, suggesting that interpreting the 
mutational data by side chain interactions is not sufficient, as reorientation can occur in the 
binding pocket of the conotoxin after a side chain replacement. 
5.3.1.2 Binding mode of gGID* at the rat α3(+)β2() interface 
According to experiments (Table 5.1), the R2A, D3A, P9A and V18A mutants display 
decreased (> 8-fold) potency at rat α3β2 nAChR compared to gGID* (16). The molecular 
model (Figure 5.3A) suggests that a salt bridge is formed between the Arg2 and D171 of 2 () 
subunit. The oxygen of Asp3 forms a stable hydrogen bond (99% of the simulation time) with 
the nitrogen of the α3 (+) -N191 as well as consistent contact with the I188, Y190 and N191 of 
the α3 (+) subunit. The side chain of Val18 interacts with the disulfide bond of the C-loop. In 
the previously reported SAR study, the E4A, R12A, N14A and N15A mutants had no change 
in activity compared to gGID* (16). However, our model (Figure 5.3B) shows that Glu4 builds 
a hydrogen bond with α3 (+)-N191, which was stable for 98% of the simulation time. Arg12  
Figure 5.3 Molecular model of the complex between gGID* and α3(+)β2(-) interface. A: 
Interactions between the receptor and R2, D3, P9, and V18 of gGID*; B: Interactions between 
the receptor and E4, R12, N14, and N15 of the gGID*. Hydrogen bonds are displayed as dotted 
black lines. Interactions between charged side chains are circled with a dotted red line. 
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side chain forms an unstable hydrogen bond with 2 ()-T59 for 41% of the simulation time 
and has charge interaction with 2 ()-D170. It also contacts S38, W57 and T59 of 2 () 
subunit. Asn14 forms hydrogen bonds with α3 (+)-Y197 (94% of the simulation time) and 
Asn15 forms a hydrogen bond with α3 (+)-E195 (99% of the simulation time).  
5.3.1.3 Binding mode of gGID* at the rat α7(+)α7() interface 
The positions 8, 9, 12 and 14 of gGID* are the main determinants of its interaction with rat α7 
nAChR according to experimental data (16). In Figure 5.4A, the molecular model shows that 
Asn8 constantly contacts with α7 (+)-Y93, α7 (+)-Y188 and α7 (+)-Y195. There is a hydrogen 
bond established between Arg12 and α7 ()-Q57 during 79% of the simulation time and the 
side chain of Arg12 interacts with Q57, S59, Q117, L119 and Q161 of α7 () subunit. Asn14 
forms two stable hydrogen bonds with α7 (+)-E193 (85% of the simulation time) and α7 (+)-
Y195 (91% of the simulation time). Apart from the four positions above, experimental 
substitution of other positions with Ala had substitution of other positions with Ala had only a 
minor impact on the inhibition of rat α7 nAChR by gGID*. Nevertheless, the molecular model 
shows that positions 3, 15, 16 and 18 have substantial interactions with the receptor (Figure 
5.4B). Specifically, the Asp3 forms a salt bridge with α7 (+)-K186. The Hyp16 forms hydrogen  
bonds with α7 ()-N111 and α7 ()-H115 during the 66% of the simulation time as well as 
contacting α7 ()-N77 and α7 ()-Q117. The Asn15 and Val18 make contact with the C-loop  
Figure 5.4 Molecular model of the complex between gGID* and α7(+)α7(-) interface. A: 
Interactions between the receptor and N8, P9, R12 and N14 of gGID*; B: Interactions between 
the receptor and D3, N15, O16 and V18 of gGID*. Hydrogen bonds are displayed as dotted 
black lines. Interactions between charged side chains are circled with a dotted red line. 
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disulfide bond. As mentioned previously, interpreting side-chain mutations using only the wild-
type model is limited. The wild-type model does not compensate for energy loss by 
conformation change or change of binding mode, which can occur in conotoxins mutated 
during an Alanine scan.  
5.3.1.4 Binding mode of rGID* at the human α4(+)α4() interface 
We proposed a molecular model of the interaction of rGID* with the α4()α4() binding site 
to inform the design of variants that could bind at this interface. According to the molecular 
model of the complex between rGID* and the α4()α4() binding site (Figure 5.4 A and B), 
the side chain of Arg2 forms a salt bridge with α4 ()-D166. However, Arg2 can also have an 
electrostatic repulsion with Arg12 of rGID*. Arg2 could possibly be used to modulate the 
activity of rGID* at the α4-α4 binding site. In Loop 1, Glu4 interacts with the C-loop disulfide 
bond as well as α4 ()-E191. Ser7 and Asn8 contact with the α4 ()-L168 and α4 ()-Y93, 
respectively.  
Figure 5.5 Molecular model of the complex between rGID* and α4(+)α4(-) interface. A: 
Interactions between the receptor and E4, N8, A10, and N14 of rGID*; B: Interactions between 
the receptor and R2, S7, P9, V13, N15, and H17 of gGID*. Hydrogen bonds are displayed as 
dotted black lines on the structure. Interactions between charged side chains are circled with a 
dotted red line. 
 
As mentioned previously, Pro9 is an important compact point for globular α-conotoxins as it 
binds in a conserved aromatic pocket of the nAChR, which is also the binding site of Ach. 
Ala10 makes contact with Y93, S148, W149, T150, Y151 and Y197 of the α4 (+) subunit. In 
the Loop 2 of rGID*, the sidechain of Arg12 establishes attractive charge interactions with α4 
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()-D166 and contacts with α4 ()-S36 and K57, but it also creates an electrostatic repulsion 
with Arg2. The sidechain of Val13 contacted α4 (+)-Y149, α4 (+)-T150, α4 ()-H109, α4 ()-
Q117, α4 ()-W118 and α4 ()-T119. Asn14 forms a transient hydrogen bond with α4 ()-E195 
(42% of the simulation time) and a stable hydrogen bond with α4 ()-Y197 (73% of the 
simulation time). Asn15 sits at a pocket formed by three disulfide bonds (disulfide bond of C-
loop and two disulfide bonds of rGID*) which seems to maintain the conformation of the 
second loop of rGID* at the binding site. His17 has charge interaction with α4 (-E59 and α4 
()-R115. 
5.3.2 ΔΔGs prediction 
5.3.2.1 Full sequence amino acid scanning of gGID* on rat α3β2, α4β2 and α7 nAChR 
We have shown in Chapter 4 that Foldx gave better energy predictions than other tested 
methods for the α-conotoxin/AChBP complex. We therefore used Foldx to calculate ΔΔGs for 
gGID*/nAChR complexes. Since the four conserved cysteines and Pro9 are crucial for 
maintaining the gGID* structure, ΔΔGs of these five positions were not calculated, except the 
P9A mutation as reported in the literature (16). The ΔΔGs of 266 gGID* mutants were 
calculated in silico using rat α3β2, α4β2 and α7 nAChRs, and the resulting predicted mutational 
energy changes are listed in Tables 5.2 to 5.4. We also calculated the accuracy and MCC of the 
predicted ΔΔGs based on published experimental IC50s using the confusion matrix (Table 5.5). 
The molecular dynamics simulations suggested that the tail of gGID* was very flexible at three 
binding sites, but as mentioned in Chapter 4, the core function of Foldx does not simulate 
backbone movement of the protein. The predictions were particularly inaccurate for mutations 
of position 13 (Red in Table 5.5), suggesting that the molecular models gave unreliable results 
at this position. We therefore excluded mutants derived from I1, R2, D3, E4 and V13 when 
calculating the accuracy and MCC of the predicted ΔΔGs for gGID* mutants. Our data show 
that the gGID*/α4β2 nAChR, gGID*/α3β2 nAChR and gGID*/α7 nAChR systems obtained 
an accuracy of 81.3%, 50%, 66.7% and a MCC of 0.46, 0, 0.32, respectively. Three mutants, 
N15K, O16A and V18N, has their ΔΔGs wrongly predicted at α4β2 nAChR. In contrast, the 
impact of eight mutants (N8A, A10S, R12A, N14A, N15A, N15K, N15H and O16A) was 
wrongly predicted for the α3β2 nAChR, and the impact of three mutants (R12A, N14A and 
O16A) were wrongly predicted for the α7 nAChR system (Table 5.5). These results indicate 
that the ΔΔGs of the 266 gGID* mutants at α4β2 nAChR, rather than α3β2 and α7 nAChR, can 
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be potentially used to identify novel peptides with favourable properties. Surprisingly, the 
mutational energy predictions suggest that the sequence of gGID* seems to be optimal for 
binding to α4β2 nAChR because activity could not be improved via single amino-acid 
substitutions. All mutations at positions 7, 8, 10, 12, 14, 15, 16, 17 and 18 in the α4β2 system 
were predicted to have a decrease or no change in activity compared to the parent peptide 
(Table 5.2). The results from Foldx suggest that it is difficult to design more selective and 
potent α4β2 nAChR inhibitors based on gGID, and therefore designing rGID mutants is 
possibly an alternative way to develop selective and potent α4β2 nAChR inhibitors.  
 
Table 5.2 Predicted mutational energy of full sequence amino acid scanning of gGID* at the 
rat α42 nAChR (266 mutants) 
 I1 R2 D3 E4 S7 N8 A10 R12 V13 N14 N15 O16 H17 V18 
G 0.11 0.96 0.25 -0.25 0.36 2.85 1.33 3.26 2.43 1.66 3.7 0.8 1.59 2.47 
A 0.11 0.77 -0.32 -0.52 -0.38 2.17  2.09 1.46 1.7 1.98 0.92 1.41 1.84 
L 0.04 0.78 -0.29 -1.01 4.75 1.52 1.7 0.32 
-
0.13 
0.33 0.79 0.67 0.63 1.16 
V 0.06 0.97 -0.26 -0.27 2.07 2.22 0.86 2.36  1.9 1.5 1.45 1.3  
I  0.91 -0.49 -0.54 4.07 2.9 1.51 2.07 0.41 1.56 1.19 1.23 0.83 0.87 
T 0.05 0.79 -0.18 -0.3 1.01 1.2 1.17 2.91 1.54 2.12 2 1.33 1.65 2.23 
S 0.08 0.8 -0.42 -0.54  1.51 0.74 2.58 2.43 1.88 2.43 0.78 1.46 2.9 
C 0.01 0.83 -0.29 -0.63 0.63 2 0.73 2.25 1.53 1.4 1.53 1.03 1.31 1.47 
M -0.16 0.87 -0.71 -1.27 4.55 0.54 0.33 0.2 
-
0.68 
0.51 0.42 0.3 0.34 1.1 
Q -0.22 0.43 -0.32 -1.06 6.68 4.45 1.35 1.92 1.96 0.93 1.61 0.63 0.9 2.32 
N -0.04 0.91 -0.26 -0.81 3.22  2.51 2.62 1.56   0.8 1.14 2.8 
R -0.74  -0.48 -1.71 8.66 2.15 0.48  3.57 1.31 0.4 
-
0.05 
0.23 1.69 
K -0.4 0.46 -0.35 -0.53 7.42 2.55 0.73 1.15 1.3 1.13 0.65 0.37 0.4 1.68 
E 0.11 0.92 -0.39  8.35 0 1.79 3.82 2.79 2.14 2.82 0.99 1.01 3.22 
D 0.31 1.39  0.11 5.25 0.29 3.42 4.18 3.11 6.14 3.35 1.08 1.36 4 
P 0.08 1.48 -0.89 2.51 1.53 4.45 0.08 9.23 3 3.71 6.14 0.11 2.65 2.42 
W -0.23 0.98 0.38 -1.49 27.43 1.85 7.68 3.07 4.76 1.85 1.86 0.34 0.4 8.15 
Y 0.09 0.79 -0.15 -1.4 24.51 0.37 7.99 1.6 0.9 1.26 1.18 0.62 -0.18 8.07 
F 0.14 0.72 -0.2 -1.31 18.27 0.06 7.02 0.86 0.1 1.2 0.93 0.2 -0.07 6.71 
H 0.25 0.89 0 -1 22.9 1.53 23.7 3.05 1.93 2.05 1.14 0.87  8.56 
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Table 5.3 Predicted mutational energy of full sequence amino acid scanning of gGID* at the 
rat α32 nAChR (266 mutants) 
 I1 R2 D3 E4 S7 N8 A10 R12 V13 N14 N15 O16 H17 V18 
G 0.35 1.3 0.18 1.23 0.47 2.64 1.48 3.32 2.02 2.67 2.89 1.97 0.31 2.25 
A 0.4 1.14 -0.31 0.72 0.17 2.03 - 2.16 1.2 2.3 1.52 1.51 0.18 1.34 
L -0.05 0.79 -0.7 0.25 1.38 0.16 4.22 0.34 -0.95 1.65 0.82 1.11 -0.47 0.99 
V 0.36 1.19 -0.1 0.67 1.43 1.84 3.99 1.8 - 2.4 1.88 1.05 0.13 - 
I - 1.06 -0.34 0.34 1.66 1.82 5.72 1.54 -0.52 2.49 1.78 2.3 -0.22 0.38 
T 0.41 1.06 0.6 0.96 1.07 0.81 3.37 2.48 1.25 2.82 2.92 2.65 0.37 1.39 
S 0.47 1.06 0.13 1.14 - 1.49 1.12 2.53 1.96 2.54 2.58 1.52 0.17 1.95 
C 0.32 1.06 -0.11 0.77 0.7 1.16 1.83 2.31 1.43 2.16 1.65 1.69 0.05 1.04 
M -0.28 0.72 -1.15 0.4 0.55 0.09 1.63 -0.07 2.95 1.82 0.88 0.71 -0.63 0.59 
Q 0.18 0.88 -0.47 0.4 1.39 1.24 3.5 2 1.15 1.87 1.42 1.55 -0.23 1.61 
N 0.39 0.64 -0.32 0.25 1.88 - 5.04 2.98 1.99 - - 1.45 0.03 1.82 
R -0.1 - -1.15 0.01 0.45 0.49 5.24 - 1.59 2.35 0.32 1.21 -0.61 1.2 
K -0.05 0.44 -0.84 0.19 0.32 0.8 3.49 0.87 0.26 1.75 0.67 1.25 -0.58 1.02 
E 0.32 1.51 -0.25 - 2.88 0.22 4.23 3.68 1.49 3.63 3.04 2.2 -0.02 2.57 
D 0.51 1.47 - 0.1 4.36 -0.82 5.65 4.81 2.79 2.79 3.95 2.98 0.39 3.9 
P 0.48 1.27 -0.17 0.42 1.08 7.56 1.25 8.53 4.07 4.4 5.62 -0.17 1.01 3.39 
W 0.16 1.11 -0.09 0.87 4.14 1.17 19.32 0.37 8.28 3.79 1.07 1.05 -0.49 4.72 
Y 0.55 1.04 -0.35 0.32 3.16 0.27 14.22 0.54 7.23 2.73 1.37 1.82 -0.77 6.66 
F 0.39 0.95 -0.2 0.22 3.24 -0.12 11.47 0.66 2.95 2.43 0.84 1.72 -0.87 4.58 
H 0.48 1.21 -0.06 0.76 3.16 0.76 44.71 2.52 2.49 2.98 0.98 2.41 - 4.44 
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Table 5.4 Predicted mutational energy of full sequence amino acid scanning of gGID* at the 
rat α7 nAChR (266 mutants) 
 I1 R2 D3 E4 S7 N8 A10 R12 V13 N14 N15 O16 H17 V18 
G 0.1 0.74 1.41 0.16 0.52 2.98 0.87 1.05 2.11 1.88 1.49 1.76 0.5 1 
A 0.11 0.66 0.84 -0.02 0.3 1.89  0.04 1.57 0.85 0.52 1.66 0.38 0.8 
L -0.03 0.02 0.05 -0.42 0.22 0.75 2.36 -0.6 -0.27 0.19 -0.45 1.26 -0.36 -0.09 
V 0.1 0.8 0.62 0.29 0.48 2.69 1.32 0.28  2.16 0.46 2.72 0.19  
I  0.4 0.19 -0.01 0.69 1.69 2.01 0.27 -0.43 2.49 0.27 2.74 -0.12 -0.2 
T 0.01 0.75 0.72 0.33 0.21 2.55 1.11 1.19 0.78 1.85 1.56 1.4 0.48 0.64 
S 0.02 0.64 1.13 -0.04  2.16 0.34 0.32 1.82 1.19 1.19 1.93 0.37 0.99 
C 0.02 0.65 0.75 0.16 0.23 1.65 1.14 0.27 1.51 1.01 0.42 1.74 0.17 0.58 
M -0.19 -0.1 
-
0.24 
-0.44 -0.3 0.35 -0.12 -0.86 0.2 0.09 -0.61 0.91 -0.58 -0.35 
Q -0.11 0.6 0.82 -0.57 1 1.6 1.53 1.08 0.99 0.62 0.87 2.06 -0.14 0.34 
N -0.08 0.72 1.25 -0.42 0.73  3.36 0.87 1.61   1.82 0.17 0.5 
R -0.63  0.93 -0.69 0.27 1.39 0.02  2.25 0.21 -0.68 2.99 -0.31 0.02 
K -0.29 0.18 0.73 -0.65 0.38 1.29 1.3 0.16 0.21 0.35 -0.66 2.61 -0.38 -0.07 
E -0.05 0.79 0.45  2.83 0.99 2.32 1.85 1.93 1.11 0.86 1.94 -0.23 0.86 
D 0.09 1.17  0.2 2.91 1.18 3.92 1.95 2.11 2.35 1.11 2.33 0.17 1.3 
P 0.11 1.05 0.05 -0.3 1.39 6.66 0.94 5.99 2.69 6.23 5.31 0.35 1.81 2.92 
W -0.11 0.74 2.32 -0.05 1.35 1.5 13.07 0.51 3.76 4.52 0.02 2.21 -0.63 0.78 
Y 0.11 0.48 1.55 -0.36 0.7 0.42 11.55 0.74 3.49 4.73 -0.63 2.12 -0.85 0.78 
F 0.03 0.43 1.41 -0.49 0.23 -0.15 11.31 -0.19 1.36 3.19 -0.82 1.48 -0.94 0.13 
H -0.14 0.46 5.05 -0.24 1.23 1.1 18.9 1.57 2.31 6.08 0.01 2.87  0.35 
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Table 5.5 Fold change in IC50 values of mutants versus wild type for gGID* and predicted 
mutational energy (ΔΔG). IC50 values were taken from Millard et al. (16) and Banerjee et al. 
(17). The ΔΔGs of gGID* mutants were calculated using Foldx on 100 frames extracted from 
MD simulations. TP: True positive; TN: True negative; FP: False positive; FN: False negative. 
 α4β2 nAChR α3β2 nAChR α7 nAChR 
Position Fold change  Foldx 
 
Fold change  Foldx 
 
Fold change  Foldx 
 
S7A 7.6 -0.38 TP 0.9 0.17 TP 2.2 0.3 TP 
N8A >17.6 2.17 TN 1.4 2.03 FN > 10 1.89 TN 
P9A >17.6 2.89 TN 59.5 2.56 TN 15.3 2.53 TN 
A10S 0.8 0.74 TP 6.4 1.12 FN    
A10T >20.8 1.17 TN >2777.8 3.37 TN    
R12A >17.6 2.09 TN 3.6 2.16 FN 8.3 0.04 FP 
V13A 2 1.46 FN 0.2 1.21 FN 1.9 1.57 FN 
V13F >20.8 0.1 FP 111.1 2.95 TN    
V13W >20.8 4.76 TN >2777.8 8.28 TN    
V13L >20.8 -0.13 FP >2777.8 -0.95 FP    
V13I 1.3 0.41 TP 3.6 -0.52 TP    
V13S 1 2.43 FN 0.4 1.96 FN    
V13T 1.2 1.54 FN 1.3 1.25 FN    
N14A >17.6 1.7 TN 0.4 2.28 FN 8.7 0.85 FP 
N15A >17.6 1.98 TN 1.1 1.52 FN 1 0.52 TP 
N15K >20.8 0.65 FP >2777.8 0.67 FP    
N15H >20.8 1.14 TN 44.4 0.98 FP    
O16A 10.6 0.92 FP 4.7 1.51 FN 2.2 1.66 FN 
H17A 10.6 1.41 TN 0.9 0.18 TP 0.8 0.38 TP 
V18A >17.6 1.84 TN 14.1 1.34 TN 1.3 0.8 TP 
V18Y >20.8 8.07 TN >2777.8 6.66 TN    
V18Q >20.8 2.32 TN >2777.8 1.61 TN    
V18N 0.4 2.8 FN >2777.8 1.82 TN    
Accuracy 81.3% 50% 
MCC                      0.46 0 
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5.3.2.2 Full sequence amino acid scanning of rGID* on human (α4)3(β2)2 nAChR  
Using the molecular model of the complex between rGID* and (α4)3(β2)2 nAChR, the ΔΔGs 
of a library of 285 rGID* mutants were calculated in silico (Table 5.6). The mutants with ΔΔG 
values ≤ -1 kcal/mol were assumed to increase activity significantly. The computations suggest 
that there are no gGID* mutations of positions 4, 17 and 18 that can increase affinity at α4β2 
nAChR (Table 5.2). By contrast, these same positions of rGID* have the potential to be 
mutated to increase affinity at (α4)3(β2)2 nAChR. Specifically, the gGID* ΔΔGs results 
 
Table 5.6 Full sequence amino acid scanning of rGID* at the human α4β2 nAChR 
 I1 R2 D3 E4 S7 N8 P9 A10 R12 V13 N14 N15 O16 H17 V18 
G -0.18 0.99 0.09 0.1 0.14 2.19 5.01 1.34 1.6 1.69 0.68 2.05 2.22 0.05 0.5 
A -0.17 0.86 -0.18 -0.27 -0.7 0.99 3.35  0.75 0.89 0.25 0.69 1.87 0.11 0.22 
L 0.08 0.27 -0.69 -0.8 -1.01 -0.54 7.69 1.99 0.17 -0.38 -0.64 0.33 1.79 0.07 -0.6 
V 0.19 1.19 0.4 0.28 -0.8 0.63 4.19 1.62 1.18  0.75 0.77 2.36 0.78 0 
I  0.74 -0.07 -0.14 0.05 0.55 5.68 3.09 0.94 0.03 0.48 1.98 2.09 0.6 -0.4 
T -0.03 1.2 0.59 0.28 0.22 1.06 4.71 2.26 1.66 1.39 0.64 1.63 2.45 0.79 0.27 
S -0.11 1.11 0.05 0.05  1.73 4.64 1.04 0.85 1.46 0.47 1.59 2.1 0.21 0.26 
C -0.02 1.1 0.13 -0.01 -0.5 1.08 4.7 1.04 1.01 0.83 0.18 0.77 2.17 0.42 0.06 
M -0.15 0.21 -0.73 -0.77 -1.02 -0.63 5.83 -0.3 -0.4 -0.63 -0.3 -0.5 1.69 -0.1 -0.9 
Q -0.14 0.62 -0.39 -0.25 0.69 0.66 8.09 1.97 1.05 1.2 0.47 1.3 2.02 0.08 -0.2 
N -0.18 0.95 -0.01 0.23 0.62  6.52 3.06 1.1 1.48   2.2 0.12 0.06 
R -0.17  -0.7 -0.77 2.54 0.23 9.69 1.03  1.52 0.31 2.62 1.74 0.21 -0.4 
K -0.22 0.63 -0.67 -0.87 0.94 0.49 9.5 1.53 0.43 0.82 0.06 1.75 1.68 0.18 -0.5 
E -0.1 0.38 -0.49  2.04 0.28 8.1 2.75 1.97 1.83 1.23 2.53 1.87 -0.3 -0.1 
D -0.03 1.21  0.72 1.67 -0.13 6.84 4.11 2.39 1.9 0.88 1.37 1.92 -0.1 0.07 
P 0.21 0.38 -1.02 0.88 -1.7 -0.25  2.18 6.8 0.84 3.12 6.22 0.02 -1.03 0.82 
W 0.18 0.54 -0.58 -0.24 9.03 -0.54 20.9 5.79 0.32 3.41 1.91 10 2.18 0.22 -0.4 
Y 0.28 0.42 -0.61 -0.65 6.66 -0.42 19.3 5.71 1.09 2.09 0.98 8.18 1.84 0.11 -0.4 
F 0.25 0.44 -0.66 -0.82 5.63 -0.54 17.6 4.76 0.56 0.14 0.8 7.01 1.65 0.02 -0.9 
H 0.26 1.14 -0.02 0.21 13.4 1.19 27.9 29.2 1.46 1.23 1.49 13.5 2.25  0.16 
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show that the S7L, S7M, S7P, H17P and V18F mutants are 4.75, 4.55, 1.53, 2.65 and 6.71 
Kcal/mol (Tble 5.2), indicating these gGID* mutants lose their activity. The corresponding 
values for rGID* are -1.01, -1.02, -1.7, -1.03 and -0.9 Kcal/mol (Table 5.6), suggesting these 
rGID*mutants can have significantly improved activity. Therefore, [S7L]rGID*, [S7M]rGID*, 
[S7P]rGID*, [H17P]rGID* and [V18F]rGID* are valuable candidates for future synthesis and 
biological activity test. The results here further suggest that optimising rGID could be a 
potential method to design selective and potent α4β2 nAChR inhibitors.  
5.4 Discussion 
In this study, we computationally investigated several variants of globular and ribbon GID*, 
which could be designed to selectively and potently inhibit α4β2 nAChR. Four molecular 
models of GID* bound to α3β2, α4β2 and α7 nAChRs were built, which were used to calculate 
mutational energies. Some mutants of rGID* were identified as potential candidates for 
improving (α4)3(β2)2 nAChR stoichiometry inhibitors according to the ΔΔG results by 
targeting the α4-α4 binding site. 
5.4.1 A suitable template can improve the quality of a molecular model 
The molecular models were built using a crystal structure of human α4β2 nAChR as a template. 
The molecular model of gGID*/rat α4β2 nAChR complex provided reasonable explanations to 
experimental mutational data. Correlation of Foldx ΔΔG computations with experimental 
activity was also reasonably good. By contrast, the predictive power of the two other models 
involving α3β2 and α7 nAChRs was poorer, possibly arising from a lower quality of homology 
models. Human α4 has 97.61%, 60.77% and 44.93 % sequence identity with rat α4, α3 and α7, 
respectively, while human β2 has 98.56% sequence identity with rat β2. Accordingly, the 
crystal structure of human α4β2 nAChR is an ideal template for the construction of rat α4β2 
nAChR, but it is not as accurate for building models of the rat α3β2 and α7 nAChR. The human 
α4 subunit and the rat α3 subunit display some difference of sequence that could lead to a 
different conformation of the binding site. For example, residues His186, I188, N191, Glu194 
and Gln198 of rat α3 (+) correspond to Asn186, Arg188, Glu191, Ala194 and Pro198 of the 
human α4 (+) subunit, and these positions are located in the C-loop and possibly influence its 
conformation. Therefore using human α4 subunit as a template to build a homology model of 
rat α3 subunit likely results in a Loop C with inaccurate conformation, affecting the binding of 
gGID* at the α3(+)β2(-) pocket. In agreement with this analysis, a previous study also 
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concluded that selecting a suitable template is crucial for reliable molecular models of the 
complex between α4β2 nAChR and α-conotoxins (36).  
5.4.2 The N- or C-terminal tail of the α-conotoxin can modulate activity on nAChRs 
Most α-conotoxins do not bind to α4β2 nAChR (11,37). A previous study found that the α4 
(+)-Arg188 (α4 (+)-Arg185 in that study) prevents α-conotoxins binding to α4β2 nAChR (36). 
Compared with other α-conotoxins, GID has a longer N-terminal tail. As described in the 
results section, the α4 (+)-Arg188 interacts with the unusual N-terminal tail of gGID* (Figure 
5.2A), showing that the N-terminal tail is vital for gGID* activity at α4β2 nAChR (16). 
Additionally, Ala substitution or deletions in the tail significantly decreased activity at α3β2, 
α4β2 and α7 nAChRs (16). These observations illustrate that the N-terminal tail is involved in 
modulating the activity of gGID* on α3β2, α4β2 and α7 nAChRs. Several other α-conotoxins 
also have an extended N- or C-terminal tail, such as AnIB (15), LsIA (38), and Lo1a (39). Like 
GID, the tail of these conotoxins was found to be involved in modulating the activity of these 
peptides (15,38,39). For example, AnIB inhibited the α7 nAChR with IC50 of 76 nM, but 
deletion of a Gly in the N-terminal tail caused a loss of activity (15). The truncation of the N-
terminal tail of LsIA resulted in a drop ~10-fold in activity at α3β2 nAChR (38). By contrast, 
truncation of the C-terminus of Lo1a result in an increased activity by ~ 4000-fold at α7 nAChR 
(39). Studying the mechanism of how modifications to N- or C- termini affect the activity of 
these peptides could help design more potent and selective nAChR antagonists.  
5.4.3 Potential (α4)3(β2)2 nAChR inhibitors suggested by Foldx 
The virtual screen of 266 gGID* point mutants did not indicate any novel peptides with 
increased binding affinity for the α4β2 nAChR. This result is consistent with experimental 
mutational studies, which did not create a globular α-conotoxin GID* variant that would 
potently block α4β2 nAChR (16-18). Alternative methods include mutating gGID* using non-
natural amino acids, which has been used to increase the activity of α-conotoxin PnIA at α7 
nAChR (40). Design of ribbon α-conotoxins is an underexploited strategy with the potential to 
influence the inhibition of nAChRs (41).  
  
The ΔΔG results of rGID* indicate that the S7L, S7M, S7P, H17P and V18F mutants are 
attractive candidates for future studies with human (α4)3(β2)2 nAChR. In the molecular model 
of rGID*/(α4)3(β2)2 nAChR (Figure 6.5), the Ser7 of rGID* only makes contact with α4 (-)-
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L168. Hence the substitution with Leu, Met or Pro would possibly increase interaction with 
other residues of the α4 () subunit. His17 and Val18 are in the second loop, which could result 
in conformational changes upon mutation of the peptide (42). Substitution of H17 by Pro and 
Val18 by Phe could result in conformational changes increasing contact of the second loop 
with the receptor, significantly increasing activity.  
 
In summary, we built a reliable molecular model of the gGID*/rat α4β2 nAChR complex and 
showed that it is important to choose a suitable template to construct the α-conotoxin/nAChR 
homology model. We demonstrated how the tail endows gGID* the ability to interact with rat 
α4β2 nAChR. Additionally, some rGID* mutants were identified, with potential to be 
developed into more selective and potent inhibitors of the (α4)3(β2)2 nAChR.  
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6.1 Conclusions  
All subtypes of nAChRs have attracted considerable attention over the last few decades because 
they are involved in various physiological diseases (1,2). It is essential to understand the 
physiological roles played by nAChRs, requiring the development of selective molecular 
probes for each nAChR subtype. In pursuit of this goal, the toxins from marine cone snails are 
an important resource to discover and develop nAChR selective probes (3,4).  
 
The largest characterised pharmacological class of conotoxins is the α-conotoxin, most of 
which display a cysteine Framework I. Framework I is characterised by two disulfide bonds 
with the first two hemi-cysteines (I and II) being adjacent along the sequence. Cysteine 
Framework I conotoxins can have three different disulfide-connected isomers: globular (Cys 
I-III, Cys II-IV), ribbon (Cys I-IV, Cys II-III) and bead (Cys I-II, Cys III-IV). The globular and 
ribbon α-conotoxins inhibit nAChR subtypes, having potential in the development of novel 
drugs (5-9). This thesis focused on the molecular design of ribbon α-conotoxins for therapeutic 
applications.  
 
Ribbon αO-conotoxin GeXIVA inhibits the rat and human α9α10 nAChR with IC50s of 7 nM 
and 47.3 nM, respectively. Despite this high potency, the therapeutic potential of GeXIVA is 
limited. Like most peptides, it is susceptible to proteolytic degradation and is challenging to 
synthesise in high yield. Chapter 2 discusses backbone cyclisation as a strategy to improve the 
folding yield and increase the serum stability, while preserving activity of ribbon GeXIVA at 
the α9α10 nAChR. Specifically, five cyclisation linkers were designed using molecular 
modelling. Conotoxin GeXIVA was cyclised using the short linker GG (hereafter named 
GeXIVA_GG) and synthesised using Fmoc-based solid phase synthesis. The yield through this 
method (8.6%) was 17-fold higher than the uncyclised ribbon GeXIVA obtained by two-step 
oxidation. The cyclic ribbon GeXIVA_GG maintained activity (IC50=37.6 ± 4.9 nM) on human 
α9α10 nAChR compared to the parent peptide (IC50=35.1 ± 2.7 nM). Additionally, cyclic 
ribbon GeXIVA_GG improved stability by 13% in human serum compared to the three isomers 
of GeXIVA.  
 
Previous electrophysiological experiments of α-conotoxin AuIB indicated that ribbon AuIB 
(rAuIB) binds to the α3(+)α3() interface at the α3β4 nAChR ligand binding domain. This 
interface is displayed by the (α3)3(β4)2 nAChR stoichiometry but not by (α3)2(β4)3, which is 
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not targeted by rAuIB (10). In Chapter 3, The SAR of rAuIB at α3(+)α3() interface was 
investigated by successively mutating each non-Cys residue of rAuIB to Ala. At 1 µM 
(corresponding to the reported IC50 of rAuIB [10]), all rAuIB mutants exhibited activity 
comparable to the parent peptide except for [S4A] and [F9A]rAuIB, which caused 25% and 
20% inhibition, respectively, indicating that positions 4 and 9 are the major determinants of the 
activity of rAuIB at (α3)3(β4)2 nAChR. Secondary Hα chemical shifts of rAuIB and its mutants 
suggested that the S4A and F9A mutants have a similar structure to the rAuIB, indicating loss 
of activity is not due to a change of structure. Interestingly, the [P7A]rAuIB variant adopts a 
different fold displaying similar secondary Hα chemical shifts to globular AuIB. Globular 
AuIB has an α-helix between Pro6 and Phe9, therefore it is likely [P7A]rAuIB demonstrates 
this feature as well.  
 
Chapter 3 discusses the binding mode of rAuIB at α3(+)α3() interface using mutational data. 
This binding mode is similar to that of globular α-conotoxins: the first loop of rAuIB binds to 
the aromatic box, similar to that of gAuIB. Slight differences occur in the second loop and 
terminus of rAuIB: these have different orientations and interactions in the binding site to those 
of gAuIB. According to the model, the substitution of Ser4 by Ala would cause the loss of two 
weak hydrogen bonds. The F9A mutant has fewer contacts with the receptor compared with 
the parent peptide, with a decrease of 194 Å2 in the buried surface area. The knowledge 
obtained from this study can be used to guide the design of ribbon α-conotoxins to inhibit 
nAChR subtypes. Similar to globular α-conotoxins, residues in the second loop of ribbon α-
conotoxins interact with a different area on each nAChR subtype, offering the opportunity to 
design subtype-selective inhibitors.  
 
Several challenges limit the development of α-conotoxins to become drugs. For example, some 
α-conotoxins are active at rat nAChRs but not at human nAChRs. The selectivity of wild-type 
α-conotoxins for a target nAChR subtype also needs to be improved (11-14). The rational 
design of selective human nAChR subtype inhibitors based on α-conotoxins is challenging 
(10,15-18). Computational energy calculation methods have been used to design highly 
selective and potent α-conotoxins inhibiting human nAChR subtypes (16). In Chapter 4, four 
methods (BeAtMuSic, Foldx, CG_US and MMPBSA/MMGBSA) were benchmarked to 
discover the optimal computational approach to rationally design α-conotoxins. The recently 
published crystal structures of the Ls-AChBP/α-conotoxin LsIA and Ac-AChBP/α-conotoxin 
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LvIA complexes as well as the associated experimental affinities of LsIA and LvIA mutants 
provide an ideal case scenario for testing these methods (19,20). The best method was Foldx, 
which reached 87.5% in accuracy and achieved a 0.75 Mathews Correlation Coefficient 
(MCC). Notably, Foldx was successful at predicting mutations with an increased or a decreased 
affinity for the receptor (See Chapter 5 for details of Foldx applied to design selective and 
potent α4β2 nAChR inhibitors). Therefore this method should be useful for designing selective 
inhibitors of human nAChR subtypes based on α-conotoxins.  
 
The α4β2 nAChR is the most abundant and widely distributed neuronal nAChR. It is involved 
in nicotine addiction (21,22), epilepsy (23), and Parkinson’s and Alzheimer’s diseases (24). 
This receptor exists as two major stoichiometries, (α4)3(β2)2 and (α4)2(β2)3, which have 
distinct functional properties (25). No conotoxin to date has been identified to selectively block 
α4β2 nAChR, which would have therapeutic applications for addiction. Nevertheless, some 
conotoxins, such as α-conotoxin GID, block α4β2 nAChR but are also more potent antagonists 
of other nAChR subtypes, such as α3β2 and α7 nAChRs. In Chapter 5, globular and ribbon α-
conotoxin GID variants are investigated to selectively block the α4β2 nAChR stoichiometries 
using a combination of molecular modelling and energy calculation methods.  
 
Using the experimental structures of human (α4)2(β2)3 and (α4)3(β2)2 nAChR as templates, we 
built molecular models of the interaction between the α4(+)2(), α3(+)2(), and α7(+)α7() 
binding sites and gGID* as well as interaction between the α4(+)α4() binding site and rGID*. 
The molecular model of the gGID*/rat α4β2 nAChR complex seems to correlate with 
experiments, as it can rationally explain experimental SAR data, suggesting that it has 
reasonable accuracy. By contrast, the molecular models of gGID* at rat α3β2and α7 nAChR 
could only be partially explained using experimental SAR data. Foldx was used to predict the 
impact of a complete scanning (i.e. mutations in all amino acids of every non-cysteine position) 
of GID in the context of the four molecular systems mentioned above. The accuracy and MCC 
of calculated ΔΔGs for the experimentally validated mutants were 81.3% and 0.46 as a function 
of the published experimental data for the gGID*/rat α4β2 nAChR complex. The 
corresponding values for the gGID*/rat α3β2 nAChR complex and the gGID*/rat α7 nAChR 
complex were only 50% and 0, 55.6% and 0.32, respectively, confirming that these models are 
not accurate enough to predict the impact of mutations using Foldx. Foldx-predicted ΔΔG 
results showed that the activity of gGID* at α4β2 nAChR cannot be improved using any 
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mutation, whereas the [S7L]rGID*, [S7M]rGID*, [S7P]rGID*, [H17P]rGID* and 
[V18F]rGID* were suggested to have favourable properties to inhibit human (α4)3(β2)2 
nAChR.  
6.2 Future directions 
Overall, this project was very successful in providing new insights into conotoxin structure-
activity relationships. However, in any project there are always new directions that are 
identified for future studies and some suggestions for areas worthy of investigation are given 
below. 
6.2.1 To investigate the physiological role of α3β4 nAChR stoichiometries and in disease 
states 
The role of the two stoichiometries of α3β4 nAChR, i.e. (α3)3(β4)2 and (α3)2(β4)3 nAChRs, 
has not yet been investigated. rAuIB has been reported to only target the (α3)3(β4)2 nAChR. In 
Chapter 3, the binding mode of rAuIB at (α3)3(β4)2 nAChR was modelled, which could be used 
to design more potent (α3)3(β4)2 nAChR inhibitors based on rAuIB. The rationally designed 
more-potent rAuIB variants could then be used to identify α3β4 nAChR stoichiometries and 
their involvement in diseases.  
 
6.2.2 Biological activity of rGID* variants at nAChR subtypes 
In Chapter 5, the ΔΔG results for rGID* indicated that the S7L, S7M, S7P, H17P and V18F 
mutants should have activity at the α4(+)α4() binding site of the human (α4)3(β2)2 nAChR. It 
would therefore be interesting to measure the biological activity of these rGID* variants at the 
two main stoichiometries of α4β2 nAChR and other nAChR subtypes. 
 
6.2.3 Biological activity test for ribbon α-conotoxins at different receptors or ion channels 
A recent study showed that globular α-conotoxin Lt1.3 blocks α3β2 nAChR but the ribbon 
Lt1.3 inhibits GABAB receptor-coupled Cav2.2 (26). Another α-conotoxin, ImI, is a potent 
inhibitor of α7 nAChR but was also shown to have weak inhibitory activity at the GABAA 
receptor (27). Hence, it would be interesting to test rAuIB as well as rGID at different receptors 
such as GABAA and GABAB. 
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6.3 Concluding remarks 
In summary, the application of a range of biochemical methods in this thesis has proven that 
the ribbon α-conotoxin can be engineered with favourable properties. The use of a multi-
faceted computational and biochemical approach has assisted in understanding how the ribbon 
α-conotoxin interacts with nAChRs. The benchmark of energy prediction methods has enabled 
to design ribbon α-conotoxin mutants rationally. The design of ribbon α-conotoxin GID has 
shown that the ribbon α-conotoxin has potential to be engineered as specific nAChR inhibitors. 
The overall findings of this thesis will facilitate for future studies of the establishment of the 
role of specific nAChR stoichiometries in disease states, and the development of the ribbon 
scaffold as a drug template for pharmaceutical applications in the future. Ribbon isomers 
should therefore be more systematically considered in the design of molecular probes and 
specific inhibitors of nAChR subtypes based on α-conotoxins.  
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